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The skeletal muscles of vertebrates are typically composed of slow and fast-twitch 
fibres that differ in morphology, gene expression profiles, contraction speeds, 
metabolic properties and patterns of innervation.  Slow-twitch muscle fibres are 
capable of repetitive low peak force contractions and are highly resistant to fatigue.  
In contrast, fast-twitch muscle fibres produce high peak force contractions for short 
durations before they become fatigued.  During myogenesis, how muscle precursors 
are induced to mature into distinct slow or fast-twitch fibre types is inadequately 
understood. In the somites of the zebrafish embryo, the activity of the zinc finger and 
SET domain containing transcriptional regulator Blimp1 is essential for the 
specification of slow muscle fibres. Here, I have investigated the mechanism by 
which Blimp1 programs myoblasts to adopt the slow-twitch fibre fate.  In slow 
myoblasts, expression of the Blimp1 protein is transient, and precedes the expression 
of slow muscle-specific differentiation genes.  I demonstrate that the competence of 
somitic myoblasts to commit to the slow lineage in response to Blimp1 changes as a 
function of developmental time. Through in situ hybridization screens, I have 
identified additional genetic markers of the slow muscle lineage and other genes that 
may play a role in slow muscle development.  Furthermore, I show that mammalian 
Blimp1 can recapitulate the slow myogenic program in zebrafish, suggesting that 
zebrafish Blimp1 can recognize the same consensus DNA sequence that is bound by 
the mammalian protein.  Functional analysis of the regulatory region of the definitive 
slow muscle marker, slow myosin heavy chain 1 (smyhc1) reveals that Blimp1 
possibly interacts with cis-regulatory elements within this promoter, regulating its 
expression.  Finally, I show that zebrafish Blimp1 can repress the expression of fast 
 vii
muscle-specific myosin light chain, mylz2, through direct binding near the promoter 
of this gene, indicating that an important function of the transcriptional activity of 
Blimp1 in slow muscle development is the suppression of fast-muscle-specific gene 
expression.  Taken together, these findings provide new insights into the molecular 
basis of vertebrate muscle development. 
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Chapter 1  1 
GENETIC CONTROL OF VERTEBRATE MUSCLE CELL IDENTITY 
CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
 
 
"Nothing in biology makes sense except in the light of evolution" 
- Theodosius Dobzhansky, 1973 
 
Darwin’s Theory of Natural Selection states that organisms with inheritable traits that 
confer reproductive advantage would become more numerous in the subsequent 
generations.  Over the course of evolution, organisms progressively acquire and 
accumulate advantageous mutations that confer competitive survival advantage.  
These beneficial developmental and survival traits will be retained and refined as the 
organism evolves.  The genetic program that dictates the development of a zygote to 
the adult animal must contain instructions that are required for the full range of 
morphogenetic events and cellular processes.  These include the establishment of the 
body axes, formation of the three germ layers through gastrulation and the 
differentiation of all the cell types required to form the tissues and organs of the adult 
animal.   
 
One of the main differences between plants and animals is that animals have 
the ability to move in and around their environment.  All animals, with the exception 
of the Sponges (Phylum Porifera) possess muscles, which are specialized contractile 
tissues which generate force that results in movement.  Locomotion confers survival 
advantage to animals as it enables animals to search or hunt for food and escape 
predation.  It is also important for many animal behaviour, such as the seasonal 
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migration of birds and to perform complex mating rituals.  The development of 
muscles also enables animals to defy gravity and adopt upright postures.  As such, 
other organ systems, such as the internal circulatory and respiratory systems, may 
have co-evolved to support the increased level of organismal complexity.  The 
development of muscles thus represents an important breakthrough in evolutionary 
history. 
 
A number of model organisms, ranging from invertebrates, such as the fruit fly 
and grasshoppers, to vertebrates, such as fish, chicken and mouse, have been used to 
study various aspects of muscle development, also referred to as myogenesis.  These 
studies have led to the identification of myogenic regulatory factors (MRFs), muscle 
identity genes, as well as mechanisms that control the fusion of myoblasts into 
multinucleate fibres during muscle differentiation.  In this thesis, I will focus on the 
development and diversification of vertebrate skeletal muscles.   
 
1.1.  Myogenesis in invertebrates 
Genetic analysis in the fruit fly (Drosophila melanogaster) has led to the 
discovery of the genes and molecular mechanisms that are involved in myogenesis.  
Many paradigms in invertebrate myogenesis such as the expression of muscle identity 
genes, asymmetric cell division, and the recruitment and formation of syncytial 
muscle fibres through the fusion myoblasts with muscle founder cells have arisen 
from work in flies (reviewed in Roy and VijayRaghavan, 1999; Chen and Olson, 
2004; Maqbool and Jagla, 2007).  Preceding myogenesis in flies, mesodermal 
derivatives begin to express uniform levels of the basic helix-loop-helix (bHLH) 
transcription factor Twist (Twi) (Thisse et al, 1987) (Fig. 1.1).  Morphogenetic signals 
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from the overlying ectoderm, in the form of secreted proteins Wingless (Wg) and 
Decapentaplegic (Dpp), subdivide the mesoderm into somatic and visceral 
components (Maggert et al., 1995, Azpiazu et al., 1996).  The somatic mesoderm is 
then patterned into regions with alternating bands of high and low Twi expression, 
through the activities of the two segmentation genes even-skipped (eve) and sloppy 
paired (slp) (Apiazu et al., 1996, Lee and Fransch, 2000).  The regions that express 
slp express high levels of Twi would acquire myogenic fates.  Within these myogenic 
competent domains, some of the somatic myogenic precursors express another bHLH 
transcription factor lethal of scute (l’sc) and give rise to myogenic equivalence groups 
(Carmena et al., 1998).  Notch-Delta mediated lateral inhibition within the myogenic 
equivalence groups result in the specification of myogenic progenitor cells, while the 
remainder of the cells become fusion-competent myoblasts (FCMs) (Brennan et al., 
1999).  The expression of the Drosophila Myocyte enhancer factor 2 (Dmef2), a 
MADS-box transcription factor, is induced by the activity of Lame duck (Lmd, which 
is also known as Myoblast Incompetent, Minc) and Gleeful (Glee, a Gli family 
transcription factor), and leads to the differentiation of these FCMs (Lilly et al., 1995, 
Duan et al., 2001, Ruiz-Gomez et al., 2002, Furlong et al. 2000).  Myogenic 
progenitor cells either divide symmetrically to generate either two founder cells or 
asymmetrically to give rise to one founder cell and one adult muscle precursor 
(AMP).  The unique identity of each founder cell is achieved through the expression 
of a specific combination of muscle identity transcription factors, such as Kruppel, 
S59/slouch, apterous and ladybird (Knirr et al., 1999, Ghazi et al., 2000, Jagla et al., 
1998).  Larval multinucleate muscle fibres are formed by fusion between individual 
founder cells and FCMs around them, to give bi-/ trinucleate precursors.  These 
muscle precursors then continue to attract and fuse with more fusion competent  
 





Fig. 1.1  Overview of Drosophila muscle development.  (i) Myogenesis begins at 
stage 11 when the Drosophila embryos express Twist (Twi) in an alternating pattern 
of high Twi expression (dark green) and low Twi expression (light green) in the 
somatic mesoderm.  (ii)  Cells that express higher levels of Twi become specified as 
muscle precursors.   (iii)  Myogenic equivalence group (cells in blue) within the 
myogenic field express Lethal of Scute (L’Sc). (iv)  Muscle progenitor cells are 
singled out within the myogenic equivalence group through lateral inhibition 
mediated by Notch-Delta signalling.  The remainder of the cells become fusion-
competent myoblasts through the activity of Lmd/Minc/Glee. (v)  Each muscle 
progenitor cell (P1, P2) undergoes asymmetric cell division to give rise to two 
founder cells (A, B) or a founder cell (C) and an adult muscle progenitor (AP). (vi)  
Fusion between founder and fusion-competent myoblasts occur mediated by fusion 
receptors to form bi- and/or tri-nucleate muscle precursors. (vii)  Muscle precursors 
continue to attract more fusion-competent cells which require the activity of 
Antisocial (Ants) and leads to the formation of multinucleate myotubes. This figure, 
taken from Chen and Olson (2004) TRENDS in Cell Biol. 14: 452-460, is reproduced 
with permission from ScienceDirect. 
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myoblasts through a second phase of fusion (Bate, 1990, Menon et al., 2005). 
 
Molecular analyses in Drosophila have also been pivotal in the identification 
of genes that are involved in muscle fusion (reviewed by Chen and Olson, 2004).  
Myoblast fusion involves the attraction of FCM by founder cells mediated by 
interactions between members from the Immunoglobulin Super family (IgSF) located 
on the surface of these cells.  The three members of the IgSF involved in the fusion of 
founder cells and FMCs are asymmetrically expressed in these cells; Dumbfounded/ 
Kin of Irre C (Duf/Kirre) and Irregular chiasm-C/Roughest (IrreC/Rst) are expressed 
in the founder cells, while the third member, Sticks and stones (Sns) is expressed in 
the FCMs (Ruiz-Gómez et al., 2000, Strunkelnberg et al., 2001, Bour et al., 2000).  
These proteins are located on the membrane of the founder cells and FMCs and are 
thought to act as ligands which mediate interactions between the two cell types.  Duf 
is believed to recruit Myoblastcity (Mbc) to the cyptoplasmic membrane through the 
adaptor protein Antisocial/Rolling pebbles (Ants/Rols) resulting in the cytoplasmic 
rearrangements that underlie changes in cell shape and membrane fusion (Chen and 
Olson, 2001, Klapper et al., 2002).  Many of the molecules that are involved in 
myoblast fusion in Drosophila appear to be conserved in vertebrates (Srinivas et al., 
2007).  A comparison between invertebrate and vertebrate myogenesis will be 
provided in the section 1.3, following a brief introduction into vertebrate myogenesis.  
 
1.2. Myogenesis in vertebrates 
Vertebrate myogenesis has been the subject of intense research in the last two 
decades (reviewed by Buckingham, 1994; Buckingham, 2001; Bryson-Richardson 
and Currie, 2008, Gilbert, 2006).  In vertebrate embryos, myogenesis is tightly 
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coupled to somitogenesis, the process of segmentation of the mesoderm in the trunk 
and tail.  Somites are iterative groups of mesenchymal cells surrounded by epithelial 
tissue formed through successive segregation of proliferative cells in the pre-
segmental plate in a rostrocaudal direction.  Somites give rise to the sclerotome and 
the dermomyotome.  In amniotes, the somite contributes largely to the sclerotome 
which develops into the vertebrae and bones while the dermomyotome gives rise to 
the dermis and muscles.  In contrast, somites in teleosts (bony fishes) contribute 
largely to the myotome.   
 
The mouse (Mus musculus) embryo is one of the most well-studied models of 
vertebrate myogenesis (reviewed in Buckingham, 2001; Bryson-Richardson and 
Currie, 2008).  The process can be broadly divided into three phases.  The first phase 
of myogenesis involves the formation of the myotome.  Epaxial and hypaxial 
mesodermal precursors, located at the dorsomedial and ventrolateral edges of the 
dermomyotome respectively, delaminate and migrate beneath the dermomyotome to 
give rise to the myotome (Fig. 1.2A).  Morphogenetic signals from surrounding 
tissues instruct these cells to become myoblasts by inducing the expression of the 
MRFs myogenic factor 5 (Myf5) and myoblast differentiation 1, MyoD (Fig 1.2B).  
Epaxial myoblasts are specified by multiple overlapping morphogenetic signals and 
autonomous factors.  Secreted morphogens Wnt1 and Wnt3a from the dorsal neural 
tube and Sonic hedgehog (Shh) from the notochord stimulate Myf5 expression which, 
in turn, induces MyoD expression (Tajbakhsh et al., 1998, Borycki et al., 1999).  In 
addition, Wnt7a from the dorsal epithelium directly induces MyoD expression 
(Tajbakhsh et al., 1998).  Cell autonomous factors Myf6 (an MRF also known as 
Mrf4) and Paired-domain transcription factor 3 (Pax3) also activate MyoD expression  
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Fig. 1.2  Schematic representation of mouse myogenesis.  (A) The dermomyotome 
of the somite (green) and the underlying myotome (beige) are initially formed from 
the migration of myoblasts from the edges of the dermomyotome (blue arrows).  
Subsequently, as the central dermomyotome loses its epithelial structure, a second 
wave of myogenic precursors enter the myotome (red arrows).  This figure is 
modified from Buckingham and Relaix (2007) Ann. Rev. Cell Dev. Biol. 23:645-673 
and used with permission from Annual Reviews. (B)  Myogenic specification and 
differentiation in the mouse embryo.  In the epaxial myotome, Pax3, Myf5 and Myf6 
(Mrf4) independently induces the expression of MyoD.  Wnt1 from the dorsal neural 
tube directly activates Myf5, while Wnt7A preferentially activates MyoD. Sine 
oculis-related homeobox proteins, Six1 and Six4, regulate Myf6.  Sonic hedgehog 
(Shh) signalling regulates myogenesis through maintenance of Myf5.  In the hypaxial 
myotome, Six1 and Six4, together with co-factors eyes-absent homologs Eya1 and 
Eya2 induces Pax3.  Pax3 activates Myf5 and Myf6 activity and consequently induce 
MyoD.  This figure is taken from Bryson-Richardson and Currie (2008) Nat. Rev. 
Genet. 9:632-646, with permission from the Nature Publishing Group.  
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 in the epaxial myotome (Marato et al., 1997).  The specification of myoblasts in the 
hypaxial myotome requires the activity of Sine oculis-related homeobox1 (Six1) and 
Six4 factors, together with the coeffectors Eyes-absent 1 homolog (Eya1) and Eya2 to 
induce Pax3 expression (Grifone et al., 2005, Grifone et al., 2007).  Pax3 activity 
induces expression of Myf5 and MRF4 which subsequently induces MyoD 
(Tajbakhsh et al., 1997).  There is also evidence that signalling molecules from the 
lateral plate mesoderm, in the form of Wnt and Fibroblast growth factor 5 (Fgf5) 
induce Pax3 expression (Cossu et al., 1996b).  Bone morphogenetic protein 4 (BMP-
4) from the overlying epidermis antagonizes the myogenic capacity of Shh and 
Noggin signalling from the midline from extending mediolaterally, and ensures the 
proper development of the sclerotome (Cossu and Borello, 1999). 
 
During the second phase of myogenesis, multinucleate fibres are formed by 
fusion of myoblasts to form myofibrils that elongate and extend towards and anchor 
onto somite boundaries.  Muscle cell fusion occurs when myoblasts exit the cell cycle 
(Konigsberg, 1971), secrete fibronectin into the extracellular matrix and bind to α5β1-
integrin (Mege et al., 1992, Menko and Boettiger, 1987).  The next step in myoblast 
fusion involves the alignment of myoblasts by glycoproteins that include several 
cadherins and CAMs (Knudsen et al., 1990, Mege et al., 1992).  Recent analysis in 
zebrafish embryos lead to the identification of the first vertebrate homolog of the 
Drosophila Kirre (Kirrel-like 3, Kirrel3), which is required for the alignment of 
myoblasts prior to fusion.  This study demonstrated that Kirrel3 is required in 
vertebrate myoblast fusion and involves G-protein mediated cytoskeleton 
rearrangement through the activity of vertebrate Rac1 (Srinivas et al., 2007).  The 
findings of this analysis are particularly significant as it is one of the first in vivo 
 
Chapter 1  9 
analyses of the mechanisms involved in vertebrate myoblast fusion.  It also provided 
evidence for the conservation of mechanisms required for myoblast fusion in 
vertebrates and invertebrates.  In addition to the requirement for calcium ionophores, 
membrane fusion is catalyzed by a class of metalloendoproteinases (Couch and 
Strittmatter, 1983).  Myotubes secrete interleukin-4 (IL4) to recruit other myoblasts to 
fuse with the myotube (Horsley et al., 2003).   
 
The third and final phase of embryonic myogenesis involves the addition of 
mitotically active cells from the dermomytome to the myotome (Venuti et al., 1995).  
These myoblasts subsequently exit the cell cycle, express myogenin (the fourth MRF) 
and become fusion-competent myoblasts that can fuse with pre-existing multinucleate 
fibres (Venuti et al., 1995).  This phase of myogenesis is estimated to contribute to a 
major part of embryonic muscle mass at embryonic day 4 (E4.0).  The continued 
differentiation of myotubes is mediated by the activity of myogenin and the MEF2 
family of transcription factors (Edmondson et al., 1994).  Thus, there appears to be a 
hierarchy of transcriptional activation through which cells become progressively 
committed to become myoblasts and mature muscle fibres.   
 
1.3. Comparison between invertebrate and vertebrate myogenesis 
Despite the great evolutionary divergence between the two phyla, Chordata 
and Arthropoda, there are significant similarities as well as differences in myogenesis 
between the vertebrates and invertebrates.  In both chordates and arthropods, 
myoblasts are derived from the mesoderm and require inductive signals from 
surrounding tissues for their specification and subsequent differentiation into muscle 
fibres.  Despite the differences in the architecture between the vertebrate and 
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invertebrate embryos, the Hedgehog (Hh), Wnt/Wingless (Wg) and Transforming 
Growth Factor-β (TGF- β) signalling pathways all play important roles in 
myogenesis.   
 
Although Hh and Wnt/Wg signalling are involved in myogenesis, they 
function differently between vertebrate and invertebrate embryos.  In Drosophila 
embryos, Hh and Wg signalling defines segment polarity and refines the positional 
information of each cell within the embryo. This, in turn, determines the specific 
combination of transcription factors each cell expresses and refines the region of Twi-
expressing myogenic precursors (Azpiazu et al., 1996, Lee and Frasch, 2000).  In 
vertebrate embryos, Shh and members from the Wnt family act as morphogenetic 
signals act directly to induce the myogenic factors Pax3, Myf5 and MyoD that defines 
the myotome (Cossu et al., 1996, Borycki et al., 1999, Münsterberg et al., 1995).  In 
both vertebrates and invertebrates, signalling molecules of the TGF-β family, namely 
BMP-4 and Decapentaplegic (Dpp) respectively, from the overlying ectoderm acts on 
the mesoderm which gives rise to the musculature (Azpiazu and Frasch, 1993, Duprez 
et al., 1996).  In flies, Dpp induces the dorsal mesoderm which gives rise to somatic 
muscles (Azpiazu and Frasch, 1993).  In vertebrate embryos, BMP-4 acts to 
antagonize the effect of Shh and to provide a balance between proliferation and 
differentiation in the myotome and ensure proper development of the sclerotome 
(Duprez et al., 1996, Murray et al., 1993, Cossu and Borello, 1999) 
 
Basic-HLH transcription factors play critical roles in both vertebrate and 
invertebrate myogenesis (Baylies and Bate, 1996, Rudniki et al., 1993).  In the 
Drosophila embryo, Twi appears to be important for the specification of mesodermal 
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derivatives into myogenic competent domains (Baylies and Bate, 1996), while in 
vertebrate embryos, the expression of MRFs results in the specification and 
differentiation of precursor cells into myoblasts and myocytes (Rudniki et al., 1993).  
Interestingly, nautilus (nau), the sole Drosophila ortholog of MyoD, does not appear 
to play a significant role in the invertebrate myogenic program (Balagopalan et al., 
2001).  Terminal myoblast differentiation in both vertebrates and invertebrates also 
require the activity of the conserved MADS box transcription factor Mef2 (Lilly et al., 
1995, Bour et al., 1995, Molkentin et al., 1995; Blais et al., 2005).   
 
Both vertebrate and invertebrate myotubes are multinucleate and are formed 
through myoblast fusion (Chen and Olson, 2004, Roy et al., 2001, Srinivas et al., 
2007).  In Drosophila embryos, fusion between founder cells and fusion competent 
myoblasts (FCMs) require heterophilic interactions between IgSF proteins Kirre and 
Rst, located at the membranes of founder cells and Sticks and stones (Sns) located at 
the membrane of FCMs (Ruiz-Gomez et al., 2000, Strunkelnberg et al., 2001, Bour et 
al., 2000).   The asymmetric distribution of the receptors gives rise to inherent 
directionality of fusion; fusion does not occur between the founder cells or between 
FCMs (Chen and Olson, 2004, Klapper et al., 2002).  A recent study revealed that a 
vertebrate homolog of Kirre (named Kirre-like or Kirrel), is required for myoblast 
fusion in zebrafish embryos (Srinivas et al., 2007).  However, it remains unclear 
whether the fusion is mediated by homophilic interactions between Kirrel-expressing 
myoblasts or through heterophilic interactions with yet unidentified “Sns-like” 
molecules.  Furthermore, this study also demonstrated that zebrafish myoblast fusion, 
like Drosophila myoblast fusion, requires Rac1-mediated cytoskeleton remodeling.   
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Vertebrate and invertebrate myogenesis may share many molecular 
mechanisms which are largely conserved, but have invariably diverged over the 
course of evolution.  Vertebrate musculature is more complex, displays higher levels 
of organization and is characterized by different types of muscle fibres that possess 
distinct metabolic properties and express different variants of contractile proteins such 
as myosins, tropomyosins and troponins (Staron and Pette, 1986).  The diversification 
of fibre types in vertebrate embryos is achieved by the progressive specification of 
precursor cells into differentiated muscle fibres through a transcriptional hierarchy. 
 
1.4. Vertebrate myogenesis is achieved through a transcriptional cascade 
1.4.1. Pax3 and Pax7   
As mentioned in the earlier section on vertebrate myogenesis, Pax3 is 
expressed in mesodermal tissues respond to morphogenic signals from axial tissues.   
Pax3 belongs to the Paired-box (or Pax) family of genes that encode transcription 
factors that play important roles in a myriad of developmental processes, especially in 
cell fate specification (reviewed in Buckingham and Relaix, 2007).  Based on domain 
structure and sequence homology, nine paralogous Pax genes can be divided into four 
subfamilies.  Mutations in Pax genes result in developmental defects and perturbation 
of their activity may also lead to cancer, reflecting their importance in the modulation 
of proliferation, survival and differentiation of stem cells.  Pax3 and Pax7 are closely 
related proteins that are required for the patterning of the nervous system, neural crest, 
the dorsal epidermis and skeletal muscles.  In addition to the paired-box (pax) 
domain, Pax3 and Pax7 also possess a homeobox domain which also features in a 
large number of developmentally important transcription factors. 
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Pax3 is initially expressed throughout the somite and subsequently become 
restricted to the dermomyotome (William and Ordahl, 1994).  Gain-of-function 
experiments have revealed that Pax3 is required for the expression of both Myf5 and 
MyoD (Maroto et al., 1997).  In the epaxial myotome, Pax3 and Myf5 is required for 
its induction of MyoD (Fig. 1.2B, Tajbakhsh et al., 1997).  By contrast, in the hypaxial 
myotome, Pax3 induces Myf5 and Myf6 which in turn activate MyoD expression.  In 
Pax3 mutants, development of the hypaxial dermomyotome is completely abrogated 
as a result of the loss of Myf5 activity.  Pax3 mutant mice also fail to develop limbs as 
the limb muscle precursors fail to migrate from the somites (Tremblay et al., 1998).  
Pax3 expression is concomitantly down-regulated with the initiation of myogenesis as 
indicated by the expression of MyoD (Buckingham, 2003).  Thus, there appears to be 
a feedback mechanism for Pax3 expression in the myotome.   
 
Pax7 does not appear to play a role in early embryonic myogenesis, but is 
required in the specification of muscle satellite cells (Seale et al., 2000).  It acts 
primarily during later phases of myogenesis, especially in the activation of satellite 
cells during adult myogenesis and skeletal muscle repair (reviewed in Buckingham, 
2006).  Pax7 activates myogenic genes through chromatin remodeling by recruiting 
the MLL2 histone methyltransferase complex (McKinnell et al., 2008).  The Pax7-
MLL2 complex directs tri-methylation of lysine 4 on Histone3 (H3K4) at the target 
loci, which includes Myf5. 
 
1.4.2. Myogenic Regulatory Factors (MRFs) 
MyoD, Myf5, Mrf4 (also known as Myf6 and Herculin) and Myogenin (Myog) 
belong to a family of bHLH transcription factors whose activities are essential for the 
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specification and differentiation of all somitic myoblasts.  These genes are expressed 
in a dynamic spatio-temporal sequence to drive muscle specification and 
differentiation throughout development (reviewed by Pownall et al., 2002).   
 
1.4.2.1. MRF expression in amniotes 
In mice, Myf5 is the first MRF to be expressed in the precursors of epaxial 
muscles (Sporle et al., 1996), while MyoD is expressed later in the lateral myotome.  
Myf5 knock-out mice lose the first wave of myogenesis (Rudnicki et al., 1992) but the 
myocytes form normally after MyoD is expressed (Braun et al., 1994).  Knocking out 
MyoD does not result in any major muscle deficiency in muscle formation per se, but 
the embryos have a reduced capacity for muscle regeneration.  Myf5 and MyoD are 
thought to be functionally redundant despite being expressed in spatially distinct 
regions of the myotome.  It has been suggested that myoblasts expressing either of 
these MRFs can expand and compensate for the lost of the other as a result of secreted 
positional cues within the myotome (Rudniki et al., 1992).  Mutants deficient in both 
Myf5 and MyoD lack all myogenic precursors (Rudniki et al., 1993).  The 
inactivation of Mrf4 results in little defect in the myotome and its derivatives due to 
functional redundancy between Mrf4 and Myf5 (Olson et al., 1996).  Myogenin is 
expressed later and more broadly in the developing myotome compared to MyoD and 
Myf5.  Deficiency in Myogenin activity results in the disruption of the second stage of 
muscle differentiation and a reduction in muscle mass (Hasty et al., 1993; Nabeshima 
et al., 1993; Venuti et al., 1995). 
 
1.4.2.2. MRF expression in zebrafish embryos 
myoD and myf5 are the earliest markers of myoblast differentiation in the 
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zebrafish embryo (Weinberg et al., 1996, Coutelle et al., 2001).  myoD is first 
expressed in the pre-adaxial cells that flank the notochord towards the end of 
gastrulation (8 hours post fertilization, hpf) and starts to accumulate in the posterior 
half of the paraxial mesoderm after 10 hpf.  Adaxial expression of myoD has been 
found to be dependent on Hedgehog (Hh) signalling from the axial structures, while 
its expression in the paraxial mesoderm is induced by signalling through retinoic acid 
activation of Fgf8 signalling (Groves et al., 2005; Hamade et al., 2006).  myf5 is 
expressed at about the same time as myoD, but in a broader spatial domain that 
subsequently encompasses the entire segmentation plate (Coutelle et al., 2001).  
Similar to the Myf5;MyoD double knock-out mice, the knock-down of both Myf5 and 
MyoD activity in zebrafish embryos through the use of morpholino oligonucleotides 
(MO) results in morphant embryos with very limited differentiated muscle fibres 
within their somites (Hammond et al., 2007; Maves et al., 2007).  Much less is known 
about the function of the two other members of the MRF family in the zebrafish.  The 
expression of mrf4 requires the activity of Myf5 and MyoD and it is expressed only in 
terminally differentiated skeletal muscle cells.  Its transcripts can be detected in the 
adaxial cells of 12 hpf wild-type embryos (Hinits et al., 2007).  At 24 hpf, mrf4 is 
broadly expressed in the myotome, with higher levels of transcripts accumulating in 
the superficial slow-twitch muscle fibres.  The expression of myogenin is also highly 
dynamic.  It is first expressed in the adaxial cells at 10 hpf and rapidly disappears 
from these cells by 12 hpf.  At this stage, its transcripts are detected in a separate 
myogenic domain referred to as the lateral somitic mesoderm (Weinberg et al., 1996).  
To date, there has been no report of gain- or loss-of-function analysis of mrf4 and 
myogenin in zebrafish embryos.  
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1.4.2.3. MyoD in transcription regulation 
MyoD is the best studied member of the MRF family and it directs the 
specification and differentiation of myoblasts through gene regulation and chromatin 
remodelling (de la Serna et al., 2005).  Ectopic expression of MyoD in fibroblasts can 
force the cells to adopt a myogenic program and display characteristics of muscle 
cells (Tapscott et al., 1988).  Biochemical analysis of MyoD has revealed that its 
activity can be modulated through protein-protein interactions and post-translational 
modifications (Lassar et al., 1991).  Basic HLH MRFs form heterodimers with E-box 
binding proteins (which also possess bHLH domains) and bind to consensus DNA 
motifs known as E-boxes (reviewed by Pownall et al., 2002).  Unlike MRFs, E-box 
binding proteins are expressed ubiquitously but can only function as co-factors and 
are unable to substitute for MRF activity.   
 
MyoD promotes myoblast differentiation through activation of myogenin and 
myocyte enhancer factor 2 (Mef2) (Molkentin et al., 1995, Blais et al., 2005).  These 
proteins act cooperatively to direct muscle-specific gene expression (Molkentin et al., 
1995, Blais et al., 2005).  MyoD directly activates its own expression and reinforces 
the myogenic differentiation program through a positive feedback loop (Blais et al., 
2005).  However, there has also been some inconsistent evidence for the existence of 
negative feedback loops that down-regulate MyoD expression during myogenic 
differentiation (Blais et al., 2005).  Another feedback mechanism which involves the 
up-regulation of Id, an inhibitor of MyoD activity in proliferating myoblasts has been 
described (Benezra et al., 1990).  Id forms heterodimers with MyoD but as it lacks the 
bHLH domain, the MyoD/Id heterodimers cannot bind DNA and thus renders MyoD 
inactive. 
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Myogenesis is tightly coupled with cell cycle regulation; proliferative 
myoblasts exit the cell cycle before they become terminally differentiated 
(Konigsberg, 1971).  The activity of MyoD is modulated in a cell-cycle dependent 
manner (Kitzmann et al., 1999).  Phosphorylation of MyoD on serine residues 5 and 
200 by Cyclin B during G-S transition during mitosis results in the exclusion of 
MyoD from the dividing chromatin, preventing its chromatin remodelling activity in 
the dividing precursor cells (Batonnet-Pichon et al., 2006).  The transcriptional 
activity of MyoD is enhanced by specific acetylation of lysine residues 99, 102 and 
104 by transcriptional co-activators CBP/p300 and PCAF.  This, in turn, enhances the 
recruitment of these co-activators to activate its transcriptional targets (Polesskaya et 
al., 2000, Polesskaya et al., 2004).  
 
A recent report by Deato and Tjian (2007) described a novel mechanism 
through which MyoD-dependent muscle-specific gene expression is mediated.  They 
showed that MyoD recruits an alternative transcription machinery comprising of cell-
type specific TATA-binding protein-associated factor 3 (TAF3) and TBP-related 
factor 3 (TRF3) to the core transcription machinery and replaces the conventional 
TFIID subunit of RNA Polymerase II to direct the transcription of muscle-specific 
genes during myogenesis.  The replacement of TFIID also results in the cessation of 
transcription of genes required for cell division in myoblasts which leads to their 
irreversible exit from the cell cycle.  This represents a novel mechanism for the 
selective transcription of cell-type specific genes that direct myocytes into an 
irreversibly differentiated state during development.   
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All the studies described above serve to highlight the complexity of gene 
regulation during myogenesis by a single transcription factor.  As they have been 
carried out in different experimental systems and animal models, it remains unclear 
whether all these complex regulatory mechanisms integrate into a congruent 
myogenic program that operates universally in all vertebrates.  For further description 
of the MyoD transcriptional regulatory network, see section 1.4.4. 
 
1.4.3. Myocyte enhancer factor 2 (Mef2) family  
The Mef2 family of proteins are MADS-box-containing transcription factors 
that bind to muscle-specific gene promoters and activate their expression.  Their 
expression is induced by Myf5 and MyoD and their activities lie downstream in the 
myogenic regulatory pathway.  The importance of Mef2 proteins in muscle 
differentiation was illustrated in Drosophila embryos which possess a single Mef2 
gene, DMef2 that is essential for muscle formation (Lilly et al, 1994, Lilly et al., 1995, 
Bour et al., 1995).  Muscle precursors in Dmef2 mutants form normally, but fail to 
fuse and differentiate into myotubes.  The four Mef2 members in mice are expressed 
in spatially overlapping expression domains and their functional redundancy renders 
the analysis of Mef2 function difficult in vertebrate embryos (Molkentin and Olson., 
1996 ibid).  There is contradictory evidence as to whether Mef2 proteins can directly 
activate muscle gene expression (Kaushal et al., 1994; Molkentin et al., 1995).  It is 
clear that Mef2 proteins act as co-regulators of muscle gene expression through 
interactions with MyoD and Myogenin (Molkentin et al., 1995; Blais et al., 2005).  
Interestingly, these MRF genes are also regulatory targets of Mef2-MRF complexes, 
thus creating the feed-forward regulatory loops that amplify and maintain the 
expression of the MRFs and muscle cell identity. 
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1.4.4. Myogenic transcriptional regulatory networks 
A recent analysis utilized a combination of genome-wide techniques to 
characterize the transcriptional regulatory network involved during myogenic 
differentiation.  This study examined the binding of MyoD, Myogenin and MEF2 to 
the regulatory region of their target genes within the genome of proliferating 
myoblasts and differentiated myotubes and compared the gene expression profiles 
between these cells (Blais et al., 2005).  Chromatin immunoprecipitation (ChIP) 
analyses of all three myogenic regulatory factors revealed that each of these 
transcription factors binds to the regulatory regions of distinct and overlapping group 
of target genes.  Combinatorial occupancy of regulatory regions by both MRF and 
MEF2 increases the levels of expression of the target genes.  More significantly, these 
myogenic factors regulate a large number of genes involved in transcription 
regulation, indicating there are further levels of transcription regulation in the 
myogenic transcriptional cascade.  Computational analysis revealed an enrichment of 
binding sites of cooperative transcription factors.  The binding of these additional 
transcription factors could alter binding of MRF and MEF2 to particular targets, thus 
refining the regulatory activity of the MRFs and MEF2.  This provides a plausible 
explanation for the differential binding of MyoD to different sets of target genes in 
proliferating myoblasts and differentiated myotubes.   
 
The outcome of this study is the construction of a transcriptional regulatory 
network where MyoD, Myogenin and MEF2 regulate a large number of known and 
newly discovered genes that are required for myogenic differentiation.  This network 
revealed the presence of many feedback and feed-forward loops that confer tighter 
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regulatory control and robustness to the myogenic process, rendering it less sensitive 
to perturbations.   
 
1.5. Characteristics of differentiated vertebrate skeletal muscle fibres 
The execution of the complex myogenic transcription program results in the 
formation of multinucleate muscle fibres that are capable of contraction, enabling the 
animal to create movement through the generation of force.  These muscle fibres 
contain reiterative arrays of sarcomeres which comprise a large number of structural 
proteins, such as actin, titin, myosin heavy and light chains, troponins, tropomyosins, 
filamin, α-actinin.  In addition, other proteins are required in the assembly of 
sarcomeric units into functional contractile apparatus that spans the length of the 
muscle fibre.  Different paralogous variants of sarcomeric proteins that make up the 
myofilaments confer different contractile and metabolic properties to the skeletal 
muscle fibres (Staron and Pette, 1986).   
 
Vertebrate skeletal muscles can generally be classified into two basic types 
based on the myosin isoform(s) they express – slow or fast (Pette and Staron, 1990).  
Slow fibres appear red as they are highly vascularized and contain more myoglobin.  
They express the type I isoforms of myosin heavy chain (MyHC), the slow isoforms, 
which undergo sustained, low-force contractions and confer increased resistance to 
fatigue.  Slow-twitch fibres undergo oxidative respiration and contain more 
mitochondria than fast fibres.  Fast muscles, in contrast, are pale in appearance, with 
less vascularization and lower myoglobin levels.  They express type II (or fast) MyHC 
that are capable of rapid, high force contraction.  Fast-twitch fibres predominantly 
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undergo glycolytic respiration for energy production and are more susceptible to 
fatigue.   
 
The diversification of myoblasts into slow- and fast-twitch types can be 
observed during early development, where they set up the pattern of the first muscle 
fibers within the embryo (Crow and Stockdale, 1986). A number of very elegant 
studies on precursors of avian limb muscles in culture, as well as transplantation 
experiments in vivo, have suggested that embryonic myoblasts are intrinsically 
committed to differentiate into muscle fibers with specific contractile properties (for 
example, see DiMario et al., 1993; Van Swearingen and Lance-Jones, 1995).  
 
1.6. Skeletal muscle fibre type plasticity 
Studies of mammalian myoblasts have shown that during post-natal 
development, the differentiation pattern of muscle fibers is instructed by extrinsic 
signals and is independent of cell lineage (Hughes and Blau, 1992). Similarly, adult 
mammalian muscle fiber-type composition can also be profoundly influenced by 
extrinsic cues.  Adult skeletal muscles can undergo fibre-type conversion in response 
to motor neuron activity as well as exercise.  Consequently, muscle fibre-type 
plasticity has received a great degree of attention with respect to sports physiology.  
In rodents, signaling by the calcium-calcineurin pathway plays a critical role in 
regulating fiber-type diversity within individual muscles in response to physiological 
stimuli and motor nerve activity (Bassel-Duby and Olson, 2006). The calcium 
signalling pathway, involving calcineurin, calmodulin-dependent kinase, the 
transcriptional cofactor Peroxisome proliferator-activated receptor-gamma coactivator 
1α (PGC-1α) and the transcription factor Peroxisome proliferator-activated receptor δ 
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(PPAR-δ) controls many of the required changes in gene activity that underlie 
conversion to slow fibre fate.  In contrast to the calcium-calcineurin mediated fiber-
type plasticity in the adult, it is much less clear how myoblasts in the embryos are 
fated to differentiate into muscle cells with distinct contractile properties.   
 
1.7. Zebrafish as a model for studying animal development 
The zebrafish (Danio rerio) has emerged as a popular organism for studying 
vertebrate genetics and development.  Its main advantage over other vertebrate model 
organisms is its transparent embryos that develop from external fertilization, which 
allow researchers to observe developmental processes with minimal perturbation.  
Zebrafish embryos develop rapidly; the basic body plan and precursors of most of the 
major tissue and organ systems are established by 24 hpf (Fig. 1.3).  The fecundity 
and relatively short generation time of the zebrafish make it suitable for forward 
genetic analysis and gene discovery.  In addition, the robust zebrafish embryo is 
amendable to a large battery of manipulation and labelling techniques which include 
DNA/RNA injection for transient transgenesis, cell transplantation for lineage tracing, 
whole-mount in situ hybridization and immunohistochemical-staining for gene 
expression and phenotypic analysis.  Loss-of-function studies can be performed on 
mutant embryos or through injection of gene-specific morpholino oligonucleotides 
(MO) which either prevent correct splicing of transcripts or block translation of the 
mature mRNAs. 
 
1.8. Zebrafish as a model for studying muscle development 
As in other vertebrates, muscle fibres in the zebrafish embryo can be broadly 
classified into fast-twitch and slow-twitch based on the type of myosin heavy chain  
 
Chapter 1  23 
 
 
Fig. 1.3.  Camera lucida sketches of zebrafish embryos at selected stages.  The 
views are of the left side of zebrafish (Danio rerio) embryos.  Arrowhead indicates 
the early appearance of some key diagnostic features at the following stages: Bud: 
polster. 3-somite: third somite. 6-somite: eye primordium (upper arrow), Kupffer’s 
vesicle (lower arrow). 10-somite: octic placode. 21-somite: lens primordium. Prim-6: 
primordium of the posterior lateral line (on the dorsal side).  This figure is adopted 
from Kimmel et al. (1995) Development Dynamics 203:253-310. 
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they express (Devoto et al., 1996).  In addition to being classified as fast or slow-
twitch, four distinct sub-populations of muscle fibres can be identified in the 
embryonic zebrafish myotome based on their position, morphology and gene 
expression (Fig. 1.4) (Wolff et al., 2003).  The four types of muscle fibres are (1) the 
Superficial Slow Fibres (SSFs), (2) Muscle Pioneers (MPs), (3) Medial Fast Fibres 
(MFFs) and (4) the Lateral Fast Fibres (LFF).   SSFs and MPs are mononucleate 
fibres that express slow MyHC and the pan-slow muscle homeodomain protein, 
Prox1.  A single layer of SSFs occupies the lateral-most part of the myotome under a 
layer of external cells and the epidermis.  MPs have a flattened morphology and 
remain adjacent to the notochord.  They span the medio-lateral extent of the future 
horizontal myoseptum, separating the dorsal from the ventral half of the somites and 
express high levels of homeodomain proteins of the Engrailed (Eng) family.  The 
remainder of the myotome is filled with syncytial (multinucleate) myotubes 
containing fast myofibrils formed from the fusion of fast myoblasts (Wolff et al., 
2001, Srinivas et al., 2005).  The fast fibres nearest to the notochord also express Eng; 
these fibres are termed MFFs, while the non-Eng-expressing fast fibres are the LFFs.   
 
1.9. The ontogeny of zebrafish embryonic muscle development 
Myogenesis in the zebrafish embryo occurs in temporally distinct waves and 
in spatially separate domains within the somite.  Through lineage tracing experiments, 
slow and fast precursors were found to occupy distinct locations relative to the 
embryonic shield at the end of gastrulation (Hirsinger et al., 2004).  Immediately prior 
to somitogenesis at around 9 hpf, an array of 5 x 4 cuboidal epithelial-like cells, 
known as adaxial cells, flank the notochord (Fig. 1.5A) (Devoto et al., 1996; Stickney 
et al., 2000). These cells express myoD and myf5, making them the first myoblasts to  
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Fig. 1.4.  Four distinct muscle fibre types can be found in the myotome of a 24 
hpf zebrafish embryo. (A) Superficial slow fibres (slow MyHC in blue, pan-slow 
muscle homeobox protein Prox1 in red). (B) Muscle pioneers, which also express 
slow MyHC (blue) and Prox1 (red) remain apposed to the notochord and reside at the 
level of the horizontal myoseptum (long arrows). (C) Muscle pioneers also express 
Eng homeobox proteins at high levels, while multinucleated medial fast fibres (MFFs, 
short arrows) express Eng at lower levels.  (D) Fast-twitch fibres express fast MyHC 
(red) and are multinucleated (counterstained with propidium iodide shown in pseudo 
coloured in green). (E) A transverse section of a zebrafish embryo showing the 
relative position of muscle pioneers (long arrows) and medial fast fibres (short 
arrows).  (F) A transverse section through the myotome showing the relative position 
of slow-twitch fibres (blue) and fast-twitch fibres (red).  This figure was kindly 
provided by Dr. Sudipto Roy. 
 
Chapter 1  26 
be specified in the zebrafish embryo (Weinberg et al., 1996).  Adaxial cells 
subsequently exhibit slow-twitch fibre properties (defined by expression of slow 
myosin heavy chain 1, smyhc1) as early as the bud stage (10 hpf) (Hsiao et al., 2003).  
As adaxial cells become incorporated into the somites, myf5 expression is down-
regulated (Coutelle et al., 2001).  myoD expression can be detected in the fast muscle 
precursors located in the posterior half of somitic paraxial mesoderm as the first few 
somites form around 12 hpf (Weinberg et al., 1996).   
 
As somitogenesis progresses, adaxial cells in the anterior-most somites 
elongate while remaining apposed to the notochord (Fig. 1.5B) (Devoto et al., 1996; 
Stickney et al., 2000).  Within a span of 20 to 30 minutes, they commence lateral 
migration to form a monolayer of slow muscles at the most superficial position 
beneath the epidermis.  This movement results in the displacement of most medial fast 
muscle fibres towards the notochord.  The coordinated and directional migration of 
slow myofibres is the result of dynamic reciprocal waves of expression of N- and M-
cadherins in the slow and fast myoblasts (Cortes et al., 2003).  This migration also 
acts as an important (but not necessarily instructive) morphogenic signal that triggers 
the maturation of fast myotubes (Henry and Amacher, 2004).  Myoblasts in the 
paraxial mesoderm begin to fuse to form syncytial myotubes at 18 hpf (Srinivas et al., 
2007; Wolff et al., 2003) and express fast-muscle specific genes, such as the skeletal 
myosin light polypeptide 2 (mylz2) (Xu et al., 2001).  By 24 hpf, a monolayer of slow 
muscle fibres resides that the lateral edge of the myotome, beneath a layer of 
epidermis (Fig. 1.5C).  A later phase of myogenesis, termed stratified hyperplasia, 
describes the addition of muscle fibres at the dorsoventral extremes of the myotome 
which leads to the growth of the embryonic myotome (Barressi et al., 2001). 
 





Fig. 1.5.  Development of slow muscle fibres in the zebrafish myotome.  Schematic 
view of a developing somite with neural crest cells in orange, motor neurons in green, 
sclerotome in blue and slow muscle cells in red.  The notochord is labeled ‘N’ and the 
clear space in the somites represent fast muscle cells.  (A) At 12 hpf, adaxial cells are 
positioned adjacent to the notochord.  (B) At about 18 hpf, slow muscle cells begin 
their migration towards the surface with fast muscle precursors position both medial 
and lateral to them.  Muscle pioneer cells, however, remain adjacent to the notochord.  
(C) At 24 hpf, slow muscle forms a monolayer at the lateral surface of the myotome.  
This figure is taken from Stickney et al. (2000) Developmental Dynamics 219: 287-
303, reproduced with permission from Wiley Liss, Inc. 
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1.10. Slow muscle development in the zebrafish embryo requires inductive 
signals from the midline 
Analysis of mutations that affect the development of the notochord and 
horizontal myoseptum provided the first insights that myogenesis in the zebrafish 
embryo may require instructive cues from axial structures (van Eeden et al., 1996; 
Weinberg et al., 1996).  The Hedgehog (Hh) family of secreted proteins from the 
notochord and floorplate are known to act in a concentration-dependent manner to 
instruct a variety of cell fates in the developing embryo (for reviews on Hh signalling, 
see Ingham and McMahon (2001) and Ingham and Placzek (2006).  Ectopic 
expression of Sonic Hh (Shh) or its paralog, Tiggy-winkle hedgehog (Twhh), but not 
Echidna hedgehog (Ehh), leads to ectopic expression of Hh target genes patched1 
(ptc1), myoD and slow MyHC at the expense of fast muscle (Blagden et al., 1997; 
Concordet et al., 1996; Du et al., 1997; Weinberg et al., 1996), while loss-of-function 
mutations in components of the Hh signalling pathway result in the loss of expression 
of these Hh target genes and compromise the specification of slow-twitch fibres.  A 
group of mutants deficient in components of the Hh signalling pathway show 
perturbation in somite morphology; this group of mutants, known as the “you-type” 
mutants, posses U-shaped somites, as opposed to the chevron shaped somites in wild-
type embryos (van Eeden et al., 1996).  U-shaped somites are believed to be the 
consequence of the loss of MPs that lie in the region of the future horizontal 
myoseptum.  The mutants within this group include you (you), you-too (yot), sonic-
you (syu), chameleon (con), choker (cho) and u-boot (ubo) (van Eeden et al., 1996).  
Most of these mutants have been cloned and found to encode components of the Hh 
signalling pathway.  Another similar mutant which also possess U-shaped somites, 
slow-muscle-omitted (smo) encodes Smoothened (Smo), the sole transmembrane 
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transducer of the Hh signal (Barresi et al., 2000).  Embryos homozygous for 
mutations in smo are completely devoid of slow-twitch fibres.  
 
A more detailed study of the requirement for Hh signalling in the specification 
of the different muscle lineages in the developing myotome was reported by Wolff et 
al. (2003).  In this study, the authors exploited genetic and pharmacological reagents 
to demonstrate that exposure to distinct levels and duration of Hh activity results in 
the specification of distinct muscle cell types within the myotome.  The requirement 
of Hh signalling for the formation of the different muscle types was dissected by 
exposing embryos to various concentrations of the cyclopamine, a plant alkaloid that 
acts to attenuate Smo function (Chen et al., 2002).  The formation of MPs requires the 
highest level of Hh signalling and their formation was perturbed with a low dose of 
the drug, while formation of SSFs and MFFs remains unaffected.  Exposure to higher 
concentrations of cyclopamine disrupted Eng expression in MFFs, while SSFs were 
unaffected.  The formation of SSFs is only perturbed by treating the embryos with 
very high levels of cyclopamine.  This assay established that formation of MPs 
requires the highest level of Hh activity followed by MFFs, then SSFs.  However, this 
raised the question as to why exposure of MFF precursors to Hh signalling did not 
result in their specification into the slow muscle lineage.  This also raises the 
possibility that myoblasts can respond to Hh signalling only within a limited range of 
developmental stages.   
 
By investigating the effects of exposing embryos to cyclopamine at different 
stages of development, it was also found that the formation of MPs requires early 
sustained exposure to Hh signalling, while relatively late exposure to Hh signalling is 
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sufficient for Eng expression in MFFs.  This suggests that the competence of 
myoblasts to commit to the slow lineage in response to Hh signalling is lost at a 
certain stage of development.   More significantly, this study has established that the 
diversification of muscle types in zebrafish embryos can be used as an assay of Hh 
activity and demonstrated the efficacy of the assay in studying novel components of  
Hh signalling or factors that may modulate the activity of this pathway.  A recent 
study has utilized this muscle induction assay to establish the role of the microRNA 
mir-214 in modulating Hh signalling by fine-tuning the activity of the inhibitory 
component, Su(fu) (Flynt et al., 2007).  
 
1.11. The zebrafish u-boot (ubo) gene encodes a transcription factor that is 
necessary and sufficient to specify slow muscle fate  
ubo mutants were first described by van Eden et al. (1996) as part of a large-
scale screen for zygotic mutants.  It belongs to the “you-type” group of mutants where 
the formation of the horizontal myoseptum is affected.  Like other Hh pathway 
mutants, ubo embryos show a disruption in the development of all slow fibres.  
However, the mutation does not appear to interfere with Hh signalling as the 
induction of Hh signalling target genes such as ptc1 and myoD remains unaffected 
(Roy et al., 2001).  This implies that ubo is not part of the core Hh signalling pathway, 
but represents a switch that is responsible for specifying slow muscle fate in response 
to Hh signalling.  Through positional cloning, the ubo gene was found to encode the 
zebrafish homolog of the mammalian B-Lymphocyte Induced Maturation Protein 1 
(Blimp1) (Baxendale et al., 2004; Turner et al., 1994).  The expression of this gene in 
the slow muscle precursors is dependent on Hh signalling; adaxial expression of 
blimp1 is lost in smo mutant embryos.  Ectopic expression of blimp1 cDNA can fully 
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recapitulate the slow muscle differentiation program in smo embryos.  This 
demonstrates that blimp1 is sufficient for the induction of the slow-twitch fibre fate 
(Baxendale et al., 2004).  
 
Expression of blimp1 is not limited to the slow muscle precursors.  Its 
transcripts can be first detected by in situ hybridization around 5.5 hpf in the external 
yoke syncytial layer (YSL) (Baxendale et al., 2004; Wilm and Solnica-Krezel, 2005).  
At mid-gastrulation, blimp1 is expressed in the non-neural ventral ectoderm and 
becomes gradually confined to a line of cells marking the boundary between neural 
and non-neural ectoderm beyond gastrulation stages.  By tail bud stages (10 hpf), 
blimp1 is expressed in the pre-chordal mesoderm and the slow muscle precursors, the 
adaxial cells.  As somitogenesis progresses and slow muscle precursors mature, 
blimp1 transcripts are gradually cleared and are lost in the anterior somites by 18 hpf.  
At later stages of zebrafish embryo development, blimp1 transcripts can be detected in 
pectoral limb buds pharyngeal arches, octic vesicles, retina, cloaca, and the median fin 
fold (Hernandez-Lagunas et al., 2005; Roy and Ng, 2004).   
 
The zebrafish Blimp1 protein is a predicted to be a polypeptide of 776 amino 
acid residues with a predicted molecular weight of approximately 87.3 KDa.  Blimp1 
possesses several recognizable protein domain structures and its sequence is well-
conserved across many vertebrate species (Fig. 1.6). The zebrafish Blimp1 shows 
54% similarity with its murine homolog and possesses a similar domain structure 
(Fig. 1.7).  The two proteins show the highest level of conservation in the zinc finger 
domain (99%).  The most distinct functional protein domain is the Su(var), Enhancer 
of Zeste, Trithorax (SET) domain which is present in several chromatin-associated 
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proteins (Jenuwein et al., 1998), some of which have been shown to possess histone 
lysine methyltransferase activity (Trievel et al., 2002).  It also possess five Kruppel-
like C2H2 zinc finger motifs in the C-terminal half of the protein, where the first two 
zinc finger motifs are required for DNA binding (Yu et al., 2000).  The ubotp39 
mutation results in an amino acid substitution at position 564 of Blimp1 (Histidine to 
Arginine, H564R).   H564 is one of the histidine residues required to coordinate the 
Zn2+ ion in the second zinc finger motif of Blimp1.  This mutation could poteintially 
diminish the ability of Blimp1 to interact with cis-regulatory elements located on the 
chromatin.  The SET domain and the zinc finger domain are separated by proline-rich 
regions are important for the recruitment of HDAC family of proteins (Yu et al., 
2000).  Through deletion analysis, critical residues required for maximal repression 
has been mapped to a region between residues 339 and 398 which is important for 
interaction with the Q domains of co-repressors of the Groucho family (Fig 1.7) (Ren 
et al., 1999).  Interestingly, a region (between residues 398 and 412) that is capable of 
transcriptional activation which is normally masked by the repressor domain was also 
identified.  Fusion of the C-termianl acidic region of Blimp1 to the Gal4 DNA 
binding domain results in increased reporter gene activity, indicating this acidic 
region contains activating function.  The Blimp1 consensus binding sequence was 
solved by selective retardation of oligonucleotides in an electromobility gel shift 
assays, and the recombinant mammalian Blimp1 protein has been shown to recognize 
the consensus sequence AGTGAAA in vitro (Kuo and Calame, 2004).   
 
1.12. Mammalian Blimp1 plays a diverse role in development 
Blimp1 is also known as Positive Regulatory Domain Binding Factor 1 
(Prdm1 or PRDI-BF1).  It was first discovered based on its induction during cytokine- 
 




Fig. 1.6. Alignment of Blimp1 orthologs from five vertebrate species.  Blimp1 
protein sequence is highly conserved across vertebrate species.  The SET (Su(var), 
Enhancer of Zeste, Trithorax) domain and the five zinc finger (ZF) motifs, highlighted 
in yellow and blue shaded boxes respectively.  These regions possess the highest level 
of conservation. “nrd” marks the position of the nonsense mutation at residue 103 
encoded by the nrdm805 allele and “ubo” marks the position of the point mutation in 
ubotp39 at residue 564 where a Histidine residue was substituted with Arginine. 
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Fig. 1.7.  Schematic representation of mouse and zebrafish Blimp1.  The two 
vertebrate Blimp1 proteins share a similar domain structure.  (Top) Mouse Blimp1 
consists of 856 amino acid residues while the zebrafish homolog (bottom) consists of 
776 residues.  Yellow boxes represent acidic patches, Orange = SET (Su(var), 
Enhancer of Zeste, Trithorax) domain, Red = proline-rich regions, Blue = C2H2 Zinc 
Finger Motifs (light blue represents an incomplete C2H2 motif).  Regions 
corresponding to the histone deacetylase (HDAC) association (black bars), activating 
(ACT, green bar) and essential repressor (REP, red bar) domains are shown above the 
schematic of mouse Blimp1. 
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dependent plasmacytic differentiation (Turner et al., 1994).  Through microarray 
analysis, mouse Blimp1 been shown to regulate more than 250 genes during 
plasmacytic differentiation (Sciammas and Davis, 2004).  In order to promote the 
terminal differentiation of B-lymphocytes, Blimp1 represses genes that are required 
for cell cycle progression and activates genes that govern antigen presentation and 
receptor signalling in B-lymphocytes (reviewed by Calame et al., 2003).  c-myc, 
Pax5, CIITA, SpiB and Id3 are transcription factors that are down-regulated by 
Blimp1-mediated repression (Lin et al., 2002; Lin et al., 1997; Tooze et al., 2006; 
Piskurich et al., 2000).  Transcriptional repression by Blimp1 is mediated through the 
recruitment of Groucho family of co-repressors and other chromatin modifying 
enzymes such as Histone deacetylase 2 (HDAC2) and Protein methyltransferase 5 
(Prmt5) (Ren et al., 1999; Yu et al., 2000).  Despite its possession of the SET domain, 
there has been no evidence to date to demonstrate that Blimp1 is capable of catalyzing 
the methylation of lysine residues in histones, an activity normally associated with 
SET domain contianing proteins.  
 
In addition to B-lymphocyte differentiation, Blimp1 is also important for 
many other aspects of mammalian embryonic development.  Mice deficient in Blimp1 
activity are embryonically lethal and the embryos die at E10.5 as a result of  
haemorrhage and placental defects (Chang et al., 2002; Vincent et al., 2005).   
Robertson et al. (2007) described developmental defects in the forelimb, caudal 
pharyngeal arches, heart and sensory vibrissae of Blimp1-deficient mice.  Blimp1 also 
governs T-lymphocyte homeostasis (Kallies et al., 2006) and has been shown to be a 
critical determinant of the progenitors of primordial germ cells (PGCs) (Kurimoto et 
al., 2008; Ancelin et al., 2006; Ohinata et al., 2005; Vincent et al., 2005).  In addition, 
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Blimp1 functions to maintain homeostasis of multipotent progenitors in the sebaceous 
gland (Horsley et al., 2006) and drives terminal differentiation of keratinocytes 
(Magnusdottir et al., 2007). 
 
Several recent studies have focused on the role of Blimp1 in the specification 
of PGCs in the mouse embryo (Kurimoto et al., 2008; Ancelin et al., 2006; Ohinata et 
al., 2005; Vincent et al., 2005).  Blimp1 is expressed in the PGCs in mouse embryos 
at E7.5; and PGCs deficient in Blimp1 activity fail to proliferate and migrate 
normally.  Blimp1 associates with the protein methyltransferase PRMT5 and directs 
arginine methylation during PGC specification.  Ancelin et al (2007) demonstrated 
that epigenetic reprogramming of the germ cells occurs at a later developmental stage 
(E11.5) as arginine methylation is removed, occurring concomitantly with the 
translocation of the Blimp1-PRMT5 complex out of the nucleus into the cytoplasm.  
This is the first evidence that Blimp1 activity is regulated through post-transcriptional 
mechanism (Ancelin et al., 2007). 
 
Blimp1 is expressed in a population of sebocyte progenitors that are important 
for the formation and maintenance of the sebaceous gland (Horsley et al., 2006).  
Using Blimp1 conditional knock-out (cKO) mice, the authors showed that the loss of 
Blimp1 activity resulted in enlarged sebaceous glands due to an increase in the 
number of highly proliferative cells, mediated through the mis-regulation of c-myc 
transcription.  Blimp1 regulates gene expression in stem cells that contribute to the 
progenitor population in sebaceous glands and converts dormant progenitor cells into 
rapidly proliferating cells by regulating key cell-cycle regulatory genes.   
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In another study, Blimp1 was found to be a key regulator of epidermal 
terminal differentiation where keratinocytes transition from the granular layer to the 
cornified layer of the epidermis (Magnusdottir et al., 2007).  In this context, Blimp1 
was found to play a crucial role in the regulation of osmotic homeostasis through the 
repression of Nfat5.  Through gene expression profiling, Blimp1 was found to 
negatively auto-regulate its own expression.  In addition to promoting terminal 
differentiation of different cell types, PRDI-BFI,  the human homolog of Blimp1, is 
crucial in the regulation of cell growth and survival through repression of p53 (Yan et 
al., 2007).  While PRDI-BFI is activated by p53 directly binding to its promoter, it 
represses p53 transcription in an autoregulatory feedback loop.  In vitro analysis 
revealed that PRDI-BFI recruits the histone methyltransferase G9a to silence the IFN-
β locus in an osteosarcoma cell line (Gyory et al., 2004).  All the studies described 
above demonstrate that Blimp1 plays diverse roles in mammalian development and 
supports the notion that it functions as a transcriptional repressor capable of recruiting 
a myriad of chromatin remodelling enzymes to mediate transcriptional silencing. 
 
1.13. Studies of Blimp1 homologs in lower vertebrates  
Xblimp1 controls anterior endomesodermal cell fate in Spemann’s organizer 
in the Xenopus gastrula.  Over-expression of Xblimp1 results in the reduction of 
antero-posterior axis of the affected embryos, with retardation of gastrulation and 
spina bifida defects (de Souza et al., 1999).  Similarly, in the zebrafish embryo, 
Blimp1 over-expression during gastrulation promotes endoderm formation through 
the repression of chordin and thus promotes BMP signalling (Wilm and Solnica-
Krezel, 2005).  This suggests that the Blimp1 functions to limit the function of the 
gastrula organizer and regulates fate specification and morphogenetic processes which 
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include the formation of structures derived from the mesoderm, such as the notochord 
and somites.  Over-expression of zebrafish Blimp1 also results in the inhibition of 
dorsoanterior structures due to repression of chordin expression, as in the Xenopus 
embryo (Wilm and Sonica-Krezel., 2005).  Conversely, knock-down of Blimp1 
activity through the injection of morpholino oligonucleotides results in dorsalized 
embryos as BMP signalling is reduced.  Thus, Blimp1 limits the function of the 
gastrula organizer in early development. 
 
In addition to its role in slow muscle specification, the role of Blimp1 in the 
development of zebrafish embryo had been studied in two other contexts – in the 
development of the pectoral fin bud (Lee and Roy, 2006) and in the specification of 
neural crest (NC) and the Rohon-Beard (RB) sensory neurons (Roy and Ng, 2004; 
Hernandez-Lagunas et al., 2005).  Blimp1 activity is essential for proper formation of 
the Apical Ectodermal Ridge (AER), an important signalling centre in the developing 
fin bud (Lee and Roy, 2006).  Blimp1 functions downstream of tbx5 and Fgf24 
signalling and is required for the induction of fgf10 in the mesenchyme and shh in the 
zone of polarizing activity (ZPA).  Deficiency in Blimp1 activity results in 
malformations of the pectoral fin, showing that Blimp1 plays an important role in 
their specification (Roy and Ng, 2004).  Loss of Blimp1 activity in ubo mutant 
embryos not only inhibits specification of NC cells but also impairs the normal 
development of Rohon-Beard sensory neurons.  Expression of Blimp1 is induced by 
BMP signalling at the boundary between the neural plate and the non-neural 
ectoderm.  This finding was corroborated by an independent analysis of the 
narrowminded (nrd) mutant, another mutation in blimp1 (Hernandez-Lagunas et al., 
2005).  In this study, the more severe defect on RB development in nrd mutants, 
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compared to that seen in ubo mutant, was correlated with the more severe defect 
encoded by the nonsense mutation after the 102nd codon, which results in a severely 
truncated polypeptide in nrd mutant embryos (Fig. 1.6).  
 
Blimp1 homologs have also been identified in lower eukaryotes.  In the sea 
urchin Strongylcentrus pupuratus, Blimp1 (SpKrox1) was found to act as an activator 
of Wnt8 and Otx in the specification of the endomesoderm (Davidson et al., 2002, 
Minokawa et al., 2005).  And in the fruit fly (Drosophila melanogaster) Blimp1 plays 
a role in the development of the tracheal (Ng et al., 2006).  However, Blimp1 
homologs have not been found in unicellular organisms such as the budding yeast 
Saccharomyces cerevisiae.  This suggests that Blimp1 homologs have evolved only in 
multicellular organisms and its gene product serves as a cell fate specification gene. 
 
1.14. Aims of this thesis  
The literature review presented above makes it reasonably clear that although 
Blimp1 is a Hh-dependent master regulator of the slow-twitch muscle phenotype, very 
little is known about the mechanism through which it does so.  In this thesis, I will 
discuss the findings I have made towards understanding of the molecular mechanism 
of Blimp1 in the specification of slow muscle fate, which include the understanding of 
its role in transcription regulation and the identification and regulation of its targets 
genes.  
 
The specific aims of this thesis are to address the following questions: 
• How is the Blimp1 protein expressed? Is its activity regulated by cellular 
localization? 
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• Not all cells within the embryo express Blimp1 in respond to Hh signalling.  What 
do somitic mesodermal cells require to express Blimp1 in response to Hh 
signalling? 
• Distinct levels and temporal exposure to Hh signalling results in the specification 
of distinct muscle fates within the developing embryos.  Does the ability of 
somitic myoblasts to respond to Blimp1 change of over time? 
• Presently, only Slow MyHC and Prox1 are used as markers of slow muscle fate.  
What other genes define slow muscle cell identity? 
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Chapter 2  
MATERIALS AND METHODS 
 
2.1 Zebrafish strains and husbandry 
All fish strains used in this study were kept according to established zebrafish 
husbandry protocols in the colony within the Zebrafish Facility at the Institute of 
Molecular and Cell Biology (IMCB), Singapore.  The facility has a controlled 
temperature of 28.5°C and operates a 14-hr light: 10-hr dark light cycle.  Wild-type 
zebrafish line used in this study are of the AB strain and other zebrafish strains, 
smuhi1640 (Chen et al., 2001), ubotp39 (Roy et al., 2001, Baxendale et al., 2004), nrdm805 
(Artinger et al., 1999, Hernadez-Lagunas et al., 2005, Tg(shh::gfp) (Ertzer et al., 
2007) and Tg(acta1::gfp) (Higashijima et al, 1997) have previously been described. 
 
2.2 Micro-injections into zebrafish embryos 
Typically, 1 nl of linearized plasmid DNA (10-25 ng/μl), synthetic mRNA 
(10-100 ng/μl) and morpholino oligonucleotides (2-5 pg) was injected into the animal 
pole of fertilized 1-2 cell stage zebrafish embryos with a gas injector (PLI-100, 
Harvard Apparatus).  Morpholino Oligonucleotides (MO) used in this study were 
purchased from GeneTools LLC. (Philomath, OR, USA) and their sequences are as 
follows:  
blimp1 MO 5’-TGGTGTCATACCTCTTTGGAGTCTG-3’ 
myoD MO 5’-GTTTTTTCTACCTCAACAGCCTATA-3’ 
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2.3 Generation of transgenic zebrafish line 
The stable transgenic heat shock-blimp1-IRES-gfp, Tg(hs::blimp1-IRES-gfp) 
line was generated through the injection of linearized DNA containing the expression 
cassette into zebrafish embryos at 100 ng/μl.  The embryos were raised for 4 months 
to give the F0 pool, and were incrossed to produce F1 embryos.  These F1 embryos 
were given a 1-hr heat at 38°C pulse at 24 hpf and screened for fluorescence from 
green fluorescent protein (GFP) expression after 4 hours the heat pulse was given.  
GFP-positive embryos were raised to give stable F2 transgenic animals.   
 
2.4 Whole mount immunohistochemistry on zebrafish embryos 
Embryos for immunohistochemical analyses were fixed for 2 hr in “Fish Fix” 
containing 4% (w/v) paraformaldehyde (PFA), 4% (w/v) sucrose and 120 μM of 
CaCl2, followed by PBS washes for 2 hr at 30 min intervals before they were being 
stored at -20°C in methanol.  F59 supernatant (used at a 1:10 dilution) contains IgG1 
monoclonal antibody (mAb) that strongly labels zebrafish slow myosin heavy chain 
(slow MyHC) and weakly labels the fast isoform (Devoto et al, 1996).  A4.1025 
(mAb) supernatant that labels all myosin isoforms was used at 1:10 dilution.  These 
antibodies were purchased from Developmental Studies Hybridoma Bank (University 
of Iowa) and rabbit polyclonal anti-Prox1, purchased from Chemicon Inc. (Billerica, 
MA, USA), was used at a dilution of 1:5000.  Alexa555-conjugated goat anti-rabbit 
and Alexa488-conjugated goat anti-mouse antibodies, purchased from Invitrogen 
(Carlsbad, CA, USA), were used at a dilution of 1:500.  Cy3-conjugated anti-rat 
antibody from Jackson ImmunoResearch Inc. (West Grove, PA, USA), kindly 
provided by Dr Yang Xiaohang (IMCB), was used at a dilution of 1:200.  For 
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histochemical staining, the Vectastain Elite kit (Vector Laboratories, Burlingame, 
USA) was used according to the manufacturer’s recommendation.  
 
2.5 Whole mount in situ hybridization 
The steps in this staining protocol were performed at room temperature unless 
specified.  All solutions used for this in situ hybridization (ISH) protocol were treated 
with diethyl pyrocarbonate (DEPC) which involves the addition of thorough mixing 
of 0.1% (v/v) DEPC followed by autoclaving at 121°C for 15 mins.  ISH were 
performed on embryos fixed overnight in Fish Fix at 4°C and subsequently stored in 
methanol.  The embryos were re-hydrated through 50:50 Methanol(MeOH):DEPC-
treated Phosphate Buffer Saline [PBS(DEPC)] and DEPC-treated PBS with 0.1%(v/v) 
Trixton-X [PBT(DEPC)] and post-fixed in Fish Fix for 20 mins followed by 
PBT(DEPC) washes for 20 mins before Proteinase K digestion (10U in 1ml 
PBT(DEPC)) for appropriate amount of time depending on the development stage, 
typically as follows: early-to-mid somitogenesis - 2 mins; 24 hpf - 3 mins; 48 hpf - 8 
mins and 72 hpf - 12 mins.   This was followed by a second post-fix for 20 mins and a 
45-min PBT(DEPC) wash.  The embryos were then pre-hybridized in Hybe A [(65% 
(v/v) formamide, 6.5x DEPC-treated SSC (975 mM sodium chloride, 97.5 mM 
sodium citrate) [SSC(DEPC)], 0.1% (v/v) TritonX-100, 0.1 mg/ml yeast tRNA, 50 
ug/ml heparin and 0.4 mg/ml salmon sperm DNA, adjusted to pH 5.5] for a minimum 
of 4 hrs at 68°C before the digoxigenin (DIG)- and/or fluorescein-labeled ribonucleic 
probes were added and incubated for at least 8hrs at 68°C before washing with five 
20-min washes with Hybe B (65% (v/v) formamide, 6.5x SSC(DEPC), 0.1% (v/v) 
TritonX-100, adjusted to pH 5.5) at 68°C.  The embryos were washed in PBT(DEPC) 
for 30 mins, followed by the addition of 0.5% (w/v) Blocking Reagent dissolved in 
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PBT(DEPC) for 30mins.  Appropriate alkaline phosphotase (AP)-coupled anti-DIG/-
fluorescein antibodies in 0.5% Blocking Reagent was applied overnight at 4°C with 
constant gentle agitation.  Excess antibodies were removed with four 30-min washes 
in PBT(DEPC) and equilibrated with In Situ Staining Buffer (100mM Tris, pH 9.5 , 
50mM MgCl2, 100mM NaCl  and 0.1% TritonX-100) for 20 mins before the addition 
of Nitro Blue Tetrazolium (NBT) and 5-Bromo 4-chloro 3-indolyl phosphate (BCIP) 
to a final concentration of 250 mg/ml and 125 mg/ml respectively.  The staining 
reaction was stopped when desired level of staining was achieved by several rapid 
washes in PBT(DEPC) before storage in Fish Fix.  Embryos for dissection and 
imaging were washed in PBS and cleared in 70% glycerol.  Proteinase K, Blocking 
Reagent and both AP coupled-anti-DIG and anti-fluorescein POD antibodies were 
purchased from Roche (Basel, Switchzerland). 
 
2.5.1 Fluorescent whole mount in situ hybridization 
Fluorescent ISH was carried out on zebrafish embryos to visualize two 
molecular markers simultaneously.  The protocol is essentially the same as described 
above with the following modifications: Peroxidase (POD) coupled-anti-DIG and/or 
anti-fluoroscein antibodies (Roche; Basel, Switzerland) were used to catalyze 
sequential tyramide signal amplification (TSA) reactions with substrates purchased 
from Perkin Elmer (Waltham, MA, USA).  After the completion of the first staining 
reaction, excess substrate was washed off with PBT(DEPC) and the POD was 
inactivated by 1% hydrogen peroxide in methanol.  This was either followed by the 
addition of the second POD-coupled antibody and the development of the second 
staining reaction or fluorescent immnochemical staining (see section 2.4).   
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2.6 Molecular biological techniques 
Standard molecular biological techniques were performed according to 
Maniatis et al. (1982) with reagents purchased from specified manufacturers and used 
according to the instructions and recommendations provided. 
 
2.6.1 Restriction enzyme digests and sub-cloning 
Restriction enzyme digests and other DNA modification techniques were 
performed with enzymes purchased from Roche (Basel, Switzerland), New England 
Biolabs (Ipswich, MA, USA), or Fermentas (Glen Burnie, MD, USA).  Ligation of 
DNA fragments were performed with Rapid Ligation Kit (Roche).  DNA fragments 
were typically resolved in 0.8% agarose gel in 1x TAE buffer (40 mM Tris-HCl, 
13.75%(v/v) acetic acid, 1 mM ethylenediaminetetraacetic acid [EDTA]), pH 8.3).  
Purification of DNA fragments from agarose gel was carried out with the QIAquick 
Gel Extration Kit (QIAGEN, Valencia, CA, USA) according to the manufacturer’s 
protocol. 
 
2.6.2 Plasmid DNA preparation 
Plasmid DNA were prepared from appropriate volumes of bacterial cultures 
(depending on the scale of the preparations) with ion-exchange columns purchased 
from QIAGEN (Valencia, CA, USA) used according to the manufacturer’s protocol. 
 
2.6.3 Quantification of nucleic acid concentration 
Concentrations of double stranded DNA or single stranded RNA were 
quantified using the NanoDrop® ND-1000 UV-Vis Spectrophotometer (Thermo 
Scientific, Wilmington, DE, USA). 
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2.6.4 Extraction of genomic DNA from zebrafish 
Genomic DNA was extracted as described in the Zebrafish Book, and is 
briefly described as follows: A 6-month old female AB zebrafish snapped frozen in 
liquid nitrogen was ground to powder with a mortar and pestle.  The powder was 
mixed with Extraction Buffer (10 mM Tris-HCl pH 8, 100 mM EDTA, pH 8, 0.5% 
SDS and 200 µg/ml Proteinase K) and incubated at 50°C for at least 3 hr with 
occasional gentle swirling.  The solution was subjected to two 
phenol:chloroform:isoamyl alcohol (25:24:1) extractions and the DNA was 
precipitated with 2 volumes of ethanol in the presence of 200 mM NaCl.  The DNA 
was transferred into a tube containing 70% ethanol for 5 mins and allowed to air dry, 
then resuspended in TE buffer (10mM Tris-HCl pH 8, 5 mM EDTA).  DNase-free 
RNase (100 µg/ml) was added to the DNA and incubated at 37°C with occasional 
gentle mixing until the DNA was fully dissolved.  The DNA solution was subjected to 
a final phenol:chloroform:isoamyl alcohol (25:24:1) extraction before it was 
precipitated from the aqueous phase with ethanol in the presence of ammonium 
chloride, followed by two washes in 70% ethanol.  The genomic DNA preparation 
was resuspended in TE buffer and aliquots were frozed at -20°C until required. 
  
 
2.6.5 Small scale extraction of total RNA from zebrafish embryos 
Total RNA was extracted from 30 zebrafish embryos of appropriate 
developmental stages using the RNeasy® Mini Kit (QIAGEN, Valencia, CA, USA) 
following the manufacturer protocol. 
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2.6.6 Preparation of zebrafish cDNA 
Two to five micrograms of RNA and 5 μM of oligo(dT) were mixed, heated to 
65°C for 5 mins and immediately cooled on ice for 1 min.  This was then added to the 
reverse transcription reaction which contains the following components: 1 mM of 
dNTP mix, 1x RT Buffer, 5 mM MgCl2, 10 mM DTT, 40U RNaseOUT and 200U of 
Superscript III reverse transcriptase from Invitrogen (Carlsbad, CA, USA).  The 
reaction was incubated at 50°C for 1hr, followed by 1 min on ice and 5 mins at 85°C 
to terminate the reaction.  RNA template was then removed by digestion with RNase 
H at 37°C for 20 mins.  The cDNA was stored at -20°C till required. 
 
2.6.7 DNA sequencing 
BigDye® Terminator v3.1 Cycle Sequencing Kit (ABI, Foster City, CA, 
USA) was used according to manufacturer’s instructions with the following cycling 
conditions: 
Step Process Temperature (°C) Time (m:sec)  
1. Denaturation 95 1:00  
2. Denaturation 95 0:30 30 cycles 
 Annealing 53 0:20  
 Extension 68 0:30  
3. Final Extension 68 10:00  
4 Storage 16   
 
The products were sent to the DNA Sequencing Facility, IMCB for further 
processing, resolution and base calling. 
 
2.6.8 Extraction of proteins from zebrafish embryos for SDS-PAGE and 
western blot analysis 
Embryos of the appropriate developmental stages were manually 
dechorionated and washed three times with ice-cold PBS.  This was followed by the 
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removal of yolk by pipetting the samples in ice cold PBS with 1 x Complete Protease 
Inhibitor (Roche; Basel, Switzerland) approximately 10 times up and down a yellow 
tip.  Disrupted embryos were centrifuged at 200 x g for 2 min at 4oC and re-suspended 
in ice-cold PBS with Complete Protease Inhibitor.  This was repeated two more times 
to achieve maximal removal of suspended yolk cells.  One microlitre of 2 x Fish Lysis 
Buffer (125 mM Tris-HCl, pH 6.8, 20% (v/v) glycerol, 7% (w/v) sodium 
dodecylsulphate (SDS), 5% (v/v) β-mercaptoethanol) was added per embryo and 
boiled for 5 mins on a 100°C heat block before the addition of equi-volume of 5 x 
SDS Loading Buffer. 
 
2.6.9 SDS Polyacrylamide Gel Electrophoresis (PAGE) and western blot 
Protein samples were resolved with an SDS-PAGE gel in Tris-Glycine 
Running buffer (pH 6.8) with the Protean Mini 3 system (BIO-RAD Laboratories, 
Hercules, CA, USA).  All the reagents required for the composition of the 
polyacrylamide gel were purchased from BIO-RAD, with the exception of TEMED, 
which was purchased from BDH Chemicals Ltd (Poole, UK).  Polyacrylamide 
concentration varies with the molecular weight of protein of interest (10% for GFP 
and 7.5% for Blimp1 or any of its tagged variants).  The SDS-PAGE gels were run at 
constant current (30 mA) for 45 minutes or when the dye front reaches the bottom of 
the gel.  The proteins were transferred to HybondTM-C Extra nitrocellulose membrane 
(GE Healthcare, Uppsala, Sweden) using the Bio-Rad Trans-Blot-SD Semi-Dry 
Electrophoretic Transfer Cell at 20 V for 38 mins.  On completion of the transfer, 
membranes were blocked in 5% non-fat milk (Anlene, New Zealand) dissolved in 
PBST (PBS, 0.1%(v/v) Tween 20) for at least 30 mins before the addition of the 
primary antibody.  The primary antibodies used in this study were the rabbit 
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polyclonal anti-GFP (ab6556, Abcam, Cambridge, UK) and the mouse monoclonal 
anti-HA and anti-actin (A2095 and AC-40 respectively, Sigma-Aldrich, USA) at a 
dilution of 1:1000 pre-blocked in 5% non-fat milk for 30 mins before adding to the 
membrane for 1 hr at room temperature or overnight at 4°C.  After three vigorous 10 
min PBST washes, the appropriate secondary antibodies [1:1000 dilution in 5% non-
fat milk dissolved in PBST of anti-rabbit-HRP or anti-mouse-HRP (RPN4301 and 
RPN4201 respectively from GE Healthcare)] were added and incubated for at least 30 
mins at room temperature.  This was followed by other three vigorous 10 min washes 
with PBST.  Enhanced Chemiluminescent (ECL) substrate (GE Healthcare) was used 
according to the manufacturer’s instructions and the Amersham Hyperfilm ECL (GE 
Healthcare) was used to detect the signal. 
 
2.6.10 Synthesis and purification of antisense riboprobes 
DIG- and fluorescein-labeled antisense riboprobes for in situ hybridization 
were synthesized by in vitro transcription of linear DNA templates with reagents 
purchased from Roche (Basel, Switzerland) and used according to manufacturer’s 
recommendations.  Briefly, 2 μg of plasmid DNA containing the coding region of the 
gene of interest was linearized at the 5’ end with appropriate restriction enzymes.  In 
vitro transcription reactions were carried out at 37°C for 2 hrs and stopped with 45 
mM EDTA (pH 8).  Synthesized riboprobes were purified by precipitation in the 
presence of 250 mM LiCl and ethanol.  RNA pellets were washed once in 70% 
ethanol, air-dried, and re-dissolved in 40 μl of DEPC-treated water.  The list of 
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2.6.11 Synthesis of messenger RNA 
Capped mRNA were synthesized with the mMESSAGE mMACHINE SP6 or 
T7 kit (Ambion Inc., Austin, TX, USA) according to manufacturer’s instructions.  
Briefly, reaction mixtures containing 1 μg of template DNA linearized at the 3’ end of 
the expression cassette, 1 x reaction buffer NTP/CAP mixture and enzyme mix were 
incubated at 37°C for 2 hrs.  The template DNA was removed with DNase I 
(incubated at 37°C for 30mins) and the synthetic mRNA was purified through LiCl 
precipitation at -20°C.  The RNA pellet was washed once with 70% ethanol, dried and 
resuspended in 40 μl of DEPC-treated water. 
 
2.6.12 Polymerase Chain Reaction (PCR) 
2.6.12.1 General Protocol 
DNA primers were purchased from Sigma-Proligo (Singapore).  cDNA from 
zebrafish cDNA library were cloned from PCR amplification using Advantage 2 
DNA Polymerase mix (Clonetech, Mountain View, CA, USA) containing 1 x 
Reaction Buffer, 50 ng of cDNA library, 0.4 μM of each forward (F) and reverse (R) 
primers, 0.5 μM dNTP, and 10U of Advantage II Polymerase with the following 
thermocycling conditions: 
Step Process Temperature  (°C) Time (m:sec)  
1. Denaturation 95 3:00  
2. Denaturation 95 0:30 25 cycles I 
 Annealing Tm – 5 II   
 Extension 68 3:00 III  
3. Final Extension 68 10:00  
4. End / Storage 16   
 
I. The number of cycles for each reaction may vary due to the efficiency of the PCR reaction. 
II. The annealing temperature may vary due to the Tm of the primers, typically between -5 to -8 of the 
calculated Tm. 
III. The extension time may increase for amplification of large fragments. The general guide is 1 min 
per kb of target fragment size. 
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Table 2.1 – List of constructs for antisense RNA probes 
Gene Vector Restriction Enzyme RNA Polymerase 
smyhc1 pSPORT1 EcoRI SP6 
smylc pME18S-FL3 SpeI T7 
tnnc(s) pDNR-LIB - T7 
cmya1 pBK-CMV SalI T7 
cited3 pSPORT1 EcoRI SP6 
mylz2 cDNA pBSK-II(+) BamHI T7 
mylz2-3’UTR pCRII-TOPO NotI SP6 
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The primers for the cloning of the following genes are as follows: 
zgc:66286_F 5’-CAGATTGAATTCACCGCTGAGCAG-3’ 
zgc:66286_R 5’-TCAGCCAGCCATGATGTGCTTTAC-3’ 
mylz2_3’UTR_F  5’-GAATCAAGAAAACGAAGAGAAG-3’ 
mylz2_3’UTR_R 5’-TTAGTCAACCACCAGAGGAGG-3’ 
 
2.6.12.2 Amplification of genomic DNA fragments 
Genomic DNA fragments were cloned from PCR amplification using 
Advantage 2 DNA Polymerase mix (Clonetech) containing 1x Reaction Buffer, 10 ng 
of genomic DNA, 0.4 μM of each forward (F) and reverse (R) primers, 0.5 μM dNTP, 
2% DMSO and 10U of Advantage II Polymerase with the following thermocycling 
conditions: 
Step Process Temperature (°C) Time (m:sec)  
1. Denaturation 95 3:00  
2. Denaturation 95 0:30 25 cycles I 
 Extension 68 3:00 II  
3. Final Extension 68 10:00  
4. End / Storage 16   
 
I. The number of cycles for each reaction may vary due to the efficiency of the PCR reaction. 
II. The extension time may increase for amplification of large fragments. The general guide is 1 min 
per kb of target fragment size. 
 
The primers used for the amplification of the smyhc1 and mylz2 promoters are listed 
below: 
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2.6.12.3 Site-Directed Mutagenesis (SDM) 
The Stratagene (QuikChange® II XL Site-Directed Mutagenesis Kit) was used 
to generate site-specific mutations in double-stranded plasmid.  SDM was achieved 
through PCR amplification of plasmid DNA with target mutations in overlapping 
forward and reverse primers using Pfu Ultra (Stratagene) high-fidelity DNA 
polymerase.  A typical reaction contains the following constituents: 1 × reaction 
buffer, 100 ng of template plasmid DNA, 0.4 μM each of the forward and reverse 
primer, 0.5 μM dNTP and 2.5U of Pfu Ultra HF DNA polymerase.  The cycling 
parameters for Pfu Ultra HF DNA polymerase SDM were as follows: 
Step Process Temperature (°C) Time (m:sec)  
1. Denaturation 95 3:00  
2. Denaturation 95 0:30 25 cycles i 
 Annealing Tm – 5 ii   
 Extension 68 3:00 iii  
3. Final Extension 68 10:00  
4.  End / Storage 16   
 
I. The number of cycles for each reaction may vary due to the efficiency of the PCR reaction. 
II. The annealing temperature may vary due to the Tm of the primers, typically between -5 to -8 of the 
calculated Tm. 
III. The extension time may increase for amplification of large fragments. The general guide is 1 min 
per kb of target fragment size 
 







mylz2_SDM2_F  5’-CATAGTTTTTCCTCGAGCTCTCTCGGTCTGCT-3’ 
mylz2_SDM2_R 5’-AGCAGACCGAGAGAGCTCGAGGAAAAACTATG-3’ 
mylz2_SDM3_F  5’-CTTAAGCCTCAAAGGGCCCTTCATGAGGGTCC-3’ 
mylz2_SDM3_R 5’-GGACCCTCATGAAGGGCCCTTTGAGGCTTAAG-3’ 
 














2.7 Synthesis of Recombinant Protein and Purification 
2.7.1 Design of immunogen of raising Blimp1 antibody 
The Blimp1 protein sequence was analyzed with the DNASTAR Protean 
Software 6.0 for regions of high surface probability and antigenicity. 
 
2.7.2 Cloning of the GST-Blimp1(aa90-309) overexpression vector  
A 642 bp fragment of blimp1 cDNA encoding the immunogen flanked by the 
restriction enzyme sites DraI and SmaI was cloned into the blunted EcoRI site of the 
vector pGEX4T-1 (Pharmacia, now a division of GE Life Sciences, Uppsala, 
Sweden). The vector was the kind gift from Dr. Yu Fengwei, Temasek Lifesciences 
Laboratory, Singapore.  This approach would result in the expression of a chimeric 
protein where GST is fused to amino acid residues 90-309 of zebrafish Blimp1. 
 
2.7.3 Overexpression and purification of the immunogen GST-Blimp1(aa90-
309) 
The plasmid pGEX4T-Blimp1(aa90-309) was freshly transformed into E. coli 
BL21(DE3) cells and plated on nutrient agar plates containing 50 µg/ml of ampicillin.  
Single colonies were picked and inoculated into a 50 ml Luria Broth (LB) containing 
ampicillin (50 µg/ml) and cultured in a shaking incubator overnight at 37°C.  Twenty 
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milliliters of the overnight culture was inoculated into two baffled flasks each 
containing 800 ml of LB and ampicillin (50 µg/ml) and incubated in a shaking 
incubator for approximately 2.5 hrs by which point the OD600 should be between 0.6 – 
0.7.  IPTG (final concentration 0.5 mM) was added to the cultures before shaking for 
4 hrs.  The bacterial cell culture was centrifuged at 1,500 x g at 4°C and washed with 
cold PBS and re-suspended in Sonication buffer.  The bacterial cells were lysed by 
sonication with a Misonix Sonicator 3000 using 18 x 10 sec pulses at power setting 3 
with 30 secs break between the pulses.   The cell debris was separated from the 
supernatant by centrifugation (20,000 x g, 30 mins at 4°C).  The supernatant was 
applied to glutathione-sepharose beads (GE Healthcare, Uppsala, Sweden) that were 
prepared according to the manufacturer’s instructions and incubated on a rotating 
platform overnight at 4°C.  The supernatant was removed and the beads were 
subjected to three High-salt and three Low-salt washes before the protein was eluted 
with 50 mM reduced glutathione dissolved in 10 mM Tris-HCl (pH 8.0).  Samples 
taken along the purification process were resolved by SDS PAGE and visualized with 
Coomassie Blue staining.  
 
2.8 Blimp1 “knock-down” mircroarray experiment 
The microarray experiment was performed by Dr. Sinnakaruppan Mathanvan 
and his team at the Genome Institute of Singapore (GIS) with the same protocol as 
described in Mathavan et al. (2005) with the exception of the RNA samples, which 
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2.8.1 Preparation of total RNA 
Total RNA was extracted from wild-type and blimp1 moprholino-injected 12 
somite-stage embryos with the protocol as follows: Embryos, manually dechorionated 
with a pair of watch-maker’s forceps and rinsed in PBS, were snap frozen with liquid 
nitrogen.  Approximately 200 frozen embryos were crushed with ice-cold mortar and 
pestle in approximately 600 μl of Trizol reagent (Gibco BRL, Maryland, USA).  This 
was followed by phenol:chloroform:isoamyl alcohol (25:24:1) extraction, then 
chloroform extraction.  The RNA was precipitated in isopropanol, followed by two 
washes in 70% ethanol and re-dissolved in 55 μl of nuclease-free water.   
 
2.9 Chromatin Immunoprecipitation (ChIP) of Blimp1HA 
2.9.1 Preparation of embryos for ChIP 
Wild-type zebrafish embryos were injected with hs-blimp1HA-IRES-gfp (15 
ng/μl) flanked by Tol2 sites and 10 ng/μl of Tol2 transposase mRNA and grown at 
28.5°C.  The embryos were transferred to 38°C for 1 hr when they reached 6-8 somite 
stage and returned to 28.5°C for 3 hrs before they were manually dechorionated and 
fixed for 15 mins with 1.9% (w/w) formaldehyde solution for 15 mins at room 
temperature.  This cross linking reaction was stopped with the addition of glycine 
solution to a final concentration of 125 mM and incubated for 5 mins at room 
temperature.  This was followed by three rinses with ice cold PBS before the embryos 
were snap frozen with liquid nitrogen and stored at -80°C until required. 
 
2.9.2 Extraction of Nucleus from zebrafish embryos 
Five hundred fixed and snap frozen embryos were thawed on ice, 
homogenized with pestle in 1100 μl of Cell Lysis Buffer [10 mM Tris-HCl (pH 7.5), 
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10 mM NaCl, 0.5% IGEPAL and Complete Protease Inhibitor (Roche)] and left on 
ice for 15 mins.  Complete lysis of the embryonic extract was ensured by pipetting 15 
times up and down a yellow tip.  The extract was centrifuged at 1200 x g for 5 mins at 
4°C to pellet the nuclei.  The supernatant, which was the cytoplasmic fraction (CY) 
was kept for analysis; the nuclei pellet was resuspended in 220 μl of Nuclear Lysis 
Buffer (50 mM Tris-HCl (pH 7.5), 10 mM EDTA, 1% SDS and Complete Protease 
Inhibitor) and incubated on ice for 10 mins (20 μl of the suspension, labeled NU, was 
kept for analysis). 
 
2.9.3 Sonication of protein-chromatin complexes 
The nuclei suspension, set in an ice bath, was subjected to three 10-second 
pulses of sonication with a Misonix Sonicator 3000 at power output set at 10.5 – 11% 
with 30 sec “off-time” between the pulses.  Eighty microlitres of 10% Triton-X was 
added to the nuclei suspension and the samples were centrifuged at 20,000 x g to 
remove precipitated matter in the sonicated nuclei suspension. 
 
2.9.4 Preparation of beads for pre-clearing and immunoprecipitation 
Twenty microlitres of Protein G-coupled Dynabeads (Invitrogen, Carlsbad, 
CA, USA) were washed in 1 ml fresh Bovine Serum Albumin (BSA)/PBS and 
collected by spinning at 3,000 revolutions per minute (rpm) for 3 mins.  This was 
followed by two more washes of the beads in 1ml of BSA/PBS, collecting the beads 
with the magnet (2 mins).  The rabbit polyclonal anti-V5 antibody (ab15828, Abcam, 
Cambridge, UK) was used for pre-clearing of the sonicated nuclei extract, while the 
rabbit polyclonal anti-HA and anti-GFP antibody (ab9110 and ab6556, respectively, 
Abcam) was used for the pull down and negative control respectively. 
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2.9.5 Chromatin Immunoprecipitation (ChIP) 
Two hundred microlitres of the sonicated nuclei extract was set aside for 
Sonicated Input (SI) which represents total sonicated DNA, while the remainder of 
the sample was pre-cleared in anti-V5 bound Dynabeads overnight on a rotating 
platform at 4°C.  The supernatant was then split into two equal aliquots and added to 
anti-HA or anti-GFP bound Dynabeads overnight on a rotating platform at 4°C.  The 
beads were subjected to eight 2- min washes with RIPA buffer (50 mM Hepes (pH 
7.6), 1 mM EDTA, 0.7% DOC, 1% IGEPAL and 0.5 M LiCl).  Immunoprecipitated 
chromatin-protein complexes were subjected to two elution steps – first with 1 mg/ml 
3x HA peptide solution (synthesized by 1st BASE, Singapore) dissolved in 50mM 
Tris-HCl pH 8.0, followed by incubation with Elution buffer (50 mM Tris-HC,l pH 
8.0, 10 mM EDTA and 1% SDS) at 65°C for 15 mins.  
 
2.9.6 Processing of ChIP DNA samples 
The sonicated ChIP samples were incubated at 65°C overnight to reverse the 
cross-links between chromatin and protein. Following RNase A and Proteinase K 
treatment (Roche, Basel, Switzerland), the chromatin was purified through 
phenol:chloroform:iso-amylalchol (25:24:1) extraction and precipitated with 
isopropanol in the presence of 20 μg of glycogen and 0.3 M sodium acetate.  SI and 
the other two ChIP DNA samples (anti-HA and anti-GFP negative control) from the 
second elution were amplified through linker-mediated PCR and used for analysis.  In 
order to ligate double stranded DNA linkers to the ChIP DNA samples, they were first 
blunted with T4 DNA polymerase (Fermentas, Glen Burnie, MD, USA).  The reaction 
mixtures for the blunting reaction consist of the entire ChIP DNA sample, 1x T4 
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DNA pol buffer, 0.5 μg BSA, 100 μM dNTP mix, and 2.5U of T4 polymerase in a 
volume of 110 μl.  After 20 mins at 12°C, the DNA samples were precipitated with 
ethanol in the presence of 92 mM sodium acetate (NaOAc) and 10 μg of glycogen.  
The blunt-end ChIP DNA samples were ligated to the linker DNA which was the 
annealing product of the two single-stranded DNA oligonucleotides: 
Ligation_linker_F 5’-GCGGTGACCCGGGAGATCTGAATTC-3’ and 
Ligation_linker_R 5’-GAATTCAGATC-3’.  The ligation mixtures which consist of 
the blunt DNA samples, 1x ligation buffer, 130 ng of the ligation linkers and 5U of T4 
DNA ligase, were incubated overnight at 12°C and purified by precipitation with 
NaOAc and ethanol.   
 
2.9.7 Amplification of ChIP DNA samples 
PCR reaction mixes were prepared from the sample pellets from the ligation 
reactions.  Each PCR reaction mix contained 1x Advantage 2 PCR buffer, 1 μM of 
Ligation_linker_F and 0.25 μM dNTP mix and Advantage 2 polymerase mix 
(Clontech, Mountain View, CA, USA) and the sample DNA were amplified under the 
following thermocycling conditions: 





1.  55 4:00  
2.  72 3:00  
3. Denaturation 95 3:00  
4. Denaturation 95 0:30 15 cycles 
 Annealing 60   
 Extension 68 3:00  
5.  Final Extension 68 10:00  
6. End / Storage 16   
 
Each DNA sample was further expanded through another round of 25-cycle 
PCR amplification with 5 μl from the first amplification reaction as template.  The 
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ChIP experiment was independently performed three times in order to ensure 
consistency of results.  
 
2.9.8 PCR Analysis of ChIP DNA 
The ChIP DNA samples were analyzed with PCR in a 25 μl reaction 
containing 0.25 μl of template DNA, 1x PCR buffer, 5%(v/v) DMSO, 0.5 μg BSA, 40 
μM dNTP, 0.4 μM each of sequence specific primers (see below) and 5U of Taq 
polymerase (Fermentas, Glen Burnie, MD, USA) using the following cycling 
parameters: 





1. Denaturation 95 3:00  
2. Denaturation 95 0:30 28 cycles 
 Annealing 55.5   
 Extension 68 3:00  
3. Final Extension 68 10:00  
4. End / Storage 16   
 
The sequences of oligonucleotide primers used for the detection of mylz2 promoter 










The sequences of oligonucleotide primers used for the detection of smhc1 promoter regions 












Primer sequences for the β-actin1 gene used as a control are as follows: 
β-actin1_I_F  5’-CCTTGAAGCCATTAGCCTAGC-3’ 
β-actin1_I_R  5’-CAAAGCAGGGGATACAAAACA-3’ 
β-actin1_II_F  5’-TCTGCAGCTTTACATCCATGA-3’ 
β-actin1_II_R  5’-TTGACAGCTAGTTGAAAACGACTC-3’ 
 
The PCR products were resolved by electrophoresis through 2% agarose gel at 60V 
for 38 mins in 1x TAE buffer. 
 
2.10 Statistical analyses 
All the experiments had a minimum sample size of 25 embryos, were 
conducted at least twice to ensure that the results can be replicated.  Two-way 
ANOVA analyses and calculation of p-values were performed with GraphPad Prism4 
software. 
 
2.11 Imaging, image processing and figure compilation 
DIC images were captured with SONY DXM1200 digital camera mounted on 
a Zeiss Axioskop compound microscope.  Confocal Microscopy was performed with 
Zeiss LSM510.  Images of zebrafish embryos were taken at 40x magnification unless 
otherwise specified.  Images were processed with Adobe Photoshop CS3 to maintain 
consistency in the orientation of the embryos.  Figures were prepared with Adobe 
Illustrator CS3. 
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CHAPTER 3 




Blimp1 has previously been established as the master regulator of slow muscle 
fate in zebrafish embryos (Roy et al., 2001, Baxendale et al., 2004).  The development 
of slow muscle fibres is a finely choreographed process which begins with the 
positioning of slow muscle precursors at the adaxial position during gastrulation and 
neurulation.   This exposes adaxial cells to Hh signalling from axial structures and 
induces the expression of the myogenic regulatory factor MyoD.  This specifies 
adaxial cells as the first myoblasts in the zebrafish embryo (Weinberg et al., 1996, 
Coutelle et al., 2001).  The adaxial cells subsequently express blimp1 and become 
differentiated into slow muscle fibres (Baxendale et al. 2004).   Beyond this, little is 
known about how Blimp1 functions in slow myogenesis. 
 
It has been previously shown that the expression of blimp1 in the slow muscle 
precursors is dynamic and transient; blimp1 transcripts are first detected in the adaxial 
cells soon after gastrulation (9 hpf) and recede in the anterior somites by 18 hpf 
(Baxendale et al., 2004).  In addition, adaxial expression of blimp1 is dependent on 
Hh signalling and ubiquitous up-regulation of Hh signalling throughout the embryo 
leads to the expansion of blimp1 expression in all the somitic myoblasts in the 
paraxial mesoderm.  This suggests that the expression of blimp1 may not solely 
depend on Hh signalling from the notochord, but may also require the activity of 
additional factor(s) that are present in the paraxial mesoderm.   
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The ability of adaxial cells to respond to Hh signalling does not persist 
throughout development.  Through the use of cyclopamine, a plant alkaloid that 
inhibits the transduction of Hh signal through the inhibition of Smo activity (Chen et 
al., 2001), it was shown that the formation of the various muscle lineages, particularly 
the muscle pioneers and surface slow fibres, require Hh signalling (Wolff et al., 
2003).  It was also shown that adaxial cells remain responsive to Hh signalling within 
a six hour window after gastrulation (Hirsinger et al., 2004).  Since Blimp1 is a 
critical determinant of slow muscle development, it would be interesting to investigate 
whether the ability of the somitic cells to respond to Blimp1 and activate the slow 
myogenic program changes with developmental time, and if so, to what extent.   
 
In this chapter, I will present the findings of my investigations into the 
dynamics of Blimp1 expression in relation to slow muscle development and the 
requirement of additional factor(s) that are required for blimp1 expression in the 
adaxial cells.  In addition, I will describe how the ability of myoblasts to respond to 
Blimp1 activity changes with time. 
 
3.2 Results 
3.2.1 Generation of an anti-Blimp1 antibody 
Although the spatial and temporal expression pattern of the blimp1 transcript 
has been described (Baxendale et al., 2004, Hernadez-Lagunas et al., 2005, Wilm and 
Solnica-Krezel, 2005), the cellular localization and perdurance of Blimp1 protein has 
not been characterized.  Currently, there are no commercially available antibodies that 
can recognize the zebrafish homolog of Blimp1.  The mouse monoclonal antibody 
3H2E8 that was raised against amino acid residues 199-409 of mouse Blimp1 cannot 
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recognize the zebrafish protein (data not shown).  Although this region of mouse 
Blimp1 contains regions that show high levels of similarity with zebrafish Blimp1 
(Fig. 1.6), the epitope recognized by 3H2E8 appears to be absent in zebrafish Blimp1. 
 
In order to raise an antibody against the zebrafish Blimp1 protein, we analyzed 
the amino acid sequence to determine the optimal region for the generation of the 
antibody.  This region must be located at the surface of the protein so that it can be 
easily accessed by the antibodies and it must contain a sequence sufficiently unique to 
avoid cross-reactivity of the antibodies with other proteins.  The region between 
amino acid residues 90–309 was chosen as it is predicted to have a high surface 
probability, as indicated by the high immunogenic index (Fig. 3.1A).  To ensure that 
the antibody generated would be specific to Blimp1, we compared the amino acid 
sequence of this region of Blimp1 through a BLAST search against the Ensembl 
zebrafish peptide database.  The results indicated that this sequence does not show 
any significant similarities to any other known proteins.   
 
The region consisting of residues 90-309 of Blimp1 was selected for the 
generation of the anti-Blimp1 antibody.  This region of the protein spans part of the 
SET domain and part of the proline rich region (Fig. 1.5).  Examination of available 
restriction enzyme sites revealed DraI and SmaI flank the corresponding coding 
region of the blimp1 cDNA.  This fragment was cloned in frame and downstream of 
the Glutathione S-Transferase (GST) cDNA to create a chimeric protein with an N-
terminal GST protein fused to amino acid residues 90-309 of zebrafish Blimp1 at the 
C-terminus.  The GST tag was chosen to facilitate affinity purification of the 
recombinant protein using sepharose-gluthatione beads. 




Fig 3.1.  Design and Purification of the GST-Blimp1(aa90-309) immunogen.   
(A) The Jameson-Wolf antigenic index calculated by the Protean 6.0 (DNASTAR) 
software aligned with the schematic representation of zebrafish Blimp1 protein. This 
region spans the SET domain and part of the proline rich region.  (B) SDS-PAGE of 
the purification process of recombinant GST-Blimp1(aa90-309) that has a predicted 
molecular weight of 49 KDa, denoted by the arrowhead.  (C) Detection of over-
expressed Blimp1 protein by the pre-adsorbed serum (1:10,000). (D) Detection of 
endogenous Blimp1 expression in a dorsally mounted 12-somite zebrafish embryo 
after affinity purification of the serum. Scale bar = 25 μm.  The scale bar in C applies 
to D. 
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The recombinant protein was purified by affinity purification (Fig. 3.1B) and 
injected into rats to raise antibodies.  Serum was obtained from the rats after 8 boosts 
over a 24 week period.  The pre-adsorbed serum (at a dilution of 1:10,000) reacted 
with Blimp1 over-expressed with the heat-inducible promoter in whole mount 
antibody staining (Fig 3.1C), but I did not detect endogenous Blimp1 protein (data not 
shown).  After enrichment by affinity purification, the antibody could be used to 
detect endogenous Blimp1 in the adaxial cells of a 14 hpf wild-type embryo (Fig. 
3.1D). 
 
3.2.2 Blimp1 is localized to nuclei of adaxial cells  
It has been previously shown that blimp1 mRNA accumulates in the 
progenitors of the slow muscle cells from the end of gastrulation (9 hpf) (Baxendale et 
al., 2004).  This expression is transient; at around 18 hpf, as slow muscle cells initiate 
their radial migration to the lateral edge of the myotome, the level of blimp1 
transcripts rapidly decreases in the more mature anterior somites.  By 24 hpf, blimp1 
transcripts are completely absent in the differentiated surface slow fibres.  Like 
blimp1 mRNA, we observed Blimp1 protein expression in the adaxial cells at around 
the same time (9 hpf) (Fig. 3.2A, arrows).  By 12 hpf, when approximately 5-6 
somites have formed, nuclear localized Blimp1 protein is detected in both the adaxial 
cells in the somitic region, as well as in the adaxial cells of the presomitic mesoderm  
(Figs. 3.2B, C).  At 18 hpf, Blimp1 protein levels begin to decline in the 
differentiating slow fibres in the anterior somites (Fig. 3.2D), while slow fibres in the 
more posterior somites and the outgrowing tail-bud continue to express substantial 
levels of the protein (Figs. 3.2E, F).  We have demonstrated earlier that the pan slow 
lineage-specific differentiation markers slow MyHC and the homeodomain protein  
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Fig. 3.2.  Expression of Blimp1 protein precedes the onset of slow muscle 
differentiation.  (A-C) Blimp1 (red) is expressed and localized in the nuclei of 
adaxial cells (arrows) of 14 hpf zebrafish embryos labeled with GFP from the 
actin::gfp transgene. Blimp1 expression (red) in the adaxial cell nuclei in the somites 
(B) and presomitic mesoderm (C).  (D-F) Blimp1 protein recedes in the more anterior 
somites (D, E) and is stronger in the newly formed posterior somites (F) in 18 hpf 
wild-type embryos.  (G-I) Double staining of Blimp1 (red) and Prox1 (green) reveals 
reduced levels of Blimp1 in anterior somites (G) where Prox1 is highly expressed, 
while Prox1 is barely detectable in cells of posterior somites (I), where Blimp1 is 
strongest.  Nuclei in panel A are stained with DAPI (blue). In panels A-C, “N” marks 
the position of the notochord.  Panel A depicts transverse section; panels B, C depict 
flat mounted embryos; panels D-I show laterally mounted embryos. In this and 
subsequent figures, all laterally and flat mounted embryos are oriented anterior to the 
left; dorsal is on top for embryos depicted in transverse sections. Scale bar = 25 μm.  
The scale bar in B applies to C; the scale bar in D applies to D–I. 
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Prox1 are activated sequentially in the differentiating slow muscle cells, with the 
expression of slow MyHC preceding the onset of Prox1 (Wolff et al., 2003).  Staining 
of zebrafish embryos with anti-Prox1 as well as anti-Blimp1 antibodies revealed that 
the two proteins were co-expressed only in the slow muscle precursors in the more 
anterior somites (Figs. 3.2G-I), indicating that Prox1 expression is turned on 
subsequent to Blimp1 expression.  Likewise, since slow MyHC expression can be first 
observed in slow myoblasts around 12 hpf, we conclude that Blimp1 is the first 
lineage-specific marker to be activated in slow myoblasts, well before the 
establishment of slow muscle-specific differentiation gene expression. 
 
3.2.3 Blimp1 expression is dependent on Hh signalling 
The current model of regulation of blimp1 expression in prospective slow 
muscle precursors is that the gene is a target of Hh signaling activity (Baxendale et 
al., 2004; Roy et al., 2001).  This notion is supported by two lines of evidence.  First, 
embryos defective in Hh signaling fail to activate blimp1 transcription in the adaxial 
cells.  Second, ectopic activation of the Hh pathway results in ectopic expression of 
blimp1 in all somitic myoblasts.  Consistent with this, we found that the expression of 
Blimp1 protein in slow muscle precursors respond in a similar fashion to the loss and 
gain of Hh function (Figs. 3.3A-C).  However, the fact that Hh signaling, even when 
ubiquitously activated, is only capable of inducing blimp1 expression in somitic 
myoblasts (Baxendale et al., 2004) suggests that the context of the cell-type is 
important for blimp1 induction. We, thus hypothesize that Hh can only induce blimp1 
expression in the somitic cells after they have been committed to the myogenic fate.  
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Fig. 3.3.  Blimp1 expression is dependent on Hh signalling.  (A) Adaxial 
expression of Blimp1 (red) in a wild-type 14 hpf embryo immediately adjacent to the 
notochord (green, highlighted by GFP expression from the shh::gfp transgene).  (B) 
Blimp1 expression is absent in a 14 hpf smo mutant embryo deficient in Hh 
signalling.  (C) Ectopic expression of Blimp1 is induced throughout the somites by 
constitutive activation of the Hh signaling pathway in response to dominant negative 
Protein Kinase A mis-expression in a 14 hpf wild-type embryo.  Panels A-C depict 
flat mounted embryos and nuclei are stained with DAPI (blue). “N” marks the 
position of the notochord.  Scale bar=25 μm. 
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3.2.4 Induction of blimp1 expression by Hh signaling in presumptive slow 
muscle precursors requires their prior commitment to the myogenic fate 
To examine this hypothesis further, we monitored the transcription of blimp1 
in embryos injected with antisense morpholino oligonucleotides against myoD and 
myf5, genes whose activities are essential for cells to commit to the myogenic fate.  
Like MyoD and Myf5 double mutant mice, which lack most skeletal muscle 
precursors (Rudnicki et al., 1993), myoD and myf5 morphant zebrafish embryos show 
very little differentiated muscle within their somites (Figs. 3.4A, B; see also 
Hammond et al., 2007, Maves et al., 2003).  The expression of the universal Hh target 
gene patched1 (ptc1), which is normally activated in the adaxial slow muscle 
precursors (Concordet et al., 1996), is unaffected in the morphants (Fig. 3.4C).  
Therefore, the transduction of Hh signaling is not compromised in the absence of 
MyoD and Myf5 function.  Moreover, adaxial cells also expressed wild-type levels of 
the myoD transcript (Fig. 3.4D), confirming that antisense morpholinos block protein 
expression but not the transcription of their target mRNAs.  Expression of blimp1, 
however, was not observed in adaxial cells of the morphant embryos (Figs. 3.4E-I), 
supporting the view that somitic mesodermal cells must first be committed to 
myogenesis before they can initiate blimp1 expression in response to Hh activity. 
 
 
3.2.5 Competence of somitic myoblasts to respond to Blimp1 and adopt slow-
twitch fate changes as a function of time 
We have generated a stable transgenic zebrafish strain that carries a transgene 
with a heat inducible promoter driving the expression of the zebrafish blimp1 cDNA 
(hs::blimp1-IRES-gfp) (Fig. 3.5A).  When embryos derived from this strain are 
exposed to heat shock (38°C for 1 hr), high and ubiquitous expression of the Blimp1  
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Fig. 3.4.  Induction of blimp1 expression by Hh signalling in presumptive slow muscle 
precursors requires their prior commitment to the myogenic fate. (A) mAb A4.1025 
staining for all MyHC in a 24 hpf wild-type embryo. (B) mAb A4.1025 staining of a myoD; 
myf5 double morphant embryo showing few differentiated muscles within the somites at 24 
hpf (arrow). (C) myoD; myf5 double morphant embryos retain functional Hh signaling as 
demonstrated by normal expression of the Hh target genes ptc1 (C) and myoD (D) in adaxial 
cells. (E, H) Wild-type embryos showing blimp1 expression in the adaxial cells (arrowheads) 
and the neuro-ectodermal border (arrows). (F) blimp1 is not expressed in the adaxial cells of 
smo mutant embryos. (G, I) blimp1 expression is specifically lost from adaxial cells in myoD; 
myf5 morphants while it appears unaffected in the neuro-ectodermal border (arrows). Panels 
A and B depict lateral views; C-I depict dorsal views of 11 hpf embryos. C, D, H, I depict 
flat-mounts; E-G depict whole mounts.  Scale bars=25 μm in A and C, and 100 μm in E. The 
scale bar in A applies to B; the scale bar in C applies to D, H and I and the scale bar in E 
applies to F and G. 
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Fig. 3.5.  Generation of the transgenic line Tg(hs::blimp1-IRES-gfp) (A) The 
schematic diagram of the linearized hs::blimp1-IRES-gfp expression cassette that was 
injected into wild-type embryos to generate transgenic embryos. (B) High level of 
Blimp1 protein expression (arrows) throughout the myotome in a heat induced 
Tg(hs::blimp1-IRES-gfp) transgenic embryo.  (C) The number of slow fibes in wild-
type (open bars) and un-induced Tg(hs::blimp1-IRES-gfp) embryos (black bars) 
plotted against the somite number reveal that the number of slow fibres do not differ 
between the two strains.  (D) Table showing the number of slow fibres corresponding 
chart in panel C.  Scale bars=25 μm. 
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protein is observed in the transgenic embryos (Fig. 3.5B).  Control transgenic 
embryos that were not subjected to heat shock develop normally and do not show any 
aberrations in the number of slow fibres (Fig. 3.5C, D).  Using this temporal control 
of Blimp1 expression, we assessed whether the ability of the somitic cells to respond 
to the protein and activate the slow myogenic program changed with time, and to 
what extent.  The process of somitogenesis progresses in an anterior to posterior 
direction over a period of about 14 hours.  By scoring the number of slow muscle 
fibres in somites 5 to 11, we are able to observe the effects of ectopic Blimp1 on 
somitic myoblast at different stages of maturation.  We found that induction of the 
transgene during early somitogenesis, at 10 hpf, resulted in a marginal increase in the 
number of slow-twitch fibers as assayed by the expression of definitive differentiation 
markers of the slow lineage, slow MyHC and Prox1 in somites 5 to 7 (Figs. 3.6A, B, 
K).  There was also an observable decrease in the number of slow fibres in somites 10 
and 11 (Figs. 3.6C, K), while there was no significant difference in the number of 
slow fibres in somites 8 and 9 (Fig. 3,6K) 
 
By contrast, induction of the transgene at 14 hpf results in a marked increase 
in the number of slow muscle fibres, which fill up most of the myotome, by 24 hpf 
(Figs. 3.6F, G, c.f. Fig. 3.6D, E, and Fig. 3.6L).  With a later heat shock at 18 hpf, we  
observed no supernumerary slow fibers, in comparison to untreated control siblings 
(Figs. 3.6H c.f. Fig. 3.6D and Fig. 3.6M); consistent with this lack of increase in slow 
muscle numbers, a substantial amount of fast-twitch muscle differentiated in these 
embryos (Figs. 3.6I).  Closer inspection revealed that although these fast fibers are 
multinucleated like wild-type fast muscles and expressed fast muscle-specific 
differentiation genes, intriguingly, they also expressed Prox1, a slow marker, in their  
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Fig. 3.6. Competence of somitic myoblasts to respond to Blimp1 and adopt the 
slow fate changes as a function of time.  (A) Somites 5-7 of a 24 hpf Tg(hs::blimp1-
IRES-gfp) embryo that did not receive a heat pulse. Slow MyHC is shown in green 
and Prox1 in red.  S7 denotes somite 7 (also in panels B, D and H).  (B) Somites 5-7 
of a 24 hpf Tg(hs::blimp1-IRES-gfp) embryo that received a heat pulse at 10 hpf 
showed a slight increase in the number of superficial slow fibers (SSFs)(cf. panel A). 
(C) Somites 9 to 11 of a 24 hpf Tg(hs::blimp1-IRES-gfp) embryo that received a heat 
pulse at 10 hpf showing a gap (arrow) in the layer of SSFs that accounts for the 
reduction in comparison to non-induced clutch mates. S9 denotes somite 9.  (D) SSFs 
in an uninduced 24 hpf Tg(hs::blimp1-IRES-gfp) embryo. S7 denotes somite 7.  (E) 
Expression of slow myhc1 mRNA (green) and mylz2 mRNA (red) in an uninduced 
Tg(hs::blimp1-IRES-gfp) embryo.  (F) Induction of ectopic Blimp1 expression in 
Tg(hs::blimp1-IRES-gfp) embryos at 14 hpf results in an increase in the number of 
SSFs.  (G) The supernumerary slow fibres (green) form at the expense of fast muscle 
fibers (red) (cf. panel E).  In both panels, the section was taken at the level of somite 9 
and the position of the notochord marked with “N”.  (H) Late induction of the blimp1 
transgene (at 18 hpf) did not result in significant differences in the number of SSFs 
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(slow MyHC, green; Prox1, red) compared to an untreated embryo (cf. panel D).  (I) 
The slow muscle marker Prox1 (red, white arrows) is ectopically induced in multi-
nucleated fast fibers (expressing Fast myosin light chain, cyan) by induction of the 
blimp1 transgene at 18hpf.  (J) smyhc1 is not ectopically induced in embryos that 
received  a late induction of the blimp1 transgene at 18hpf.  (K-M) The numbers of 
SSFs in somites 5–11 of Tg(hs::blimp1-IRES-gfp) embryos were scored and 
presented as bar charts for blimp1 induction at 10 hpf (K), 14 hpf (L) and 18 hpf (M). 
There are significant differences in the number of slow fibers in somites 5-7 with 
induction of blimp1 at 10 hpf (p<0.05, n=12). More myoblasts were responsive to 
Blimp1 activity at 14 hpf resulting in a more significant increase in the number of 
SSFs (p<0.01, n=12).  Induction of blimp1 at 18 hpf did not result in significant 
changes in the number of SSFs (n=15).  The error bars represent the standard error of 
mean (S.E.M), ** represents p-value<0.01 and * represents p-value<0.05.  Panels A–
D, F, H and I depict lateral views; panels E, G and H depict transverse sections.  Scale 
bars=25 μm. The scale bar in A applies to B-D, F, H and J and the scale bar in E 
applies to G and I. 
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nuclei (Figs. 3.6J).  However, expression of smyhc1 was not apparent in these cells 
(Fig. 3.6I).  Together, these results reveal that as the fast muscle precursors proceed 
through the myogenic pathway, their competence to respond to Blimp1 activity and 
initiate the slow muscle-specific program of differentiation is gradually attained, and 
then progressively lost. 
 
3.3 Discussion 
3.3.1 Blimp1 is localized in the nuclei of adaxial cell and it is the first molecular 
marker of the slow muscle lineage 
Immunohistochemical staining with the anti-Blimp1 antibody clearly showed 
that Blimp1 is localized in the nuclei of adaxial cells.  The expression of Blimp1 is 
dynamic and transient, and its perdurance does not differ significantly from its 
transcript.  Its expression preceeds slow muscle markers, slow MyHC and Prox1, and 
thus represents the first molecular marker of the slow muscle lineage.  We observed 
that Blimp1 is present in each adaxial cell for about 8 hours.  This brief period of 
Blimp1 protein expression in the slow muscle cells suggests that the protein functions 
as an epigenetic switch, whereby transient exposure of target promoters to the 
transcription factor is adequate for instituting stable changes in gene expression via 
chromatin modification.  
 
A recent study which characterized the role of Blimp1 in the specification of 
primordial germ cells (PGCs) in mouse embryos provided evidence that the activity of 
Blimp1 could be regulated by altering its cellular localization.  In this context, Blimp1 
interacts with the protein methyltransferase, PRMT5 (Ancelin et al., 2007).  This 
complex becomes excluded from the nucleus of the PGCs by E11.5, at a time when 
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extensive epigenetic reprogramming takes place in the PGCs (Ancelin et al., 
2007).  However, in our analyses, we did not observe the same dramatic exclusion of 
Blimp1 outside the nuclei of the adaxial cells.  There are two likely explanations for 
this.  First, it is possible that the anti Blimp1 sera we have generated is not sufficiently 
sensitive (or enriched) to detect cytoplasmic Blimp1.   A second plausible explanation 
is that zebrafish Blimp1 does not work via the same mechanism in the slow-twitch 
muscle context as in the mammalian PGCs.  The exclusion of Blimp1 from the nuclei 
of PGCs is dramatic, with most, if not all, of the protein translocating into the 
cytoplasm.  As our anti-Blimp1 antibody is capable of detecting Blimp1 in the nuclei 
of adaxial cells, it is unlikely that the antibody would fail to detect the same amount 
of protein in the cytoplasm.  Furthermore, we observed that, like somitogenesis, the 
removal of Blimp1 progresses in an anterior to posterior direction, evident by the 
progressive reduction in the level of Blimp1 in the adaxial cells (Figs. 3.2D-F).  This 
precludes the possibility that we have failed to observe the phenomenon of Blimp1 
translocation during myogenesis.  Moreover, the expression of Blimp1 in slow muscle 
cells is transient (approximately 8 hours) in comparison with the 4.5 days Blimp1 is 
detectable in PGCs (Ancelin et al., 2007).  Together, these observations support the 
proposition that Blimp1 acts via different mechanisms in the two different 
developmental contexts.  
 
3.3.2 The specification of slow muscle fibres in the zebrafish embryo requires a 
transcriptional cascade mediated by Hh signalling via MRF activity 
The formation of the slow fibres is a precisely choreographed developmental 
event which begins as slow muscle precursors are positioned apposed to the 
notochord by the end of gastrulation (Hirsinger et al., 2004).  This exposes the adaxial 
Chapter 3  78 
cells to Hh signalling from the notochord, subsequently triggering the expression of 
myoD in these cells, resulting in their specification as the first myoblasts in the 
developing embryo.  Hh-dependent expression of blimp1 in the adaxial cells is 
required for their specification and differentiation into slow muscle fibres.  Ubiquitous 
up-regulation of Hh signalling throughout the embryo leads to the expansion of 
blimp1 expression in all the somitic myoblasts in the paraxial mesoderm (Baxendale 
et al., 2004).  This suggests that the expression of blimp1 may not solely depend on 
Hh signalling from the notochord, but also requires the activity of additional factor(s) 
that are present in the paraxial mesoderm.  Here, we show that MyoD and Myf5 
activity are required to switch on blimp1 expression (Fig. 3.3).  Thus, the initiation of 
slow muscle development in the zebrafish myotome occurs through induction by a 
morphogenetic signal from axial structures, which triggers sequential activation of a 
transcriptional cascade that culminates in the expression of the master regulator for 
slow muscle specification. 
 
3.3.3 The competence of somitic myoblasts to respond to Blimp1 and adopt 
slow-twitch fate changes as a function of time 
The ability of adaxial cells to respond to Hh signalling does not persist 
throughout development.  Through the use of cyclopamine, a plant alkaloid that 
inhibits the transduction of Hh signal through the inhibition of Smo activity (Chen et 
al., 2001), it has been shown that the formation of the various muscle lineages, 
particularly the muscle pioneers and surface slow fibres, require Hh signalling (Wolff 
et al., 2003).  Adaxial cells can only respond to Hh signalling in a six hour window 
after gastrulation, beyond which they fail to adopt slow muscle fate (Hirsinger et al., 
2004).  Through the induction of ectopic Blimp1 expression in Tg(hs::blimp1-IRES-
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gfp) embryos at various developmental stages, I have shown that the ability of 
myoblasts to respond to Blimp1 activity changes with time (Fig. 3.6).   
 
3.3.4 The increase in the number of slow fibres correlates with the increase in 
the number of MyoD-expressing cells in the myotome 
The ectopic Induction of Blimp1 in Tg(hs::blimp1-IRES-gfp) embryos at 10 
hpf and 14 hpf produced vastly different outcomes.  The induction of ectopic Blimp1 
at 10 hpf results in marginal increase in the number of slow muscle fibres in somites 
5-7, while induction at 14 hpf results in the formation of supernumerary slow muscle 
fibres that occupy most of the anterior myotome at the expense of fast-twitch fibres.  
There are two possible sources of myoblasts from which the extra slow muscles fibres 
are derived.  They can be derived from the conversion of fast muscle precursor cells 
or from the proliferation of slow muscle progenitors in response to the induction of 
Blimp1.  There are four reasons that support the hypothesis that the extra slow fibres 
are formed from the conversion of fast muscle precursors.  Firstly, myoblasts 
generally exit the cell cycle as they undergo terminal differentiation (Guo et al., 
1995).  Secondly, slow muscle progenitors, which express Blimp1, do not divide 
beyond the 3-somite stage (Hirsinger et al., 2004).  Thirdly, the increase in the slow 
fibres appears to coincide with the increase in the number of myoblasts as myoD 
expression expands into the domain of the fast muscle precursors by mid-
somitogenesis (Weinberg et al., 1996, Groves et al., 2005).  Lastly, there is a nearly 
complete loss of fast muscle fibres in these embryos.  Taken together, it is likely that 
the supernumerary slow fibres originated from myoblasts which would otherwise 
become fast muscle fibres.  One way to test this hypothesis is to induce ectopic 
Blimp1 expression in Tg(hs::blimp1-IRES-gfp) embryos that lack MyoD expression 
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in the paraxial mesoderm.  The induction of myoD expression in the fast muscle 
precursors requires Fgf8 activity (Groves et al., 2005).   The injection of fgf8 
morpholinos (MO) or the inhibition of phosphorylation of Fgf receptors with the 
chemical inhibitor SU5402 can inhibit the expression of myoD in the lateral plate 
mesoderm and abrogate the specification of fast myoblasts (Groves et al., 2005).  We 
can compare the number of slow muscle fibres formed in Tg(hs::blimp1-IRES-gfp) 
embryos with impaired Fgf signalling upon induction of ectopic Blimp1 at 14 hpf 
with that in wild-type embryos.  We would not expect to see an increase in the 
number of slow muscle fibres if the extra fibres are derived from fast muscle 
precursors.  Throughout our analysis of the Tg(hs::blimp1-IRES-gfp) strain, we did 
not observed any induction of either slow MyHC or Prox1 beyond the myotome of the 
developing embryo.  This observation implies that Blimp1 does not have myogenic 
competence by itself but can convert naïve myoblasts into slow muscle fibres. 
 
3.3.5 Are adaxial cells in the posterior presomitic mesoderm mitotically active? 
Ectopic induction of Blimp1 at 10 hpf resulted in a reduction in the number of 
slow muscle fibres. (Figs. 3.5C, K).  One possible explanation for this observation is 
that the ectopic Blimp1 induction could promote the premature differentiation of the 
adaxial myoblasts and expedite their premature exit from cell cycle.  This hypothesis 
requires the assumption that these adaxial myoblast are mitotically active and would 
contradict the conclusion from a previous study which reported that slow muscle 
precursors complete their terminal cell division by 10 hpf (Hirsinger et al., 2004).  
The study arrived at the above conclusion through cell transplantation experiments 
where fluorescently-labeled donor cells from 10 hpf embryos were deposited into 
unlabeled hosts and the number of fluorescent muscle fibres was determined at the 
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end of segmentation as a read out whether the transplanted myoblasts have undergone 
cellular division.  An increase in the number of labeled fibres (compared to the 
number of transplanted cells) at the end of segmentation would indicate that the 
transplanted cells have undergone cell division.  In this experiment, donor cells were 
obtained from the anterior portion of the presomitic plate of 10 hpf embryos.  At this 
time, the embryos possess 2 to 3 somites and the donor cells were obtained from the 
region where the fourth and fifth somite would form.  As the somitogenesis and 
myogenesis progress in a rostro-caudal direction, it is possible that more posteriorly 
located myoblasts may be developmentally immature and mitotically active in 
comparison with more anterior myoblasts.  In order to achieve a more accurate 
understanding of myogenesis, it is important to establish whether adaxial myoblasts in 
the posterior presomitic mesoderm undergo further rounds of cell division. 
 
There are two experimental approaches that can be taken to answer the 
question of whether adaxial cells in the presomitc mesoderm are mitotically active.    
Firstly, we can emulate the cell transplantation experiment described above, but alter 
the region where the donor cells are obtained.  In this experiment, fluorescently-
labeled donor cells can be obtained from a relatively more posterior region in the 
presomitic plate, for example, around the region where the tenth and eleventh somite 
would form.  These cells can then be transplanted into the equivalent region of an 
unlabeled host.  A comparison of the number of labeled slow fibres compared to the 
number of transplanted cells would reveal whether these relatively immature 
myoblasts undergo cell division.  Alternatively, we can make use of BrdU 
incorporation as a means of labelling cells that have undergone cell division.  BrdU is 
a synthetic thymine analog that becomes incorporated into the DNA of dividing cells.  
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Embryos can be exposed to BrdU at different stages of development and assayed for 
BrdU incorporation into the DNA of slow muscle fibres at the end of segmentation.  
Incorporation of BrdU into slow muscle fibres would imply that adaxial cells are 
mitotically active.  These experiments would allow us to determine if the relatively 
immature adaxial cells undergo further round(s) of cell division beyond 10 hpf and 
refine our understanding of slow muscle development in the zebrafish embryo. 
 
3.3.6 Blimp1 activity is not able to reverse the differentiated fast muscle fate 
There are several important myogenic events that happen around 18 hpf.  At 
this time, slow muscle precursors from the anterior most somites begin their lateral 
migration to the edge of the myotome (Devoto et al., 1996) and this migration has 
been implicated as a morphogenetic signal that triggers the timely maturation of fast 
muscle fibres (Henry and Amacher., 2004).  It has also been reported that the fusion 
of fast muscle precursor cells commences at 18 hpf (Srinivas et al., 2007).  From our 
analysis of Blimp1 expression in the myotome, we observed the disappearance of 
Blimp1 from the anterior most somites at this stage.  This signifies that Blimp1 has 
fulfilled its role and its activity is not longer required for slow muscle development 
beyond this developmental stage.  Thus, it is not surprising that the induction of 
ectopic Blimp1 in the Tg(hs::blimp1-IRES-gfp) embryos at 18 hpf did not result in 
any significant differences in the number of slow muscle fibres nor affect the 
specification of fast muscle fibres in these embryos.  What is surprising is the ectopic 
expression of the pan slow muscle marker Prox1 in these matured fast fibres.  These 
results are significant as they inform us that by this stage, all the myoblasts in the 
myotome have been specified into fast or slow fate, and there are no naïve myoblasts 
within somites 5 to 11 that are capable of responding to Blimp1 activity to become 
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slow muscle fibres.  It also reveals that Blimp1 activity is insufficient to transfate 
differentiated fast myoblasts into slow-twitch fibres.  Investigations into the molecular 
basis that underlies the loss of the ability to respond to Blimp1 activity would advance 
our understanding of Blimp1 function in slow specification and differentiation.  
 
3.4 Conclusion 
In this chapter, I described the expression of Blimp1 in the nuclei of adaxial 
cells.  The expression of Blimp1 precedes both known markers of slow muscle 
differentiation and is the earliest marker of the slow muscle lineage.  The perdurance 
of Blimp1 does not differ significantly compared to that of its transcripts and the 
protein is degraded once slow muscle specification is complete.  This suggests that 
Blimp1 may mediate epigenetic modifications that modulate gene expression required 
for slow muscle development.  This and other studies have shown the myoblasts have 
a finite window to respond to both extrinsic and intrinsic cues to acquire their final 
fate.  The coordinated activity of MyoD and Myf5 induces Blimp1 expression in the 
adaxial cells, leading to their specification and differentiation as slow muscle fibres.  
Blimp1 activity can drive naïve myoblasts to adopt a slow-twitch fibre fate, but 
cannot reverse the fate of matured fast fibres or cause non-myogenic cells to become 
slow-twitch muscle fibres. 
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Chapter 4 
GENE REGULATION BY BLIMP1 DURING SLOW MUSCLE DEVELOPMENT 
 
4.1 Background 
Blimp1 is a SET domain-containing transcription factor whose activity is 
required for the specification of slow-twitch skeletal muscle fibres in zebrafish 
embryos (Roy et al., 2001; Baxendale et al., 2004).  Slow muscle fibres are 
mononucleate fibres located on the surface of the embryonic zebrafish myotome that 
express slow myosin heavy chain (MyHC) and Prox1 (Devoto et al., 1996, Wolff et 
al., 2003).  Perturbation in Blimp1 activity results in disruption of slow muscle fibre 
formation characterized by a dramatic reduction in slow MyHC expression and a 
complete loss of Prox1 expression (Roy et al., 2001, Baxendale et al., 2004).  
Presumptive slow myoblasts in blimp1 mutants fuse to give multinucleate myofibrils 
that fail to migrate to the lateral extreme of the myotome (Roy et al., 2001).  In order 
to fulfil its role as a slow muscle switch, Blimp1 must promote the expression of the 
genes that are required for slow muscle development.  These genes include slow 
muscle-specific structural genes, prox1 and others whose activity are required for 
migration of slow muscle fibres to the lateral extremes myotome.  On the other hand, 
it must repress the genes that are required for fast muscle development, such as the 
fast muscle structural genes and those that are involved in myoblast fusion.  The 
identification of Blimp1 target genes in slow muscle fibres would not only shed light 
on how Blimp1 functions to specify slow muscle fate, it would also advance our 
understanding of the genetic elements that define slow muscle identity.   
 
There are several approaches that can be taken to identify genes that are 
involved in a particular biological process.  These approaches include candidate gene 
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approach, forward and reverse genetic screens, subtractive hybridization and DNA 
microarray analysis of differential gene expression.  The description and discussion of 
these techniques forms the basis of entire books/chapters (Gilbert, 2006, Alberts et al., 
2002) and will only be briefly described here. 
 
The candidate gene approach seeks to identify genes that are suspected to be 
involved in a particular biological process based on available knowledge derived from 
searches through published literature.  Alternatively, with the advent of information 
technology and the creation of expression pattern databases (e.g. at Flybase and 
ZFIN), candidate genes can also be identified from searches through these databases, 
based on the assumption that their expression in a particular tissue or group of cells 
may imply a possible role for these genes in the biological process of interest. 
 
Forward genetic screens have been widely used to discover genes that are 
involved in a wide range of developmental and behavioural processes.  This is 
achieved through the screening of a population of mutants which display variations in 
phenotypes compared to wild-type animals.  It requires the creation of a population of 
mutants either by chemical mutagens, irradiation or through insertional mutagenesis.  
Gene discovery follows the mapping of the mutations by positional cloning.  This 
process is tedious and time consuming but a saturated screen may yield many 
different alleles and genes of interest.  The u-boot (ubo) mutant, which was later 
found to encode the zebrafish homolog of Blimp1, was first identified as part of a 
large scale mutagenesis screen for zygotic mutants (Baxendale et al., 2004, van Eeden 
et al., 1996). 
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Reverse genetics refers to the approach taken to discover the function of a 
candidate gene.  This can be achieved through gain- and loss-of-function analyses.  
The function of the candidate gene can be abrogated by a number of different 
techniques depending of the experimental model system being used.  These 
techniques include targeted mutagenesis, gene silencing, interference using 
transgenes, morpholino oligonucleotides, overexpression of dominant negative forms 
and the use of drug inhibitors. 
 
Subtraction hybridization enables the comparison of gene expression between 
two sets of transcriptomes by allowing selective PCR-amplification of cDNA 
fragments that differ in relative abundance between two experimental samples.  This 
would allow the identification of genes that are differentially expressed, and of those 
that potentially have a role in the biological process of interest.  In fact, the mouse 
homolog of Blimp1 was first cloned by this technique (Turner et al., 1991).  With the 
advent of the DNA microarray technology, this technique has become less commonly 
used.  Microarray technology enables the rapid and high-throughput assay of relative 
levels of expression of a large set of genes between two samples.  This technique 
relies on the quantification of the relative levels mRNA transcripts through the 
hybridization of cDNA that is synthesized from two different mRNA preparations 
onto DNA arrays bound to a solid support (Shalon et al., 1996).  It allows the 
comparison of gene expression profiles under different experimental conditions, such 
as a gene knockdown, and reveals the genes that are differentially expressed.  These 
microarrays contain a large number of genes and enable the identification of new 
genes that may be involved in the biological process of interest.   
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We adopted two approaches to identify Blimp1 target genes – the candidate 
approach and microarray analysis of differential gene expression.  In this chapter, I 
will describe and discuss the results obtained from our efforts towards the 
identification of Blimp1 target genes and how these results have advanced our 




4.2.1 Short-listing of candidate Blimp1 target genes through the candidate 
approach 
A short-list of potential Blimp1 target genes was compiled through searches in 
the literature (PubMed, http://www.ncbi.nlm.nih.gov/) and gene expression profile 
database (ZFIN, http://zfin.org/).  The genes that are of special interest can be 
classified into two broad categories.  The first category, referred to as slow-specific 
genes, consists of genes whose expression patterns are confined to the adaxial cells 
(slow muscle precursors) or mature slow fibres.  The second category consists of 
genes that are expressed in the fast myoblasts and fibres (referred to as fast-specific 
genes) whose expression could be repressed by Blimp1.  We then used whole mount 
in situ hybridization as an assay for differential gene expression.  The comparison of 
the expression patterns of candidate genes in embryos where Blimp1 activity is 
perturbed, e.g. in ubo, nrd or blimp1 morpholino-injected embyos, to that in wild-type 
embryos would reveal whether the expression of these candidate genes are dependent 
on Blimp1 activity.  The expression of slow-specific genes is expected to be reduced 
or abrogated in ubo, nrd or blimp1 morphants while fast-specific genes would be mis-
expressed in the presumptive slow muscle cells in these embryos.   
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4.2.2 Expression of slow-twitch specific structural genes are dependent on 
Blimp1 activity 
Slow MyHC is one of the definitive markers of slow muscle fibres during 
muscle development (Devoto et al., 1996, Blagden et al., 1997, Du et al., 1997, Roy et 
al., 2001, Wolff et al., 2003).  Here, we examined whether the transcription of the 
smyhc1 is dependent on Blimp1 activity.  This gene is expressed exclusively in the 
adaxial cells at 12 hpf and its transcripts persist in differentiated slow muscle fibres 
(Fig. 4.1A, see also Bryson-Richardson et al., 2005; Hsiao et al., 2003).  Expression 
of smyhc1 in adaxial cells is reduced in ubo embryos during early somitogenesis (Fig. 
4.1B) and becomes undetectable by 24 hpf (Figs. 4.1D-G).  The reduction in smyhc1 
expression in ubo embryos could possibly correspond to the hypomorphic nature of 
this allele (Baxendale et al., 2004).  This led us to examine the expression of this gene 
in the narrowminded (nrd) mutant where Blimp1 is truncated after the first 154 amino 
acid residues due to a nonsense mutation (Hernandez-Lagunas et al., 2005).  This 
mutation results in a more severe defect in the Blimp1 activity and is believed to 
encode a null mutation of blimp1.  Expression of smyhc1 in nrd embryos is similar to 
that in ubo embryos despite the absence of Blimp1 activity (Fig. 4.1C).  These results 
suggest that Blimp1 activity is required for the induction and maintenance of smyhc1 
expression in slow muscle fibres.   
 
zgc:66286 1  was first described in a microarray analysis of Hh-modulated 
genes, and its expression was found to be dependent on Hh signalling (Xu et al., 
2006).  It is expressed exclusively in the adaxial cells of wild-type embryos from  
                                                 
1 The Zebrafish Gene Collection (ZGC) is a collection of full-length cDNA sequences of genes that are 
expressed in the zebrafish.  For more details, see http://zgc.nci.nih.gov/Info/Summary  
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Fig. 4.1.  Slow muscle specific genes are mis-regulated in ubo mutant embryos 
(A-G) Expression of smyhc1 in (A) 6-somite wild-type (wt) embryo (arrowheads), (B) 
6-somite ubo embryo (arrowheads), (C) 6-somite nrd embryo (arrowheads), (D,E) the 
superficial slow fibres (SSF) of a 24 hpf wt embryo (arrow in E), (F,G) but not in 24 
hpf ubo embryo.  (H, I) Expression of zgc:66286 (slow myosin light chain, smylc) can 
be seen in the SSF of 24 hpf wt embryos (arrow in I).  (J, K) Expression of smylc is 
lost in 24 hpf ubo embryos. (L, M)  Expression of slow muscle specific troponin C, 
tnnc(s), in slow muscles of wild-type 24 hpf embryos. In (M) staining in the 
superficial slow muscle layer is visible (arrow). (N, O) Expression of slow tnnc(s) is 
lost in 24 hpf ubo embryos. Panels A, B, and C depict dorsal flat mounts.  Panels, D, 
F, H, J, L and N depict lateral views; panels E, G, I, K, M and O depict transverse 
sections. Scale bars=25 μm. Scale bar in A applies to B and C, Scale Bar in D applies 
to F, H, J, L and N.  Scale Bar in E applies to G, I, K, M and O. 
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early somitogenesis and its transcript continues to accumulate in slow muscle fibres 
and remains detectable up to 5 dpf (Thisse et al., 2004).  From its amino acid 
sequence, it is predicted to encode a polypeptide resembling a myosin light chain.  
The cDNA of this gene was amplified from a cDNA library prepared from a pool of 
18 to 24 hpf wild-type embryos.  The cDNA clone of this gene was used to prepare 
the antisense probe against its transcript.  The probe recapitulated the published 
expression pattern in 24 hpf wild-type embryos (Fig. 4.1H, I, see also Thisse et al., 
1994).   zgc:66286 is expressed exclusively in the slow-twitch muscle fibres of 24 hpf 
wild-type embryos but its transcripts are not detectable in 24 hpf ubo mutant embryos 
(Figs. 4.1J-K).  We conclude that the expression of zgc:66286 is dependent on Blimp1 
activity and could encode the slow muscle-specific myosin light chain (smylc). 
 
zgc:86932 encodes a slow muscle-specific variant of troponin C (tnnc(s)) that 
is positively modulated in response to increased Hh signalling (Xu et al., 2006).  The 
transcript of this gene was lost in smo embryos and it is ectopically expressed in the 
myotome when Hh signalling was ectopically induced throughout the embryo (Xu et 
al., 2006).  The transcripts of this gene are restricted to the superficial slow fibres of 
24 hpf wild-type embryos (Figs. 4.1L, M) and cannot be detected in 24 hpf ubo 
mutant embryos (Figs. 4.1N, O).  Thus, we have shown that Blimp1 activity is 
required for the expression of three slow muscle-specific sacromeric genes. 
 
4.2.3 Expression of cardiomyopathy-associated 1 (cmya1) and CBP/p300-
interacting transactivator (cited3) are dependent on Blimp1 activity 
In addition to the genes identified from the literature, we compiled a list of 
genes based on their expression pattern in the ZFIN expression database 
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(http://zfin.org) for those expressed in the adaxial cells during early to mid-
somitogenesis stages (Table 4.1).  Two of these genes, cardiomyopathy-associated 1 
(cmya1) and CBP/p300-interacting transactivator (cited3) are expressed in adaxial 
cells during somitogenesis (Figs. 4.2A, C, Thisse et al., 1994).  In situ hybridization 
with probes to detect these genes in 14 hpf blimp1 morphant embryos revealed that 
their expression is severely impaired in the absence of Blimp1 activity (Figs. 4.2B, 
D).  We conclude that the expression of these genes is also dependent on Blimp1 
activity. 
 
4.2.4 Fast muscle specific gene mylz2 is mis-regulated in the adaxial cells in the 
absence of Blimp1 activity 
Mammalian Blimp1 mediates transcriptional repression through the 
recruitment of a number of co-repressors and chromatin modifying enzymes such as 
histone deacetylase, HDAC2, protein methyltransferases, Prmt5 and G9a (Calame et 
al., 2003, Ren et al., 1999, Yu et al., 2000, Ancelin et al., 2006, Gyory et al., 2004).  It 
is also likely that Blimp1 represses the fast muscle development program in slow 
muscle cells.  To test this hypothesis, we determined the expression of the fast muscle 
specific gene myosin, light polypeptide 2, skeletal muscle (mylz2).  This gene is 
commonly used as a marker of the fast muscle lineage (Groves et al., 2005, Hammond 
et al., 2007; Hinits and Hughes, 2007; Maves et al., 2007; Xu et al., 2000).  
Transcripts of mylz2 can first be detected in the developing fast myoblasts around 18 
hpf (Xu et al., 2000).  Whole mount in situ hybridization analyses of mylz2 expression 
had previously been performed with an antisense riboprobe synthesized from the full-
length cDNA clone (henceforth referred to as the mylz2 cDNA probe) (Groves et al., 
2005, Hammond et al., 2007; Hinits and Hughes, 2007; Maves et al., 2007; Xu et al.,  
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Table 4.1 – List of genes that are expressed in the adaxial cells 
Gene symbol Gene Name Predicted function 
cmya1 cardiomypathy1 Myofibril assembly 
cited 3 Cbp/p300-interacting 
transactivator, with Glu/Asp-rich 
carboxy-terminal domain 
Transcription co-activator 
casz1 castor zinc finger 1  – 
IM:7149588 (alpi) alkaline phosphatase, intestinal intestinal alkaline phosphatase 
zgc:100917 hmnt  histamine N-methyltransferase   histamine N-methyltransferase  
zgc:113625 – 
 
GTP binding,  
GTPase IMAP family member  
zgc:63557 – Nucleolar transcription factor 1 
zgc:86810 tropomyosin beta chain   
zgc:66286 – Possible myosin light chain 
zgc:86932 troponin C (slow) 
 
Muscle structural gene 
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Fig. 4.2. Expression of cmya1 and cited3 are lost in blimp1 morphant embryos. 
(A) Expression of cmya1 can be seen in the adaxial cells of 12-somite wild-type 
embryos (arrowheads). (B) cmya1 expression is lost in 12-somite blimp1 morphant 
embryos. (C)  Expression of cited3 can be seen in the adaxial cells of 12-somite wild-
type embryos (arrowheads). (D) cmya1 expression is lost in 12-somite blimp1 
morphant embryos.  All panels depict dorsal flat mounts. Scale bar=25 μm. 
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2000).  The application of this probe on embryos derived from an ubo heterozygous 
incross yielded an unexpected result – the transcripts of this gene were detected in the 
adaxial cells of all the embryos with approximately a quarter (13/53) of them showing 
a more intense signal (Figs. 4.3A, B).  This observation is inconsistent with previous 
RT-PCR analysis that showed that this transcript is only expressed beyond 18 hpf (Xu 
et al., 2000).  This prompted us to perform a BLAST search on the Ensembl genomic 
database (http://www.ensembl.org) as it was possible that the probe may cross-
hybridize to other redundant transcripts that contain significant sequence identity.  
The BLAST search results revealed that zgc:103639 possess significant sequence 
identity with the 5’-end but not the 3’ end of mylz2; 83% out of the first 500 bp of 
mylz2 are identical to the corresponding sequence of zgc:103639 (Fig. 4.4).  It also 
revealed that the 3’ portion of the mylz2 transcript did not contain significant 
similarity to other sequences in the genome.  Thus, a 526 bp fragment from the 3’-
untranslated region (3’-UTR) was subcloned by PCR to facilitate the synthesis of a 
riboprobe that is specific for mylz2 (Fig. 4.4).  This probe is henceforth referred to as 
the mylz2 3’UTR probe.  In contrast with the results obtained with the mylz2 cDNA 
probe, the mylz2 3’UTR probe did not detect any expression in adaxial cells of 14 hpf 
wild-type embryos (Fig. 4.3C), but mylz2 transcripts can be detected in adaxial cells 
of 14 hpf blimp1 morphant embryos (Fig. 4.3D).  This analysis confirmed that the 
mylz2 cDNA probe cross-hybridizes with other mRNA (possibly with the transcript of 
zgc:103639) and that Blimp1 activity represses the expression of the fast muscle 
specific genes in the  slow muscle lineage in wild-type embryos.  In addition, we also 
examined the expression of fast myosin light chain in ubo embryos with 
immunohistochemical staining.  We observed that fast myosin light chain is similarly 
mis-expressed in the adaxial cells of ubo embryos (Fig. 4.3E, F).   
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Fig. 4.3. Fast muscle specific gene mylz2 is mis-regulated in the adaxial cells in 
the absence of Blimp1 activity.  (A) Whole mount in situ hybridization with the 
mylz2 cDNA probe in 12-somite wild-type embryos reveals that the probe possibly 
cross-hybridizes with other transcripts in the adaxial cells of these embryos.  (B) The 
mylz2 cDNA probe reveals that mylz2 and possibly other transcripts are mis-regulated 
in the adaxial cells of ubo embryos.  (C) The mylz2 3’UTR probe is highly specific for 
mylz2 transcripts.  The transcripts of this gene are not detected in 12-somite wild-type 
embryos. (D) The mylz2 3’UTR probe reveals that mylz2 is mis-expressed in the 
adaxial cells of 12-somite blimp1 morphant embryos (arrowheads).  (E) Fast myosin 
light chain is expressed exclusively in the fast myoblast (arrow) but not the adaxial 
cells (arrowheads) of 15-somite wild-type embryos.  (F) Fast myosin light chain is 
mis-expressed in the adaxial cells of ubo embryos (arrowheads) in addition to the fast 
myoblasts (arrow). “N” in panels E and F denote the position of the notochord.  All 
panels depict dorsal flat mounts. Scale bar=25 μm.  
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Fig. 4.4. Sequence alignment between mylz2 (AF081462) and zgc:103639.  The 
alignment of these two sequences reveals a high degree of similarity between the 
nucleotide sequences (red boxes represents identical bases).  A 562 bp region within 
the 3’UTR of mylz2 (shaded yellow box) was used for the synthesis of the mylz2 
3’UTR probe. 
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4.2.5 Identification of Blimp1 target genes by microarray analysis 
Microarray experiments enable rapid and high-throughput assay of differential 
gene expression of a large set of genes between two experimental conditions.  The 
unbiased nature of the assay allows identification of new genes that may be involved 
in any biological process of interest.  With this in mind, we carried out a microarray 
experiment in hope of identifying new genes that are involved in slow muscle 
development.  The experiment was conducted with the help of Dr. Sinnakaruppan 
Mathavan and his team from the Genome Institute of Singapore (GIS).  The 
microarray which contains 16,177 non-redundant genes had been used in previous 
studies to characterize the gene expression profiles of embryos during the course of 
development and to identify genes that are differentially regulated by  Hh  signalling  
(Mathavan et al., 2005,  Xu et al., 2006).  In this experiment, total RNA were 
extracted from 12-somite stage (14 hpf) blimp1 morphant embryos for the experiment, 
and RNA from wild-type embryos at the same stage was used as the reference sample.  
Subsequent steps in processing of the RNA samples and hybridization of the array 
were carried out at the GIS.   
 
4.2.5.1 Filtering of differentially expressed genes 
Since the microarray experiment yielded a long list of differentially expressed 
genes, we first filtered for statistically reliable data by excluding the results obtained 
from less than three technical replicates and those that displayed large variations 
between replicates.  The maximum allowable variation was defined as a standard 
error > 20% relative to the extent of the fold change.  We also removed genes that 
showed less than a 1.5 fold differential expression.  In this experiment, genes that are 
down-regulated in the blimp1 morphants relative to wild-type embryos would be 
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those normally activated by Blimp1, and are henceforth referred to as Blimp1-
activated genes.  Conversely, genes that are up-regulated through Blimp1 knockdown 
would be normally repressed by Blimp1 and are henceforth referred to as Blimp1-
repressed genes.  We began our analysis with a list of 2236 GenBank sequences.  Out 
of these, 996 are up-regulated (repressed by Blimp1) and 1239 are down-regulated 
(activated by Blimp1) (see Table 4.2).  Using the Gene Ontology Annotation Tool 
(DR build #122_61 at http://giscompute.gis.a-star.edu.sg /~govind/unigene_db/), we 
found only 804 up-regulated and 934 down-regulated genes possess Unigene IDs 
(Appendix I).   
 
4.2.5.2 Clustering of genes into functional categories 
In our attempt to derive biologically relevant information from the list of 
differentially expressed genes, we used to the web-based gene ontology (GO) 
clustering program DAVID 2008 (The Database for Annotation, Visualization and 
Integrated Discovery, http://david.abcc.ncifcrf.gov/) (Huang et al., 2007; Sherman et 
al., 2007).  This program aids in the discovery of functional-related gene groups 
through the identification of enriched biological themes and clustering of genes into 
functional categories based on gene ontology annotation.  The main advantage of this 
program over many others is its integration of multiple well-known databases into its 
DAVID knowledgebase which significantly improves gene annotation.  The DAVID 
Functional Annotation Clustering Tool condenses heterogeneous and redundant 
annotation terms into functional clusters and facilitates the interpretation of the 
biological data.  The lists of 1239 activated and 996 repressed genes were analyzed 
separately, of which 638 Blimp1-activated and 660 Blimp1-repressed genes were 
annotated and clustered by DAVID (Table 4.2 and Table 4.3).   
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Table 4.2 – Number of differentially regulated genes from microarray analysis of 
differentially regulated genes 
 Activated Repressed Total 
Differentially Expressed (filtered) 1239 996 2236 
Number of genes without  
Unigene ID 
306 (24.7%) 193 (19.3%) 499 (22.3%) 
DAVID Annotated and Clustered 638 (51.5%) 660 (66.3%) 1298 (58.1%) 
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Table 4.3 – Summary of functional clustering by DAVID  
DAVID CLUSTERED – ACTIVATED GENES 
 Count Enrichment 
Score 
p-value Bonferroni 
Receptor activity  66 5.56 7.00E-11 9.50E-08 
Multicellular organismal process  70 2.14 1.60E-06 3.70E-03 
POU-specific  4 1.89 1.00E-02 1.00E+00 
DNA replication initiation  6 1.46 2.00E-05 4.50E-02 
Response to DNA damage stimulus  4 1.35 3.00E-03 1.00E+00 
 Nuclear hormone receptor, ligand-binding  5 1.35 1.20E-02 1.00E+00 
Sensory organ development  11 1.21 1.80E-02 1.00E+00 
System development  35 1.11 1.40E-02 1.00E+00 
Visual perception  6 0.91 3.20E-02 1.00E+00 
DNA-binding  32 0.8 2.40E-04 8.80E-02 
Response to external stimulus  8 0.72 3.90E-02 1.00E+00 
Serine/threonine protein kinase  3 0.68 2.10E-02 1.00E+00 
Cellular process  26 0.67 2.60E-02 1.00E+00 
Parvalbumin  3 0.38 4.40E-02 1.00E+00 
 
DAVID CLUSTERED – REPRESSED GENES 
 Count Enrichment 
Score 
p-value Bonferroni 
Response to stress  18 2.42 2.40E-03 1.00E+00 
Enzyme inhibitor activity  23 2.36 4.40E-04 4.50E-01 
ATPase activity, coupled to transmembrane 
movement of ions, phosphorylative mechanism  
6 1.77 1.10E-02 1.00E+00 
Cellular component assembly  15 1.66 1.20E-02 1.00E+00 
eIF5C  4 1.51 2.30E-03 6.90E-01 
Inorganic cation transmembrane transporter 
activity  
16 1.46 3.60E-05 4.70E-02 
Cysteine-type endopeptidase activity  8 1.37 8.40E-03 1.00E+00 
Protease inhibitor I4, serpin  3 1.25 4.70E-02 1.00E+00 
Alcohol metabolic process  10 1.21 1.30E-02 1.00E+00 
Regulation of apoptosis  9 1.19 1.10E-02 1.00E+00 
Cation transmembrane transporter activity  32 1.05 1.20E-03 8.10E-01 
Organ development  30 1.01 2.70E-02 1.00E+00 
Embryonic hemopoiesis  4 0.86 4.20E-02 1.00E+00 
ATPase activity, coupled to transmembrane 
movement of ions, phosphorylative mechanism  
6 0.84 1.10E-02 1.00E+00 
Macromolecular complex  86 0.78 6.20E-04 2.30E-01 
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The Blimp1-activated genes are grouped into 14 functional clusters with p-
values < 0.05 (Table 4-3).  However, after the Bonferroni correction2, only three of 
these clusters are statistically significant.  The most significantly enriched cluster 
consists of genes implicated in olfactory receptor and signal transduction activity.    
 
The second cluster of genes consists of those that are required for the 
“development of multi-cellular organisms”.  The third statistically significant cluster 
Blimp1-repressed genes are clustered into 15 functional groups with p-value < 0.05 
(Table 4.3), out of which only one remains statistically significant after Bonferroni 
correction.  This cluster comprises of 16 inorganic cation transmembrane transporter 
proteins, including several ATP-dependent Ca2+ pumps which serve to maintain 
correct Ca2+ homeostasis in muscle cells.  The functional clustering by DAVID did 
not reveal any enrichment of genes that are involved in muscle development within 
the lists of differentially expressed genes. 
 
4.2.5.3 Manual clustering of differentially expressed genes 
As the systematic approach to derive relevant biological information from the 
microarray experiment did not lead to the identification of genes that are involved in 
muscle development, we proceeded to manually dissect the list of differentially 
expressed genes.  The initial approach was to list the genes in Gene Ontology (GO) 
terms that are related to skeletal muscle development, and see if these genes are 
present in the lists of differentially expressed genes from the microarray experiment.  
                                                 
2 The Bonferroni correction is a safeguard against multiple tests of statistical significance on 
the same data falsely giving the appearance of significance, as 1 out of every 20 hypothesis-
tests will appear to be significant at the α = 0.05 level purely due to chance. 
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There are 70 zebrafish genes that are listed under the broad GO term of “muscle 
development” (GO:0007517) (Appendix II, http://www.geneontology.org/).  We 
observed that only 4 genes from the “Blimp1-repressed gene” list can be found under 
this GO annotation.  These genes are dystroglycan 1, heat shock protein 90-alpha 1, 
troponin T2, cardiac and unc-45 homolog B.  However, it is clear from manual 
inspection of the lists of differentially expressed genes that some of the genes known 
to be expressed during muscle development, such as smyhc1 and mylz2, are not listed 
under this GO term.  We found that smyhc1 is listed under broad GO terms such as 
“ATP-binding”, “myosin complex” and “cytoplasm” and mylz2 is annotated under 
“calcium ion binding”.  Thus, the approach to manually cluster the genes based upon 
GO annotation for many genes may be inadequate and imprecise. 
 
As the primary aim of the microarray experiment was to identify genes that 
are involved in Blimp1-dependent slow muscle development, we manually searched 
the lists and sorted the genes into functional categories which may be important for 
differentiation of myoctyes into myofibres (Table 4-4).  These categories are “muscle 
development”, “stress response”, “transcription factors” and “signalling molecules”.  
In the following subsections, I will first describe genes that are listed under the 
subheading of “muscle development”, followed by a brief description of the possible 
significance of the genes listed under the other subheadings. 
 
4.2.5.3.1 Differentially regulated muscle development genes 
The results from the microarray analysis corroborate with the results from our 
earlier analysis of muscle gene expression with whole mount in situ hybridization.  
smyhc1, smylc and tnnc(s) are present in the “Blimp1-activated” list and mylz2 is  
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present in the “Blimp1-repressed” list.  There were also other fast- muscle  specific  
genes,  such  as  mylz1,  mylz3,  myhz1  and  myhz2  are  also  down-regulated by 
Blimp1 (Table 4-4).  It is interesting to note that there are some “cardiac” myofibrillar 
proteins that are regulated by Blimp1, although Blimp1 is not expressed in the 
developing heart.  These observations may be because these genes are expressed in 
both skeletal and cardiac muscles (Thisse et al., 1994).  Myogenin, which is an MRF 
important for the differentiation and maturation of myofibrils, is down-regulated by 
Blimp1.  Interestingly, Blimp1 appears to auto-regulate its own expression. 
   
4.2.5.3.2 Differentially regulated transcription factors and chromatin 
modifying enzymes 
The list of differentially expressed transcription factors and chromatin 
modifying enzymes are rather extensive; there are 55 genes whose expression is up-
regulated by Blimp1 and 36 that are down-regulated.  A manual search through the 
ZFIN expression database for each of these genes revealed that most of these 
transcription factor econding genes are expressed in the developing eye or brain and 
thus would not play a role in slow muscle development.  There are a few up-regulated 
transcription factors and chromatin modifying enzymes that were expressed in the 
adaxial cell or somites.  These include t-box 15 (tbx15), POU domain gene C (pouc), 
zic family member 1 (zic1), engrailed 2b (eng2B), DNA (cytosine-5-
)methyltransferase 1 (dmnt1), zgc:110766.  There are 5 transcription factor econding 
genes that are repressed by Blimp1 that are expressed in the somites; these genes are 
forkhead box o5 (foxo5), muscle segment homeobox a (msxa), blimp1 and myogenin 
and Kreisler (mouse) maf-related leucine zipper homolog 2.2 (mafbb).  The role of 
these transcription factors and DNA modifying enzymes in vertebrate myogenesis has 
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not been previously described.   
 
4.2.5.3.3 Differentially regulated stress response proteins 
In this collection of genes, there appears to be a large number of genes that are 
up-regulated in the presence of Blimp1 activity.  Most genes in this category encode 
proteins by one of two groups: the heat shock proteins and the Minichromosomal 
Maintenance (MCM) family.   Heat shock proteins are protein-folding chaperons that 
have been reported to be required for the assembly of sarcomeric complexes during 
the formation of myofibrils (Hawkings et al., 2008).  Thus, the induction of these 
genes by Blimp1 suggests that they may play a role in slow muscle development. 
 
4.2.5.3.4 Differentially regulated signalling molecules 
This category can be subdivided into several subcategories of proteins that are 
involved in calcium binding, G-protein signalling, kinases and phospatases, 
membrane bound receptors and ligands (Table 4-4).  These proteins are involved in a 
variety of cellular processes and may be involved in slow muscle development.   
 
Calcium ions are important secondary messengers in the cell; Ca2+ can 
mediate signalling by binding to calmodulin (CaM) to effect downstream signalling 
by activating the activity of CaM-dependent kinase.   The phosphorylation of 
regulatory myosin light chains by CaM-dependent kinase is required for muscle 
contraction (Zhi et al., 2005, Ryder et al., 2007).  Thus, the regulation of the proteins 
that regulate intracellular Ca2+ concentration may have important implications in 
muscle development and activity.    
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G-protein signalling has been implicated in the regulation of a number of 
biological activities, such as cell migration, cytoskeleton remodelling and cell-cell 
fusion.  Rac1, a Rho GTPase, has been shown to be important for myoblast fusion 
(Srinivas et al., 2007).  Thus, it is likely that other molecules required for mediating 
G-protein coupled signal transduction may be involved in cellular processes that are 
required for slow muscle development.   
 
There are also a number of kinases and phophotases present on the list of 
differentially regulated genes.  Post-translational modification of proteins through 
phosphorylation and dephosphorylation is involved in a wide range of biological 
processes including development.  The significance of these molecules in muscle 
development is presently unknown.   
 
4.3 Discussion 
4.3.1 Blimp1 activity is required for the induction and maintenance of slow 
muscle-specific gene expression 
In addition to position, morphology and function, cell identity is also defined 
by the repertoire of genes that are expressed.  To date, slow muscle identity is defined 
by the expression of two molecular markers, slow MyHC and Prox1 (Devoto et al., 
1996, Wolff et al., 2003).  In this study, we identified two additional molecular 
markers of the slow muscle lineage - tnnc(s) and smylc which are expressed 
exclusively in slow muscle precursors and fibres, and we have shown that their 
expression is dependent on Blimp1 activity.  In addition, we have also identified two 
novel genes that are expressed exclusively in the slow muscle precursors.  These 
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observations reinforce the idea that Blimp1 acts as a master regulator in the induction 
of genes that are specifically required for the formation of slow muscle fibres. 
 
Through in situ hybridization analysis, we found that smyhc1 transcripts are 
not fully induced in the absence of Blimp1 activity and become undetectable by the 
end of segmentation in ubo embryos (Figs. 4.1A-H).  This suggests that Blimp1 
activity is required for the proper induction as well as maintenance of smyhc1 
expression.  Blimp1 is expressed during the initial phases of slow muscle 
specification and is lost from the adaxial cells of the anterior most somites by 18 hpf 
(section 3.2.1).  In contrast, smyhc1 expression is initiated in slow myoblasts with the 
onset of their differentiation and maintained throughout larval stages of zebrafish 
development (Elworthy et al., 2007).  Taken together, these observations suggest that 
the Blimp1-mediated enhancement of smyhc1 expression does not require continuous 
occupation by Blimp1 at its regulatory region; rather, Blimp1 activity either mediates 
epigenetic modifications at the smyhc1 locus, or results in the expression of additional 
transcription factor(s) required for sustained expression of the gene. 
 
In addition to identifying candidate Blimp1 target genes through literature 
searches, we were also able to identify candidate Blimp1 targets through searches of 
gene expression profile database.  The expression of two of these genes, cmya1 and 
cited3 is also shown to be dependent on Blimp1 activity.  The human homolog of 
Cmya1, Xin, binds to filamin c at the specialized structures where the ends of 
myofibrils are attached to the sarcolemma (van der Ven et al., 2006).  It is possible 
that zebrafish Cmya1 may have a role in sarcomere assembly in slow muscle 
development.   
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cited3 was identified on the basis of the 32 amino acid residue glutamate/ 
aspartate-rich domain at its carboxy terminus (Braganca et al., 2002).  There has not 
been any study on cited3 or its paralogs in any developmental context.  Cited proteins 
interact with the CBP/p300 transcription activation complex.  The CBP/p300 has been 
shown to be recruited by acetylated MyoD for transcriptional activation during 
myogenesis (Wei et al., 2008).  Thus, Cited3 may play a role in transcriptional 
activation of genes that are required for slow muscle fibre formation through 
interaction with the MyoD-CBP/P300 transcriptional complex.  Further functional 
analysis of these two genes will be required to extend our understanding into the 
molecular mechanisms involved in vertebrate muscle development. 
 
4.3.2 Blimp1 represses fast muscle-specific genes in adaxial cells during slow 
muscle formation 
In our attempt to analyze the expression of the fast muscle specific light chain, 
mylz2, we discovered that the mylz2 cDNA probe that has been extensively used as a 
marker of fast muscle cells in the zebrafish embryo cross-hybridizes with other 
transcripts in the adaxial cells of wild-type embryos.  To rule out the possibility of 
cross-hybridization, we designed a probe that is synthesized based on the sequence in 
the 3’UTR of the gene and found that this new probe did not produce the same 
expression pattern as the mylz2 cDNA probe.  With this probe, we showed that mylz2 
is mis-expressed in adaxial cells of blimp1 morphant embryos.  In addition, we also 
found that fast MyHC is also mis-expressed in a similar fashion in adaxial cells of ubo 
embryos.  These results suggest that Blimp1 represses mylz2 and other fast muscle 
specific genes during slow muscle differentiation.  It would be interesting to 
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investigate whether Blimp1 binds directly to their promoters to mediate their 
repression. 
 
4.3.3 Difficulties with the identification of genes involved in muscle 
development through microarray analysis 
As Blimp1 is the master regulator of slow muscle identity in zebrafish 
embryos, we performed a microarray experiment in the hope of identifying “novel” 
genes that are involved in slow myogenesis.  The validity of the microarray 
experiment is verified by the whole mount in situ hybridization experiments that have 
been described earlier in the chapter; the slow muscle markers smyhc1, smylc and 
tnnc(s) were on the list of Blimp1-activated genes and mylz2, a fast muscle marker, is 
on the list of Blimp1-repressed genes.   
 
The output of the microarray experiment represents the cumulative effects of 
the loss of Blimp1 activity throughout the 14 hours of development in all the tissues 
where Blimp1 is expressed.  Thus, the lists of differentially expressed genes would 
contain some genes that are not relevant to slow myogenesis.  We were unable to 
efficiently derive information from the vast lists of differentially expressed genes due 
to a lack of information on gene annotation, gene ontology and spatial expression 
pattern.  This is evident throughout our attempts to process the microarray data.  After 
filtering out the statistically insignificant and unreliable information, 2236 GenBank 
accession entries that remained on the lists.  22% of these entries do not have 
associated gene identities and only 58% of the total were annotated and recognized by 
the DAVID Functional Annotation Clustering Tool.  Furthermore, the lack of up-to-
date and accurate Gene Ontology (GO) annotation results in the inability for the 
Chapter 4  117 
program to return significant and meaningful clustering of the differentially expressed 
genes.   
 
With the continual refinement of the zebrafish genomic sequence and gene 
annotation on Ensembl, we can take a bioinformatics approach to systematically 
BLAST all the GenBank accession entries that do not have associated Unigene IDs 
and map them onto the genome.  As the Ensembl database combines sequence 
information of orthologs from other species, it provides significantly better annotated 
information, which will aid in the identification of these entries.  However, to do so 
manually for the hundreds of unannotated sequences would be tedious and infeasible.  
We would benefit from the automation of the process through the use of computer 
programming scripts to automatically retrieve the sequence information of these 
ESTs, BLAST the sequences, obtain the genomic coordinates and retrieving the 
annotated information from Ensembl.  This will greatly improve the proportion of 
annotated genes and aid in our understanding of the role these genes may play in slow 
muscle development. 
 
One of the initial objectives of the microarray experiment was to identify 
“novel” genes that may play a role in slow muscle development.  However, it would 
not be possible to identify “novel” genes based on GO annotation.  This is because if 
the genes are already annotated with “skeletal muscle development”-related GO 
terms, they would have already been found to play a role in this process, and would 
not be “novel”.  The next approach to refine the analysis would be to filter the 
differentially regulated genes by spatial expression pattern, retaining only genes 
expressed in the myotome.  However, as the list is rather extensive, it would be 
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tedious and infeasible to process them manually.  Although spatial expression pattern 
data is downloadable from ZFIN, an advanced level of bioinformatics skills would be 
required to combine these two pieces of information to derive a refined list of genes 
without tediously going through the list one entry at a time.  In addition, we must bear 
in mind that the expression database may be incomplete and would inadvertently 
result in the removal of false negatives.  Once the methodology for comparing the 
differentially expressed list of genes and spatial expression data is established, the 
lists can be reviewed whenever new expression data becomes available.  With 
available resources, we can also embark on cataloguing the spatial expression patterns 
of the differentially expressed genes with high-throughput in situ hybridization. 
 
Due to a limitation of resources and competing interests in studying the other 
interesting aspects of Blimp1-dependent slow muscle development, the lists of 
differentially regulated genes remain to be thoroughly explored to yield new insights 
into the genetic elements required for slow muscle development.   
 
4.4 Conclusion 
Through a candidate approach, we identified several molecular markers of 
slow muscle lineage whose expression require Blimp1 activity.  In situ hybridization 
analysis in embryos deficient in Blimp1 revealed that its activity is required for the 
induction and maintenance of slow muscle specific genes and the repression of fast 
muscle genes in slow muscle fibres.  These observations reinforce the idea that 
Blimp1 acts as a master regulator in specifying slow muscle cell identity.  The results 
obtained from the Blimp1 knockdown microarray experiment are valid and form the 
basis for future efforts in the identification of Blimp1 target genes.   
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Blimp1 is a SET domain-containing transcription factor that is required for the 
specification of slow-twitch muscle fibres (Roy et al., 2001; Baxendale et al., 2004).  
To understand the molecular function of any transcription factor, we must first 
identify target genes that are directly regulated by it.  This involves demonstrating 
physical interaction to its enhancer sites and modulation of gene expression levels 
upon binding.  Next, we need to determine how the interaction of the transcription 
factor to its enhancer sites lead to activation or repression of these target genes. 
 
Numerous techniques have been developed to investigate the interactions 
between transcription factors and their DNA recognition site.  These techniques can 
be broadly classified into three groups: in vitro, in silico and in vivo binding site 
identification.  
 
Once the target genes have been identified, one can modulate the activity of 
the transcription factor, make chimeric proteins, and alter the identified binding sites. 
These experiments can reveal the second aspect of the function of the transcription 
factor, namely whether it acts as a transcriptional activator or repressor.  Each of these 
techniques has both strengths and weaknesses, and these will be discussed in detail 
here.  Ultimately, a combination of the techniques is the best approach for 
unequivocally defining the mechanism of a transcription factor’s activity. 
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DNA foot-printing is one of the earliest in vitro techniques developed to 
demonstrate direct interaction between a transcription factor and DNA (Galas and 
Schmitz, 1978).  This technique is based on the principle that the binding of the DNA 
binding protein protects the bound DNA from cleavage induced by either DNase or 
small chemical molecules such as methidiumpropyl-EDTA-Fe(II) (van Dyke and 
Dervan, 1983).  5’-labeled fragments of double stranded DNA are partially cleaved by 
DNase in the presence and absence of the transcription factor.  These fragments are 
subsequently resolved and visualized by electrophoresis alongside the reaction 
products of the Maxam-Gilbert sequencing method.  Comparing the two samples 
reveals the protective "footprint" of the binding protein on the DNA sequence.   
 
Other in vitro techniques have been developed to reveal the consensus 
sequence of transcription factors.  These techniques include electrophoretic mobility 
shift assay (EMSA), systematic evolution of ligands by exponential enrichment 
(SELEX) and cyclic amplification and selection of targets (CASTing) (Kuo and 
Calame, 2004, Woodring et al., 1991, Roulet et al., 2002).  They generally involve the 
enrichment of specific DNA species from random sets of oligonucleotides, defining 
the sequence of the preferred binding sites of the transcription factors in vitro.   
 
With the knowledge of transcription factor consensus binding sequences and 
genomic sequence, potential transcription factor binding sites can be mapped in silico 
onto the genome.  In recent years, techniques such as clustering of predicted binding 
sites in addition to searching for closely related sites have greatly improved in silico 
searches (Roulet et al., 2002, Hvidsten et al., 2005). 
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Chromatin Immunoprecipitation (ChIP) has emerged as one of the most 
powerful methods for identifying transcription factor binding sites in vivo (reviewed 
by Massie & Mills, 2008).  ChIP involves the chemical cross-linking of DNA-protein 
complexes in living cells to fix transcription factors to their binding sites in the 
genome.  Cross-linked transcription factor-chromatin complexes are then fragmented 
and immunoprecipitated with antibodies that are specific for the transcription factor of 
interest.  The immunoprecipitated DNA (abbreviated as ChIP DNA) can then be 
purified from the complex by reversing the cross-linkages with the transcription 
factor.  ChIP can be combined with standard assay techniques such as polymerase 
chain reaction (PCR) or quantitative real-time PCR (RT-PCR) to reveal enrichment of 
specific regions of genomic DNA within the ChIP sample.  However, the limitation of 
ChIP-PCR is that it requires the identification of candidate regions where 
transcription factors are likely to bind, which can often be long distances from the 
transcription start site (Lettice et al., 2003).  The power of ChIP is fully realized by 
combining it with whole genome analyses, including genomic microarrays (ChIP-
chip), paired-end ditags (ChIP-PET) or other high-throughput sequencing platforms 
such as Solexa (ChIP-seq) to reveal global occupancy of transcription factor binding 
sites in the genome (Wardle et al., 2005, Wei et al., 2006, Robertson et al., 2007).  
These ChIP derivatives can not only reveal global targets of transcription factor 
binding, the data can be further analyzed to reveal enriched sequence motifs which 
represent the consensus binding sequence of the transcription factor and other 
cooperative transcriptional factors.  ChIP data can be combined with results from 
differential gene anaylsis (e.g. microarray data) to reveal direct regulatory targets.   
 
Chapter 5  122 
Through promoter analysis with reporter gene assay, the interactions between 
transcription factors and their cis-regulatory elements within the promoter of their 
target genes can be dissected.  This approach requires the sub-cloning of a functional 
promoter upstream of a reporter gene.  These reporter genes can be enzymes, such as 
β-galactosidase or luciferase whose activity can be measured, or any protein that can 
be visualized and detected by western blotting, for example, the green fluorescent 
protein (GFP).  Site-directed mutagenesis can be employed to remove the putative 
transcription factor binding sites within the promoter constructs to assess the 
functionality of the sites; mutations that affect the expression of the reporter indicate 
that the site is required for transcription factor binding.  This approach is highly 
informative as it not only reveals specific binding sites of the transcription factor in 
question within a particular promoter, but it also reveals whether the transcription 
factor is activating or repressing the activity of the promoter. 
 
In addition to the identification of the direct targets of transcription factors, the 
second major aspect for understanding the function of a transcription factor is to know 
whether it acts as a transcriptional activator or repressor and how transcriptional 
regulation is mediated.  Promoter analysis, mentioned above, can also reveal the 
regulatory function of transcription factors.  Enhancement of reporter activity in the 
presence of the transcription factor would imply transcriptional activation.  An 
alternative approach commonly used to delineate the activity of transcription factors 
involves the use of recombinant chimeric proteins generated through the fusion of a 
known activator domain (such as the VP16 activator domain, Friedman et al., 1988) 
or a repressor domain (e.g. Drosophila even-skipped repressor domain, Han and 
Manley, 1993) to the DNA-binding domain of the transcription factor of interest.  The 
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fusion protein that mimics the normal activity of the transcription factor reveals its 
transcriptional activity; while the chimera with the opposing activity should produce a 
dominant negative effect.   
 
Our understanding of the molecular mechanism of mammalian Blimp1 is 
derived from the accumulation of a large number of studies that have been carried out 
with a variety of techniques mentioned in the preceding paragraphs (review by 
Calame et al., 2003; Hayashi et al., 2007).  The domain swap approach was used to 
analyze the role of the Xenopus Blimp1 (XBlimp1) in the Spemann organizer (de 
Souza et al., 1999).  In this study, synthetic mRNA encoding activator and repressor 
chimeric constructs were separately injected into Xenopus embryos.  De Souza et al 
(1999) found that the activator chimera mimicked the loss-of-function phenotype and 
produced a dominant negative effect in wild-type embryos.  The authors concluded 
that XBlimp1 functions as a transcriptional repressor in its role in the Spemann 
organizer. The consensus sequence of mouse Blimp1 has been delineated through 
EMSA (Lin et al., 1997, Kuo and Calame, 2004).  The role of Blimp1 as a 
transcriptional repressor is reinforced by the identification of its interacting partners; 
the transcriptional repressor activity of mouse Blimp1 is mediated through the 
recruitment of a number of co-repressors and chromatin modifying enzymes such as 
histone deacetylase 2 (HDAC2), protein methyltransferases Prmt5 and G9a whose 
activities are associated with transcriptional silencing (Ren et al., 1999; Yu et al., 
2000; Ancelin et al., 2006; Gyory et al., 2004).   
 
In this chapter, I will describe the efforts that have been made towards 
understanding the molecular mechanism of Blimp1 function during slow muscle 
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development.  As much more is known about the mechanisms through which mouse 
Blimp1 mediates transcription regulation, we first investigated whether the activity of 
the mouse protein could organize slow muscle development in zebrafish embryos that 
are deficient in endogenous Blimp1 activity.  To further dissect the transcriptional 
activity of Blimp1 during slow muscle development, we studied the effects of 
chimeric repressor and activator constructs on slow muscle development.  We then 
focused our analysis of the regulation of two myosin genes, mylz2 and smyhc1, whose 
transcription are dependent on Blimp1 (Chapter 4).  Through a combination of in 
silico binding site identification, ChIP-PCR assays and promoter reporter analyses, I 




5.2.1 Mouse Blimp1 can induce slow myogenesis in zebrafish embryos deficient 
in Blimp1 activity 
To attain a deeper understanding of the molecular basis of slow muscle 
specification by Blimp1 in zebrafish, we investigated whether the mouse Blimp1 
could organize slow muscle development in zebrafish embryos that are deificient in 
Blimp1 activity.  Using transient transgenesis, we expressed mouse Blimp1 from a 
heat inducible promoter in ubo and smo embryos.  The transmembrane protein Smo is 
essential for intracellular transduction of the Hh signal and thus, smo mutant zebrafish 
embryos are unable to induce blimp1 expression in their presumptive slow muscle 
precursors.  Consequently, these embryos entirely lack the slow muscle lineage (Figs. 
5.1A, B; see also Baxendale et al., 2004; Roy et al., 2001; Barresi et al., 2000).  In 
both ubo and smo mutant embryos, expression of mouse Blimp1 with a heat shock at 
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14 hpf efficiently restores the development of slow-twitch muscle cells within the 
myotome (Figs. 5.1C, D).  Like slow fibers in wild-type embryos, the slow fibers 
induced by mouse Blimp1 are mononucleate, and express the slow lineage markers, 
slow MyHC and Prox1.  Based upon the ability of mouse Blimp1 to substitute for 
zebrafish Blimp1 in slow muscle specification allows us to conclude that the two 
proteins function through conserved molecular mechanisms and share similar DNA 
recognition motifs.  Since the consensus binding sequence of mouse Blimp1 has been 
determined, it is likely that zebrafish Blimp1 recognizes the same motif, AGTGAAA 
(Kuo and Calame., 2004). 
 
5.2.2 Blimp1 mediates both transcriptional activation and repression in its role 
in slow muscle formation 
Based upon the results above, we speculated that zebrafish Blimp1, like mouse 
Blimp1, functions as a transcriptional repressor in its role during slow muscle 
differentiation.  To dissect the role of Blimp1 during slow muscle development, we 
generated a chimeric repressor construct that directs transcriptional repression of 
Blimp1 target genes.  The repressor construct Eve-ZFD comprises of the fusion of the 
Drosophila Even-skipped (Eve) repressor domain (residues 334-1126) (Han and 
Manley, 1993) and the zinc-finger DNA-binding domain (ZFD) of Blimp1 (residues 
491-666).  We also generated an activator construct by fusing the activator domain of 
the Human Simplex Virus Viral Protein 16 (VP16, Friedman et al., 1988) to the ZFD 
as a control (Fig. 5.2A).  Ectopic induction of the repressor construct, Eve-ZFD, 
effectively recapitulated slow muscle development in smo embryos (Figs. 5.2B, C).  
Surprisingly, ectopic expression of the VP16-ZFD activator construct also resulted in 
the expression of slow MyHC and Prox1 in smo embryos (Figs. 5.2D, E).  However,  




Fig. 5.1.  Mammalian Blimp1 protein can rescue slow myogenesis in zebrafish 
embryos that lack endogenous Blimp1 activity. (A) smo embryos lack all slow 
muscle fibers.  (B) ubo embryos possess a few residual slow MyHC positive cells 
(green, arrow). These cells are not properly differentiated slow muscle fibers, as they 
do not express Prox1 (red).  (C, D) Expression of mammalian Blimp1 from a heat-
inducible promoter can rescue slow muscle development in both smo (C) and ubo 
embryos (D). All panels depict lateral views of 24 hpf embryos stained with mAb F59 
(green) and anti-Prox1 (red). Scale bar=25 μm. 
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Fig. 5.2. Both activation and repression of Blimp1 target genes can recapitulate 
slow muscle fate in smo embryos.  (A) Schematic representation of the chimeric 
constructs that consist of the zinc finger DNA binding domain (ZFD) which targets 
the VP16 activation domain (VP16AD), Even-skipped repressor domain (EveRD) to 
Blimp1 target sites.  Induction of ZFD, VP16AD-ZFD and EveRD-ZFD results in 
recapitulation of slow muscle fate in smo embryos (B, C and D respectively).  All 
panels depict lateral views of 24 hpf embryos stained with mAb F59 (green) and anti-
Prox1 (red).  Scale bar=25 μm. 
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there was no slow muscle formed when the ZFD alone was induced in smo mutant 
embryos (Fig. 5.2B).  These results did not provide a conclusive answer as to whether 
Blimp1 acts as an activator or a repressor in slow muscle development.  It is possible 
that Blimp1 mediates both transcriptional activation and repression in its role in slow 
muscle formation. 
 
5.2.3 Regulation of mylz2 by Blimp1 
We have previously shown that mylz2 is mis-regulated in the absence of 
Blimp1 activity through in situ hybridization analysis of its transcripts (Fig. 4.2).  A 
2kb region upstream of the mylz2 has been previously described to recapitulate the 
expression pattern of the gene through the expression of a GFP reporter (Ju et al., 
2000), suggesting that this 2kb region contains most of the necessary regulatory 
elements required for tissue-specific induction of mylz2.  We searched this sequence 
for the presence of the Blimp1 binding consensus sequence, AGTGAAA (Kuo and 
Calame, 2004), allowing a 1-base mismatch in the first 4 bases in the consensus 
sequence, as the last AAA motif was found to be invariant in the consensus (Kuo and 
Calame, 2004).  Six putative Blimp1 binding sites were identified within this 2 kb 
region (Fig. 5.3A).   
 
5.2.3.1 Blimp1 directly represses the expression of mylz2  through conserved 
binding sites located within the promoter 
To adduce evidence for the regulation of the mylz2 promoter by Blimp1, we 
performed ChIP with extracts from embryos that overexpressed Blimp1 from the heat 
shock-blimp1HA (hs::blimp1HA) transgene.  We subjected the ChIP DNA to PCR 
analysis using primer pairs that tiled the mylz2 promoter.  Using this assay, we found 
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Fig. 5.3.  ChIP analysis reveals that Blimp1 binds to the promoter of the mylz2 
gene.  (A) The mylz2 gene promoter region contains six putative Blimp1 binding sites 
(red arrows, direction indicates orientation) based on variations of the mouse Blimp1 
consensus binding sequence. Numbers indicate base pairs relative to the transcription 
start site (black arrow). Positions of PCR primers designed to test for Blimp1 binding 
are indicated (red bars, mylz2 I-IV). (B) PCR analysis of chromatin before ChIP 
(Input), and after immunoprecipitation with anti-HA antibodies or a negative control - 
anti-GFP antibodies.  Sequences near the β-actin1 gene served as a control for non-
specific ChIP (β-actin I, II). 
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the specific enrichment of genomic regions upstream of mylz2 with 
immunoprecipitation of Blimp1HA (Fig. 5.3B).  No signal was detected in the 
negative control preparations where the same extracts were subjected to 
immunoprecipitation with an anti-GFP antibody.  In addition, two sets of primer 
probes were designed to detect genomic regions upstream of the β-actin gene which 
are unlikely to be bound by Blimp1.  The lack of amplified signal with these probes 
further indicated that the enrichment of the mylz2 promoter region was specific and 
not the result of a difference in the quantity of the template ChIP DNA present in the 
two samples.  These results demonstrate specific binding of Blimp1 to regions in the 
mylz2 promoter that harbour the putative Blimp1 binding sites.  Thus, we conclude 
that Blimp1 directly acts on the promoter of mylz2 to repress the expression of this 
gene in muscle precursors committed to the slow-twitch fate. 
 
5.2.3.2 The loss of Blimp1 binding sites in the mylz2 promoter leads to an 
increase in reporter gene expression in slow muscle fibres 
Based on the observation that mylz2 transcripts are mis-regulated in the 
adaxial cells of ubo embryos (section 4.2.3), we reasoned that if the previously 
characterized mylz2::egfp promoter reporter faithfully mimics expression of the gene 
(Ju et al., 2000), this promoter should express EGFP in the presumptive slow muscle 
cells in ubo embryos.  We found that this was indeed the case; we observed EGFP 
expression in the presumptive slow fibres when the mylz2::egfp reporter construct 
was injected into ubo embryos as the lack of functional Blimp1 activity results in the 
dysregulation of its activity (Fig. 5.4A).  This observation supports the possibility that 
Blimp1 negatively regulates the activity of this promoter.  We went on to use this 
promoter reporter as a tool to analyze whether the putative Blimp1 binding sites 




Fig. 5.4. The lost of Blimp1 binding sites in the mylz2 promoter leads to an 
increase in reporter gene expression in slow muscle fibres. (A) A transverse 
section of a 24 hpf ubo embryo showing expression of the EGFP reporter (green) 
from mylz2::egfp in presumptive slow muscle fibres (red, arrow). (B)  A transverse 
section of a 24 hpf wild-type embryo with majority of the EGFP reporter (green) in 
the fast muscle cells and an occasional EGFP-positive slow-twitch fibre (red, arrow). 
(C) Schematic representation of mylz2::egfp (top) and mylz2(mut)::egfp (bottom) 
constructs where red arrows represent putative Blimp1 binding sites and black X 
represents deleted Blimp1 binding sites.  (D) Quantification of GFP positive slow 
fibres as a proportion of total GFP positive fibres.  When injected into wild-type 
embryos, mylz2(mut)::egfp gave rise to a higher proportion of EGFP-positive slow 
fibres than mylz2::egfp.  More than 1000 fibres were scored in each group. Scale 
bar=25 μm. 
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within this region are indeed required for Blimp1-mediated transcriptional repression 
of this locus.   
 
We performed site-directed mutagenesis to remove the three putative Blimp1 
binding sites proximal to the transcription start site within the mylz2 promoter.  We 
hypothesized that Blimp1 represses the transcription of mylz2 through binding to 
these sites, and their removal would lead to an increase in the number of EGFP-
positive superficial slow fibres in wild-type embryos as Blimp1 would no longer be 
able to effectively repress the activity of this promoter.  Approximately 3% of all 
EGFP expression was seen in superficial slow fibres when the mylz2::egfp was 
injected into wild-type embryos (Figs. 5.4B, C).  By comparison, 8.1% of all EGFP-
positive muscle fibres were located in the superficial slow fibres when the mutated 
reporter construct, mylz2(mut)::egfp was injected.   This represents a 2.6-fold increase 
in the proportion of EGFP-positive slow fibres as a function of the total number of 
EGFP-positive fibres.  These results suggest that the promoter harbours bona fide 
Blimp1 binding sites that are functional in vivo. 
 
5.2.4 Regulation of smyhc1 by Blimp1 
5.2.4.1 A 2kb fragment upstream of the transcription start site is sufficient to 
recapitulate trunk expression of smyhc1 
Through in situ hybridization analysis, we have previously shown that smyhc1 
transcripts are not fully induced in the absence of Blimp1 activity (Fig. 4.1A-C).  Our 
approach to delineate the regulatory region of smyhc1 was to clone increasingly larger 
fragments of genomic DNA upstream of the transcription start site of the gene.  
Through this analysis we found a genomic fragment of approximately 2070 bp 
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immediately upstream of the transcription start site, when subcloned in front of the 
EGFP reporter gene, can effectively recapitulate the expression pattern of smyhc1 in 
the slow muscle fibres in the trunk (Fig. 5.5B).  This promoter reporter construct, 
termed smyhc1(p22)::EGFP, also faithfully mimics the expression of slow MyHC 
expression in smo and ubo embryos (Figs. 5.5C, D respectively).  Deletion analysis, 
utilizing an internal Hind III site within the smyhc1(p22) promoter, revealed that a 
626 bp fragment can also drive lineage-restricted expression of the reporter gene in 
slow muscle fibres at lower levels (Figs. 5.5E, cf panel B).  In silico analysis of 
smyhc1(p22) revealed six putative Blimp1 binding sites, raising the possibility that 
Blimp1 could bind to these sequences to regulate the expression of this gene. 
 
5.2.4.2 The loss of Blimp1 binding sites in the smyhc1 promoter renders it 
unresponsive to Blimp1 activity 
In the preceding section, we have shown that the smyhc1 promoter contains 
putative Blimp1 binding sites.  In order to verify that the predicted motifs are   
functional Blimp1 binding sites, we used site-directed mutagenesis to remove the 
three proximal-most binding sites relative to the transcription start site of smyhc1.  
The mutated variants of the reporter constructs were injected into zebrafish embryos 
and the level of activity was assayed by quantifying the amount of reporter gene 
product (i.e. EGFP) expressed at 24 hpf by western blot analysis.  The western blot 
data was quantified through densitometric measurements of the band intensities which 
were normalized and displayed as levels relative to that of the full-legth wild-type 
construct, smyhc1(p22) (Fig. 5.6).  Mutations of the putative Blimp1 binding sites 
within smyhc1(p22) did not result in any compromise in the lineage specificity from  
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Fig. 5.5.  A 2kb fragment upstream of the smyhc1 transcription start site is 
sufficient to recapitulate trunk expression of smyhc1. (A) The schematic 
representation of reporter constructs smyhc1(p22)::egfp (top) and the truncated 
smyhc1(p23)::egfp (bottom). (B) smyhc1(p22)::egfp drives EGFP expression (green) 
specifically in superficial slow fibres (stained with F59, red) (C, D) EGFP expression 
(green, arrows) from smyhc1(p22)::egfp faithfully mimics the expression of slow 
MyHC (red) in smo (C) and ubo (D) mutant embryos. (E) The truncated (626 bp) 
smyhc1(p23)::egfp reporter retains lineage-restricted expression of the reporter gene 
(green, arrows) in slow muscle fibres (red). Scale bar=25 μm. 
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Fig 5.6.  Deletion of putative Blimp1 binding sites in the smyhc1 promoter leads 
to a reduction of reporter gene expression in slow muscle fibres. (A) The 
schematic representation of smyhc1(p22)::egfp and smyhc1(p23)::egfp and their 
variants.  Putative Blimp1 binding sites are shown in red and the direction of the 
arrows represent the orientation of the site. “m1” represents mutation of the putative 
Blimp1 binding site most proximal to the transcription start site (TSS), while “m2” 
represents the mutation of the group of two putative binding sites located more 
distally to the TSS and “m1+m2” represents the mutation of all three sites. (B)  The 
graphical representation (top) of the relative levels of expression of GFP expression 
determined by Western blot analysis (bottom half, top panel) from the 
smyhc(p22)::egfp and its variants (dark blue bars) and smyhc1(p23)::egfp and its 
variants (light blue bars). Actin was used as loading control (bottom half, bottom 
panel).  Error bars represent standard error from 3 biological replicates. 
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the promoter variants but resulted in a marked reduction in the level of EGFP 
expression (Fig. 5.6).   
 
Although the removal of putative Blimp1 binding sites correlates with 
reduction in the activity of the smyhc1 promoter, it does not provide direct evidence 
that Blimp1 functions through the occupation of these sites.  To demonstrate that 
these putative sites are required for the Blimp1-mediated up-regulation of smyhc1, we 
compared the level of reporter gene expression from smyhc1(23)::egfp and the 
mutated variant smyhc1(p23-m1+2)::egfp (Fig. 5.7A) in the presence or absence of 
ectopic Blimp1HA (Fig. 5.7B).  If these predicted binding motifs are bona fide 
Blimp1 binding sites, occupancy by Blimp1 would enhance the activity of this 
promoter.  On the other hand, the reporter construct where these predicted motifs are 
mutated would not be responsive to Blimp1 activity.  Co-expression of Blimp1HA 
with smyhc1(p23)::egfp results in a 2-fold increase in EGFP expression compared to 
expression from smyhc1(23)::egfp in the absence of Blimp1HA (Fig. 5.7B).  In 
contrast, smyhc1(p23-m1+2)::egfp appears to be unresponsive to the induction of 
Blimp1HA as the level of reporter gene expression from smyhc1(p23-m1+2)::egfp did 
not differ significantly when Blimp1HA was induced.  These results show that the 
predicted Blimp1 binding sites within smyhc1(p23)::egfp are functional Blimp1 
binding sites required for Blimp1-mediated up-regulation of smyhc1. 
 
5.3 Discussion 
5.3.1 Molecular Mechanism of Blimp1 function 
Based on the high level of conservation between the vertebrate orthologs of 
Blimp1, it is not surprising that mouse Blimp1 can recapitulate the slow muscle 




Fig. 5.7.  Mutation of Blimp1 binding sites in the smyhc1 promoter renders it 
unresponsive to Blimp1 activity.  (A) The schematic representation of the constructs 
used in this experiment; smyhc1(p23)::egfp which possess “functional” putative 
Blimp1 binding sites and smyhc1(p23-m1+m2)::egfp where all the putative Blimp1 
binding sites have been mutated. (B) The graphical representation (top) of the relative 
levels of expression of GFP expression determined by Western blot analysis (second 
last panel from the bottom) from the smyhc(p23)::egfp and its variant with or without 
Blimp1HA induction (indicated by ‘+’). Actin was used as loading control (bottom 
panel).  Error bars represent standard error from 3 biological replicates. 
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development program in ubo and smo embryos (Fig. 5.1).  This result is significant as 
it suggests that mouse Blimp1 recognizes the same target sites as zebrafish Blimp1.  
The consensus binding sites for mouse Blimp1 in vitro has previously been 
characterized as AGTGAAA (Kuo and Calame, 2004).  In addition, mouse Blimp1 
was also found to act primarily as a transcriptional repressor and, thus, we 
hypothesized that zebrafish Blimp1 could act as a repressor in the development of 
slow muscle fibres.   
 
We made use of chimeric constructs that either ectopically activate or repress 
Blimp1 target genes to verify this finding.  To our surprise, this experiment produced 
confounding results.  We found that ectopic expression of both activation and 
repression of Blimp1 target genes lead to the recapitulation of slow muscle 
development in smo embryos.  These “rescued” fibres express slow MyHC and Prox1 
and are located on the surface of the myotome.  These fibres are also mononucleate, 
which imply that they did not undergo fusion, the default fate of presumptive slow 
cells that fail to differentiate into slow muscle fibres (Roy et al., 2001).  These results 
together may suggest that Blimp1 function both as an activator and a repressor in the 
process of slow muscle differentiation.  Blimp1 could activate genes required for slow 
muscle fate while repressing repressors of slow muscle specific genes, in addition to 
repressing genes required for fast muscle fate.  Thus, it is likely that the net result of 
Blimp1-mediated transcriptional repression and activation result in gene expression 
that is required for slow muscle differentiation. 
 
Almost all of the analyses on the role of Blimp1 in transcriptional regulation 
have revealed its role as a transcriptional repressor (Calame et al., 2003, Hayashi et 
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al., 2007).  A recent study on specification of the germ cell lineage in mice provided 
evidence that Blimp1 can directly upregulate gene expression (Kurimoto et al., 2008).  
By combining ChIP (Blimp1 binding data) and microarray data (of differential gene 
expression), the authors found that Blimp1 is responsible for the activation of half the 
genes that are up-regulated in these cells.  The ability of the chimeric Blimp1 
activator construct to recapitulate slow muscle development in zebrafish provides new 
evidence in support of an activating role of Blimp1. 
 
5.3.2 Blimp1 ChIP experimental design 
There have been very few studies involving ChIP from zebrafish embryos.  
One recent study reported a ChIP-chip analysis of actively transcribed genes in 
zebrafish embryos through the immunoprecipitation of tri-methylated lysine 4 in 
Histone 3 (H3) (Wardle et al., 2006).  The protocol described in this study was used 
as a reference for the design of our ChIP experiment.  It details the immuno-
precipitation of histones which are abundant in all cells within zebrafish embryos, 
thus modifications were necessary to adopt the protocol for its application to our 
analysis of Blimp1 in slow muscle development.   
 
There are two important considerations that are critical to the success of the 
ChIP experiment – first, it is the abundance of the transcription factor of interest and 
second, it is the availability of an antibody of sufficiently high purity that specifically 
recognizes the transcription factor.  Blimp1 is a transcription factor that is expressed 
in the adaxial cells.  This is in stark contrast with histones, which are ubiquitously 
expressed in all cells and in abundance.  Furthermore, the polyclonal antibody that 
was raised against the zebrafish Blimp1 is not of sufficiently high purity for the ChIP 
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experiment.  To overcome these limitations, we over-expressed a HA-tagged version 
of Blimp1 using the heat inducible promoter.  This allows us to overcome the problem 
of insufficient quantities of Blimp1 protein and the high quality of commercially-
available anti-HA antibodies also improved the efficiency and specificity of the 
immunoprecipitation.   
 
There are, however, drawbacks with the over-expression strategy.  The 
binding of transcription factors to chromatin depends on the chromatin structure and 
conformation, and may vary with the cellular context.  The over-expression of Blimp1 
in non-slow muscle cells may consequently lead to the pull down of exogenous 
genomic fragments that interact with Blimp1 beyond a physiologically relevant 
context.  This strategy would not be suitable if our goal is to perform an unbiased 
genome-wide analysis of the ChIP DNA.  However, as the focus of this study is to 
investigate the interactions between Blimp1 and the regulatory regions of a specific 
group of genes with PCR assays, this approach is not expected to significantly affect 
our analysis.   
 
In our final protocol, we incorporated two modifications to the protocol 
described by Wardle et al. (2006).  The first of which is the pre-clearing of the 
sonicated nuclear extract through anti-V5-coupled magnetic beads before application 
of the supernatant to the anti-HA or anti-GFP-coupled beads for immunoprecipitation.  
The pre-clearing step removes constituents in the sonicated nuclear extract that bind 
non-specifically to the reagents.  The next modification is in the elution procedure – 
the Blimp1HA-chromatin-bead complex is treated with 3x HA peptide before eluting 
with the elution buffer.  The ChIP DNA subjected to this treatment shows significant 
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reduction in the background signal.  With these enhancements to the protocol, we 
were able to achieve the results described in this chapter. 
 
5.3.3 Blimp1 directly represses the expression of mylz2  by binding to 
conserved binding sites located within the promoter 
We have provided genetic evidence that mylz2 is regulated by Blimp1; mylz2 
which is normally only expressed in the fast muscle cells after 18 hpf, was mis-
expressed in the slow muscle precursors at 12 hpf of ubo embryos.  Through ChIP 
analysis, we showed that Blimp1 binds to the regulatory region of this gene.  These 
results taken together provide valuable new insights into the molecular mechanism of 
Blimp1 transcription regulation of slow myogenesis; Blimp1 binds to the promoter of 
fast muscle-specific genes and represses their expression in slow muscle precursors.   
 
Based on our hypothesis that Blimp1 represses the mylz2 promoter, we 
designed and performed an experiment that aims to test whether the putative binding 
sites within the promoter region are required for interactions with Blimp1.  We tested 
if there was any increase in the proportion of GFP-positive slow muscle fibres when 
the putative Blimp1 binding sites are removed from the mylz2 promoter.   
 
Surprisingly, we observed expression of the GFP reporter in slow muscle 
fibres when the wild-type mylz2::egfp reporter construct was transiently expressed in 
wild-type embryos (Fig. 5.4B).  This observation increased the difficulty of the 
functional analysis as it increased the “background” of what is already a small 
quantifiable number.   
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As surface slow fibres are less abundant than fast muscle fibres, the 
probability of the construct being present in a slow muscle fibre is lower than it being 
present in a fast fibre, making the measurable effect relatively small.  Despite these 
limitations, we were able to detect a small but significant change with the removal of 
the three proximal most putative Blimp1 binding sites.   
 
Although there is an observable change from the removal of the three most 
proximal Blimp1 binding sites, it will be interesting to test if removal of the 
remaining three sites would result in a more pronounced effect.  Furthermore, the 
reported transcriptional repression mediated by mammalian Blimp1 involves the 
recruitment of chromatin modifying enzymes to mediate its function.  It is not known 
how Blimp1 regulates the reporter construct that is not in the chromatin context.  A 
more definitive study would require the generation of a stable transgenic zebrafish 
strain that carries the promoter-reporter construct that lacks all Blimp1 binding sites.  
Based on our hypothesis that these sites are important for Blimp1-mediated repression 
of mylz2, we would expect that most, if not all, of the slow muscle fibres in these 
transgenic animals would express EGFP. 
 
5.3.4 Blimp1 directly activates the expression of smyhc1 through conserved 
binding sites located within the promoter 
The analysis of smyhc1 expression in blimp1 mutants (ubo and nrd) revealed 
that the level of its transcript is reduced compared to its heterozygous and wild-type 
siblings during early somitogenesis (section 4.2.1.2), and the transcript is undetectable 
by 24 hpf.  These observations suggest that Blimp1 is not required for the induction of 
this gene, and its activity is also necessary for sustained expression of the gene at 
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wild-type levels.  The functional analysis of the promoter supports the notion that 
occupancy of Blimp1 consensus sites within the promoter results in enhanced 
expression of the reporter gene (Fig. 5.6, section 5.2.4.2).  These observations would 
concur with our previous observation that slow MyHC is expressed with the VP16-
ZFD chimeric construct wa ectopically induced (section 5.2.2).  These results support 
the notion that Blimp1 can directly up-regulate its target genes, which is a deviation 
from its previously described role as a transcriptional repressor.  However, we believe 
that the continued occupancy of the promoter by Blimp1 is not required for the 
maintenance of smyhc1 expression since Blimp1 expression disappears from maturing 
slow muscles.  Thus, it appears that there may be additional mechanisms, such as 
chromatin remodelling or the induction of additional transcription factors required for 
the sustained expression of smyhc1 during slow muscle differentiation. 
 
5.3.5 Blimp1-mediated repression of fast muscle specific gene is corroborated 
by an independent analysis 
During the preparation of this thesis, there was an independent study which 
corroborated with our finding that Blimp1 directly represses fast muscle-specific 
genes in slow muscle precursors (von Hofsten et al 2008).  The authors reported that 
the zebrafish Sry-Box 6 (Sox6) homolog acts as a repressor of slow muscle genes in 
the fast muscle precursors and its expression is normally repressed by Blimp1 in the 
adaxial cells.  In ubo mutants, sox6 expression in the adaxial cells is de-repressed and 
slow MyHC is repressed.  However, the loss of Sox6 is not sufficient to completely 
restore slow fibre formation in blimp1 mutants.  This indicates that the repression of 
sox6 is one aspect of Blimp1 function in the induction of the slow-twitch fibre fate.  It 
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is also noteworthy that the ChIP-chip performed in this study revealed that Blimp1 
did not bind to the vicinity of the sox6 locus. 
 
5.4 Conclusion 
In this chapter, we have found that mouse Blimp1 is capable of rescuing the 
slow muscle development program in zebrafish embryos that are deficient in Hh 
signalling and Blimp1 activity.  Activation and repression of Blimp1 target genes 
result in the rescue of slow muscle fibres.  This suggests that Blimp1 could act as both 
an activator and repressor in the development of slow muscles and the net effect of its 
activity results in the specification and differentiation of both superficial slow fibres 
and muscle pioneers in the embryonic myotome.  I have previously demonstrated that 
smyhc1 and mylz2 are differentially regulated by the Blimp1.   Through a combination 
of ChIP-PCR and reporter assays coupled with functional analysis of putative binding 
sites, I have demonstrated that the binding of Blimp1 to the promoter regions of these 
genes is required for their regulation.  smyhc1 expression is induced in the adaxial 
cells and Blimp1 activity is required for the maintenance of expression of this gene.  
mylz2 is a fast muscle specific gene that is directly repressed by Blimp1 binding to its 
promoter.  In ubo embryos where there is a deficiency in Blimp1 activity, mylz2 
expression is de-repressed and is induced in the presumptive slow muscle precursors.  
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Chapter 6 
DISCUSSION AND CONCLUSION 
 
In this chapter, I will outline the advances made by this study towards the 
understanding of the molecular mechanisms that underlie Blimp1 function during 
slow muscle development.  I also include a list of direct Blimp1 target genes based on 
available evidence and a proposed updated model for genetic regulation of slow 
muscle development.  I will raise the questions that still need to be addressed with 
respect to the function of Blimp1 during slow muscle development and discuss the 
possible directions for future research.  Finally, I summarize the findings made in this 
study towards understanding the genetic control of vertebrate muscle cell identity.  
 
6.1 Advances made towards the understanding of the molecular mechanisms 
that underlie Blimp1 function during slow muscle development 
Genetic analyses revealed that Blimp1 encodes an Hh-dependent regulator of 
slow-twitch muscle fibre specification.  Its activity is necessary and sufficient for the 
slow muscle development program in zebrafish (Baxendale et al., 2004).  The loss of 
Blimp1 activity results in the failure to express slow MyHC and Prox1 and leads to 
the fusion of presumptive slow cells to form multinucleate fibres (Roy et al., 2001).   
 
The expression of myoD and blimp1 in the adaxial cells require Hh signalling 
from the notochord (Concordet et al., 1996, Baxendale et al., 2004).  In this study, we 
showed that the acquisition of myogenic fate is required for the expression of blimp1.  
Our analysis revealed a transcriptional regulation cascade that is required for the 
specification and differentiation of slow muscle fibres – Hh signalling induces the 
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expression of MyoD and Myf5 in the adaxial cells.  Together with Myf5, the activities 
of these MRFs induce the expression of Blimp1 which specifies adaxial myoblasts 
into slow muscle fibres. 
 
Blimp1 is expressed during the initial phases of slow muscle specification and 
represents one of the earliest markers of this lineage (section 3.2.1).  Its expression is 
transient.  It is present in adaxial cells for approximately 8 hours and is extinguished 
in the most matured slow muscle fibres by 18 hpf.  The activity of Blimp1 is required 
for the induction of smyhc1, a definitive slow muscle marker, during the early phases 
of slow myoblasts differentiation.  In contrast to the transient expression of Blimp1, 
the expression of smyhc1 persists throughout the larval stages of development 
(Elworthy et al., 2007).  Taken together, these observations suggest that Blimp1-
mediated induction of smyhc1 expression does not require its continuous occupation 
of the smyhc1 promoter.  Thus, Blimp1 activity may either mediate epigenetic 
changes at the smyhc1 locus allowing it to be accessible for continuous expression, or 
it may induce the expression of additional transcription factor(s) that are in turn 
required for the sustained expression of smyhc1.  It is also possible that these and 
other mechanisms may act in concert to maintain gene expression required for slow 
muscle development. 
 
Consistent with previous analysis which showed that mammalian Blimp1 
functions as a transcriptional repressor (Calame et al., 2003, Hayashi et al.,2007), we 
found that zebrafish Blimp1 directly represses the expression of the fast muscle-
specific mylz2 in the slow muscle precursors by binding directly to the cis-regulatory 
motifs located within its promoter (section 4.2.5, Ju et al., 2000).  Furthermore, our 
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study has also revealed that both repression and activation of Blimp1 targets together 
result in the recapitulation of slow muscle development.  These results suggest that 
the effects of repression and activation of Blimp1 target genes reinforce the effects of 
one another during slow muscle differentiation.   
 
A recent paper published during the preparation of this thesis concurs with our 
conclusion that Blimp1 directly represses fast muscle-specific genes in slow muscle 
precursors during slow myogenesis (von Hofsten et al., 2008).  With genome wide 
analysis of Blimp1 binding sites through ChIP-chip analysis, the authors showed the 
binding of Blimp1 to genomic regions in the vicinity of a large number of fast 
muscle-specific structural genes which are mis-expressed in the adaxial cells of ubo 
embryos. 
 
However, there appears to be two discrepancies between the findings of von 
Hofsten et al. (2008) and our study.  Firstly, the study by von Hofsten et al (2008) 
reported that Blimp1 does not bind directly to the regulatory elements of any of the 
slow muscle-specific genes.  This result appears to contradict our finding that 
implicated a direct regulation of smyhc1 by Blimp1.  This difference could be due to 
the fact that the probes on the microarray used by von Hofsten et al (2008) were 
designed based on an older release of the genomic annotation in Ensembl, which had 
incorrectly annotated the transcription start site of smyhc1.  As a result, their probes 
would not be able to detect ChIP DNA of the bona fide regulatory region of smyhc1.  
The second discrepancy between the results from the two studies is the difference in 
the ability of the chimeric Blimp1 activator construct to recapitulate slow muscle 
development in smo embryos.  While we were able to show that the VP16-ZFD 
Chapter 6  148 
construct robustly recapitulates expression of slow MyHC and Prox1 in smo embryos 
(section 5.2.2), the VP16-Prdm1 construct described by von Hofsten et al. (2008) did 
not rescue Prox1 expression in smo embryos.  Based on the description for the 
construction of the VP16-Prdm1 chimeric construct, it appears that it is almost 
identical to the VP16-ZFD described in our study.  The reason for this discrepancy in 
the results obtained with the two constructs remains unknown. 
 
von Hofsten et al (2008) also showed that Blimp1-dependent repression of 
sox6 is necessary for the proper execution of slow fiber differentiation.  They showed 
that the zebrafish sox6 is expressed in the presumptive fast muscle precursors in wild-
type embryos and is mis-regulated in the adaxial cells of ubo mutant embryos.  They 
proposed that Blimp1 (the master regulator of slow muscle fate) represses sox6 
expression in the adaxial cells and allows the expression of slow muscle-specific 
genes.  The loss of blimp1 activity in ubo mutant embryos results in the mis-
regulation of sox6 in the adaxial cells, which in turn results in the repression of the 
slow muscle markers, slow MyHC and Prox1.  However, unlike the effect of ectopic 
Blimp1 reported in our study (section 3.2.5), loss of Sox6 is unable to fully institute 
the slow-twitch differentiation program in precursors of the fast-twitch lineage.  It is 
noteworthy that the ChIP-chip performed by von Hosten et al. (2008) revealed that 
Blimp1 did not bind to the vicinity of the sox6 locus.  This data suggests Blimp1 does 
not directly repress sox6 expression and that there may be other Blimp1-dependent 
transcription factors that are involved in the repression of Sox6.  Together, our study 
and that by von Hofsten et al. (2008) suggest that the proper execution of slow muscle 
developmental program involves additional layers of transcriptional regulation. 
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6.2 List of direct Blimp1 target genes 
We attempted to identify novel Blimp1 target genes through a microarray 
analysis comparing the differential gene expression between wild-type and blimp1 
morphant embryos.  This experiment yielded an extensive list of genes that are 
differentially regulated by Blimp1 in the myoblasts and other tissues within the 
embryo.  The results obtained from the microarray is consistent with our 
understanding of slow muscle development as it shows that slow muscle-specific 
genes are up-regulated by Blimp1, while fast muscle-specific genes are down-
regulated.   
 
We compared our list of differentially regulated genes obtained from the 
microarray experiment with the list of genes obtained from Blimp1 ChIP-chip 
analysis published by von Hofsten et al. (2008) in the hope of identifying direct 
Blimp1 target genes.  As the ChIP-chip was performed on enriched FACS-sorted 
adaxial cells, the targets on this list would represent targets of Blimp1 interaction 
within the slow muscle precursors.  By combining the data from this study, a 
definitive list of direct Blimp1 target genes was compiled (Table 6.1).  Based on the 
available evidence to date, there are only 28 direct Blimp1 targets.  Nine of these 
genes are up-regulated while 19 are down-regulated by Blimp1 activity.   
 
There are no transcription factors amongst the 9 direct target genes which are 
up-regulated by Blimp1.  cyclin G2 (ccng2) is one of the direct targets that is activated 
by Blimp1.  It is likely that Blimp1 promotes terminal differentiation of the adaxial 
cells by preventing their progression through cell cycle through activating ccng2 
expression which has been associated with growth arrest (Horne et al., 1997).  A 
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survey of the expression pattern of the Blimp1-activated genes on the ZFIN 
expression database revealed that at least two of these genes, zgc:100989 and fga, do 
not appear to be expressed in the slow muscle lineage.  This finding is rather 
confounding as these target genes were supposed to have been derived from the ChIP 
of endogenous Blimp1 in adaxial cells.   
 
The list of direct Blimp1 targets contains 3 fast muscle-specific genes, mylz2, 
tnnt3a and myhz2, which are directly repressed by Blimp1.  hif1a and n-myc are the 
only transcription factors that are directly repressed by Blimp1.  While n-myc may be 
repressed by Blimp1 thus suppressing cell cycle progression of adaxial cells, the role 
of hif1a in muscle development is unknown.  The remaining genes on the list encode 
membrane proteins and proteins involved in a range of signalling pathways.   
 
From this analysis, we observed that the transcriptional activation and 
repression activities of Blimp1 play complementary roles in promoting the exit of 
adaxial cells from the cell cycle, that is, through the activation of cyclin G2 and 
repression of n-myc.   
 
 Based on our current understanding of Blimp1’s role in the regulation of slow 
muscle development, we hypothesize that there must be additional levels of 
transcriptional regulation to account for the repression of sox6 and the sustained 
expression of smyhc1 mentioned earlier in this discussion.  Thus, the identity of the 
transcription factors that may function in the intermediate steps remains to be 
discovered. 
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6.3 Updated model of vertebrate muscle cell fate specification 
The results from this study have advanced our understanding of the genetic 
regulatory pathway that is required for slow muscle differentiation.  Taken together 
with the conclusions from other studies, we are able to construct an updated model of 
the genetic regulatory pathway involved in the specification of slow muscle fibres 
(Fig. 6.1).  We have shown that expression of blimp1 in adaxial cells requires 
myogenic competence.  Blimp1 activity directly represses fast muscle specific genes 
in the slow muscle precursors (the adaxial cells). 
 
  Although we provide some evidence for a direct activation of the definitive 
slow muscle marker smyhc1 by Blimp1, work by von Hofsten et al. (von Hofsten et 
al., 2008) suggests that de-repression through the loss of Sox6 can also result in its 
expression.  As there is no evidence to support that Blimp1 directly represses the 
expression of sox6, we hypothesize that this repression may be mediated through 
other transcription modulators whose expression is dependent on Blimp1 activity.   
 
6.4 Future work 
Blimp1 is expressed in multiple tissues during zebrafish development.  It 
must, therefore, regulate different sets of genes within these different contexts.  In 
addition, Blimp1 mediates transcriptional activation and repression of different sets of 
target genes within the context of slow muscle development.  These observations raise 
several questions about the underlying mechanisms of Blimp1 function: what confers 
the contextual response to Blimp1?  How does Blimp1 mediate activation of its target 
genes while repressing others?  Does it act through chromatin remodelling events or  
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Fig. 6.1.  Schematic representation of the genetic pathway that regulates 
specification and differentiation of slow muscle fibres.  Hh signalling from the 
midline induces MyoD expression in the adaxial cells.  MyoD and Myf5 activity in 
the adaxial cells induces myogenesis and these myoblasts express Blimp1, the slow 
muscle master regulator.  Blimp1 directly represses fast muscle specific genes and 
induces smyhc1.  Blimp1 activity is also required for the repression of Sox6 which 
would otherwise repress the expression of slow muscle markers.  Based on available 
genetic evidence, there may be yet unknown transcriptional modulators that are 
required for the induction of slow muscle specific genes.  [*] denotes contributions 
made by this study.  Blue arrows represent up-regulation, solid red bars denote direct 
repression, green arrow denotes direct up-regulation, dashed red bars denotes indirect 
repression, or where direct repression has not been demonstrated, dashed blue arrows 
denote hypothetical pathways and “X” denotes hypothetical transcriptional 
modulator(s).  Gene symbols in red and green are direct targets of Blimp1. 
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through induction or recruitment of other transcription modulators to these loci?  
What are the identities of these transcription modulators?   
 
The identification of Blimp1 interacting partners may provide the answers to a 
few of the questions above.  This can be achieved through a number of techniques 
such as yeast two hybrid (Y2H) screens (Gietz et al., 1997) or through tandem affinity 
purification (TAP) coupled with mass spectrometry.  TAP allows rapid purification 
and identification of proteins within native macromolecular complexes without prior 
knowledge of the components within these complexes (Puig et al., 2001).  The 
identification of these interacting partners could reveal how Blimp1 has the ability to 
regulate different sets of target genes in different cell types.  Such studies would also 
shed light on the molecular mechanism through which Blimp1 differentially represses 
fast muscle-specific genes while activating slow muscle-specific genes.   
 
Through our microarray experiment, we have uncovered a list of genes that 
are differentially regulated in the absence of Blimp1 activity.  However, current 
efforts to yield information from this list of genes have not been successful in 
identifying novel candidates that are important for slow muscle development.  The 
analysis of the microarray data was hampered by insufficient gene annotation and 
expression pattern information.  Thus, the next phase of the analysis could be directed 
towards obtaining better gene annotation information and generating expression data 
for the list of differentially expressed genes.  Efforts will first be made to map the 
GenBank entries represented on the microarray onto the zebrafish genome.  Through 
the use of automated scripts, we can continually update the annotation information of 
these genes whenever they become available.  Next, gene expression screens could be 
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conducted by in situ hybridization experiments.  With spatial expression data, we can 
then short-list candidate genes that are expressed in muscle or somites and perform 
functional analysis through morpholinos screens to determine if these candidate genes 
play a role in muscle development. 
 
The ChIP-chip experiment described by von Hofsten et al (2008) was based on 
the ChIP of endogenous Blimp1 from FACS-sorted adaxial cells.  Thus, the ChIP 
DNA obtained by this method would be more contextually relevant compared to that 
obtained in our study.  However, one of the major limitations of the ChIP-chip 
experiment is the limited genome coverage of the DNA microarray.  The design of the 
microarray is critical to the success of the experiment and its efficacy would be 
determined by the accuracy of annotated genomic information and the coordinates of 
transcription start sites.  The promoter DNA microarray employed by von Hofsten et 
al. (2008) was designed to cover approximately half the number of genes encoded by 
the zebrafish genome and was limited to 9kb upstream and 3 kb downstream of the 
transcription start site of the genes.  Moreover, the version of genomic annotation on 
which the design of the microarray chip was based on has become outdated and 
contains some inaccurate information.  Thus, it is possible that many bona fide 
Blimp1 binding sites have been missed.  In this context, it may be of benefit to 
globally survey Blimp1 binding sites by sequencing the ChIP DNA obtained with the 
protocol described by von Hofsten et al. (2008).   
 
We have shown that ectopic induction of Blimp1 at 18 hpf throughout the 
embryo does not result in the expression of smyhc1 in fast muscle fibres, but induces 
Prox1 expression in these cells.  Although this lost of competence coincides with the 
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maturation of fast muscle cells, we still do not fully understand how these cells lose 
their competence to respond to ectopic Blimp1.  What are the changes within these 
differentiating myoblasts which inhibits the expression of smyhc1, but not the 
expression of Prox1?  Is it a change in the chromatin landscape or the presence of 
factors that inhibit Blimp1 from binding to the promoters of its target genes?  The 
answers to these questions would allow us to understand how cells are progressively 
committed to a particular cell type and how the competence to respond to autonomous 
and non-autonomous cues change over time.   
 
6.5 The future of studying genetic regulation 
A recent paper that described the transcriptional regulatory network in 
myogenic differentiation has set an example for future investigations into 
transcription regulation.  This study combined information from genome-wide ChIP 
analyses with high-throughput microarray analyses of differential gene expression to 
construct a transcriptional regulatory network involved in myogenic differentiation 
(Blais et al., 2008).  This study examined the global occupancy of three transcription 
factors MyoD, Myogenin and MEF2 at the promoters of their target genes by ChIP-
chip in differentiating myoblasts and in differentiated myotubes.  A genetic regulatory 
network involving these three transcription factors was constructed by combining this 
information with the differential gene expression profiles in growing myoblasts and 
differentiated myotubes.  This analysis revealed that some of the genes are unique 
targets of these transcription factors, while others are regulated though combinatorial 
occupancy by two or more of these MRFs.  More significantly, the study revealed that 
combinatorial occupancy of target gene promoters by the various transcription factors 
resulted in synergistic effects on transcription regulation.  Through this approach, it 
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was found that the myogenic factors regulate a large number of additional genes 
involved in transcription regulation, indicating there are different tiers of 
transcriptional regulation in the myogenic transcription cascade.  Computational 
analysis of the ChIP data also revealed the enrichment of binding sites of other 
cooperative transcription factors.  The outcome of this analysis is the construction of a 
complex transcriptional regulatory network that depicts how a myriad of known and 
novel genes involved in myogenic differentiation are regulated. 
 
The example cited above provides an insight into how gene regulation 
analyses in the future will have to focus more on the interactions between multiple 
transcription factors.  Over time, the cumulative information of the complex 
regulatory transcriptional networks may reveal how different combinations of 
transcription factors are required for context-specific gene expression.   
 
Even after we have constructed the “complete” transcriptional regulatory 
network of the biological process of interest – identifying all the genes involved, 
understanding all their functions, linking them to the transcription factors that regulate 
them, and identifying all the feed-forward and feed-back loops – can we claim that we 
have fully understood this biological process?  Clearly, the ability to replicate a 
biological process with a minimum set of components cannot be used to define 
complete understanding of a biological process.  For instance, we know that ectopic 
expression of eyeless can induce ectopic eye formation in Drosophila (Halder et al., 
1995), but we cannot claim that we have completely understood eye formation in 
Drosophila based on this information alone.  Alternatively, could the complete 
understanding of a biological process be defined by our ability to simulate it through 
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computational methods?  This will require the identification of all the cellular 
components involved in the process, understanding how they interact with one 
another and knowing the rate constants for each of these interactions.  Ultimately, 
biological research must enable us to gain sufficient understanding of biological 
processes for us to identify and diagnose problems within biological contexts, so that 
we can device intervention strategies to restore “normal” function. 
 
6.6 Conclusion 
In this thesis, I have investigated the mechanism by which the transcription 
factor Blimp1 programs myoblasts to adopt the slow-twitch fiber fate in the zebrafish 
embryo.  In slow myoblasts, expression of the Blimp1 protein is transient, and 
precedes the expression of slow muscle-specific differentiation genes.  I demonstrated 
that the competence of somitic myoblasts to commit to the slow lineage in response to 
Blimp1 changes as a function of time.  Furthermore, I have provided evidence that 
mammalian Blimp1 can recapitulate the slow myogenic program in zebrafish, 
suggesting that zebrafish Blimp1 can recognize the same consensus DNA sequence 
that is bound by the mammalian protein.  Finally, through a combination of ChIP-
PCR and reporter assays coupled with functional analysis of putative binding sites, I 
have demonstrated the binding of Blimp1 to the promoter regions of smyhc1 and 
mylz2 result in their regulation.  Taken together, these findings provide new insights 
into the molecular basis of vertebrate slow muscle fiber-type specification, and 
underscore the importance of Blimp1 as the central determinant of this process. 
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Appendix I –List of differentially expressed genes in Blimp1 MO microarray 
 
Blimp1 MO microarray – Blimp1 Repressed Genes 
 
GenBank Unigene Gene symbol Gene Name Fold 
Change 
AF114262 Dr.78161 foxo5 Forkhead box O5 12.79 
AF273220 Dr.10334 casp8 Caspase 8, apoptosis-related cysteine peptidase 12.07 
BI866375 Dr.107253 lnx1 Ligand of numb-protein X 1 11.22 
BI672148 Dr.14396 LOC572175 Similar to Muc2 protein 11.11 
AF010255 Dr.75764 mdm2 Transformed 3T3 cell double minute 2 homolog (mouse) 10.62 
BM037402 Dr.15033  CDNA clone IMAGE:6034066 10.60 
BM155067 Dr.78145 zgc:136826 Zgc:136826 10.46 
AI384708 Dr.27107 gadd45al Growth arrest and DNA-damage-inducible, alpha like 9.05 
AI545475 Dr.79400 im:7145180 Im:7145180 7.99 
AI959372 Dr.76134 ccng1 Cyclin G1 7.84 
AB062116 Dr.115994 LOC560210 Similar to Hsp70 protein 7.36 
U60804 Dr.75100 tp53 Tumor protein p53 7.36 
BI889917 Dr.77773 prdm1 PR domain containing 1, with ZNF domain 6.62 
BE605310 Dr.12986 fos V-fos FBJ murine osteosarcoma viral oncogene homolog 6.54 
BG307513 Dr.81507 zgc:92153 Zgc:92153 6.54 
BI430331 Dr.6419 LOC796249 Similar to multidrug resistance protein (MRP5) 6.14 
AW115906 Dr.78829 gtpbp1l GTP binding protein 1, like 6.13 
AI584510 Dr.18920 zgc:136871 Zgc:136871 6.06 
BM154124 Dr.130702  Transcribed locus 5.97 
BM183983 Dr.78126 parp3 Poly (ADP-ribose) polymerase family, member 3 5.82 
BG307570 Dr.107277 zgc:158431 Hypothetical protein LOC100007549 5.65 
AW281681 Dr.1448 zgc:77231 Zgc:77231 5.60 
AF006007    5.56 
BI673285 Dr.76747 zgc:73230 Zgc:73230 5.55 
BI878036 Dr.32020 sesn1 Sestrin 1 5.43 
BG308520 Dr.107277 zgc:158431 Hypothetical protein LOC100007549 5.38 
BG303940 Dr.82460 LOC100003259 Similar to MGC115247 protein 5.32 
BI891654 Dr.78968 bax Bcl2-associated X protein 5.10 
AL591401    4.90 
BI842933 Dr.79973 zgc:171577 Zgc:171577 4.46 
BI885558 Dr.75558 slc4a2 Solute carrier family 4, anion exchanger, member 2 4.44 
AF097480 Dr.47843 si:rp71-1n18.2 Si:rp71-1n18.2 4.42 
AF180891 Dr.31421 mylz3 Myosin, light polypeptide 3, skeletal muscle 4.16 
AF081462 Dr.75115 mylz2 Myosin, light polypeptide 2, skeletal muscle 4.14 
BG304082 Dr.80559 gclm Glutamate-cysteine ligase, modifier subunit 4.12 
BI891737 Dr.34711 LOC560838 Similar to DnaJ-like subfamily A member 4 4.07 
BI888545    4.06 
BM182277 Dr.76397 mmp2 Matrix metalloproteinase 2 3.98 
AF210640    3.95 
BI846526 Dr.14198 zgc:101840 Zgc:101840 3.77 
BI887770 Dr.80340 wu:fi04f09 Wu:fi04f09 3.76 
BI891065 Dr.75518 LOC559158 Similar to LOC494737 protein 3.73 
 A-2 
GenBank Unigene Gene symbol Gene Name Fold 
Change 
BG302962 Dr.51739 rasl11b RAS-like, family 11, member B 3.73 
AF194333 Dr.8145 igf2a Insulin-like growth factor 2a 3.67 
AA497156 Dr.105788 LOC793133 Similar to LOC570832 protein 3.54 
AW076817 Dr.80230  Transcribed locus 3.52 
AB042252 Dr.132705 cry3 Cryptochrome 3 3.50 
AW466712    3.46 
AW117109 Dr.80155 LOC792591 Hypothetical protein LOC792591 3.38 
AF165817 Dr.132261 myhz2 Ns:zf-e523 3.32 
BI887066 Dr.75861 zgc:65909 Zgc:65909 3.26 
BI886778 Dr.84101 scaper S phase cyclin A-associated protein in the ER 3.24 
BM095161 Dr.119316 ptp4a3 Protein tyrosine phosphatase type IVA, member 3 3.18 
BI882356 Dr.37875 LOC562862 Similar to nucleoporin 214kDa 3.11 
BI476891 Dr.76397 mmp2 Matrix metalloproteinase 2 3.04 
AW171484 Dr.37483 zgc:152898 Zgc:152898 2.97 
BI891793 Dr.125361  Transcribed locus 2.94 
BM095591 Dr.14748 LOC792042 Hypothetical protein LOC792042 2.82 
BG892008 Dr.78122 LOC100000403 Similar to Si:dkey-220f10.6 2.81 
BG891864 Dr.1128 cpn1 Carboxypeptidase N, polypeptide 1 2.81 
BI891953 Dr.11945 si:dkeyp-89c11.2 Si:dkeyp-89c11.2 2.77 
BG303848 Dr.79310 tob1a Transducer of ERBB2, 1a 2.63 
BI882489 Dr.83539 LOC100004135 Hypothetical protein LOC100004135 2.62 
AW232464 Dr.132688 ctssb.2 Cathepsin S, b.2 2.62 
BG303034 Dr.78613 plk3 Polo-like kinase 3 (Drosophila) 2.61 
AW184269 Dr.114932 LOC566223 Hypothetical LOC566223 2.60 
BE605395 Dr.82223 zgc:114150 Zgc:114150 2.60 
BI896834 Dr.83698  Transcribed locus 2.59 
BM156904 Dr.26675 zgc:55492 Hypothetical LOC554468 2.59 
BI708483 Dr.123649  Transcribed locus, moderately similar to NP_035175.1 
proliferating cell nuclear antigen [Mus musculus] 
2.57 
BI892352    2.57 
AI544884 Dr.77306 upb1 Ureidopropionase, beta 2.54 
AI588190 Dr.75636  Transcribed locus 2.53 
BM154092 Dr.76235 zgc:92631 Zgc:92631 2.50 
AY050507 Dr.19203 gngt2 Guanine nucleotide binding protein (G protein), gamma 
transducing activity polypeptide 2 
2.49 
BM095868    2.48 
U16310 Dr.48765 msxa Muscle segment homeobox A 2.48 
AI964259 Dr.21039  Transcribed locus 2.48 
AW421620 Dr.132930 rps6ka3 Ribosomal protein S6 kinase, polypeptide 3 2.47 
BM156717 Dr.76347 zgc:171980 Zgc:171980 2.47 
AW116961    2.47 
AI522349 Dr.104896  Transcribed locus 2.46 
BG985718 Dr.78701 zgc:110212 Zgc:110212 2.46 
BG728782 Dr.122751  Transcribed locus 2.45 
BI846005 Dr.117590 zgc:123267 Zgc:123267 2.44 
BI704401 Dr.78374 zgc:101724 Zgc:101724 2.44 
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AI522347 Dr.4199 serpinc1 Serine (or cysteine) proteinase inhibitor, clade C (antithrombin), 
member 1 
2.43 
AW076700 Dr.121712  Transcribed locus, strongly similar to NP_991213.1 hypothetical 
protein LOC402948 [Danio rerio] 
2.43 
BI980610 Dr.107621 zgc:110343 Zgc:110343 2.43 
BI533153 Dr.76395 zgc:110340 Zgc:110340 2.41 
BM095862 Dr.26118 arrdc2 Arrestin domain containing 2 2.40 
BM104515 Dr.13960 s100a1 S100 calcium binding protein A1 2.39 
BI534070 Dr.83635  Transcribed locus 2.38 
BF717548 Dr.104980 apoc2 Apolipoprotein C-II 2.38 
AW170881    2.36 
BI672130 Dr.83423 LOC569187 Similar to PHD finger protein 6 2.35 
BI671271 Dr.6402 LOC558422 Hypothetical LOC558422 2.35 
AF068773 Dr.75834 hsp90a.1 Heat shock protein 90-alpha 1 2.34 
BM185985 Dr.132724 atp2a1l ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 like 2.34 
AW421191 Dr.107310 si:ch211-241e15.2 Si:ch211-241e15.2 2.33 
BI430212 Dr.133013 tspan18a Tetraspanin 18a 2.33 
AW281762 Dr.122355  Transcribed locus, weakly similar to NP_036365.1 RAB3 GTPase-
activating protein [Homo sapiens] 
2.33 
BI889255 Dr.79060 zgc:162126 Zgc:162126 2.32 
AW018573 Dr.132244 LOC799537 Similar to serine protease 2.31 
BM186492 Dr.143198  Transcribed locus, strongly similar to NP_055278.1 Lsm3 protein 
[Homo sapiens] 
2.31 
AW342711    2.29 
BI887446 Dr.80098  Transcribed locus 2.29 
U31079 Dr.32911 hsp47 Heat shock protein 47 2.29 
BI896532 Dr.11244 gpia Glucose phosphate isomerase a 2.28 
BI867264 Dr.84500 zgc:92287 Zgc:92287 2.27 
BI889700 Dr.5715 LOC796684 Hypothetical protein LOC796684 2.27 
AW232425 Dr.21044  Transcribed locus 2.27 
BM182280 Dr.83931 zfand2a Zinc finger, AN1-type domain 2A 2.25 
BE201596 Dr.75317 si:ch211-181p1.5 Si:ch211-181p1.5 2.22 
BI885653 Dr.10261 zgc:85717 Zgc:85717 2.22 
BG303611 Dr.3374 ctsba Cathepsin B, a 2.22 
BI879932 Dr.132472  Transcribed locus, weakly similar to NP_683761.1 oxysterol-
binding protein-like protein 10 [Mus musculus] 
2.21 
BE605408 Dr.10390 arpc5b Actin related protein 2/3 complex, subunit 5B 2.20 
BI891643 Dr.132936 zgc:109924 Zgc:109924 2.20 
AW232866 Dr.3394  Transcribed locus 2.18 
BI879489 Dr.78467 rassf1 Ras association (RalGDS/AF-6) domain family 1 2.17 
BI475963    2.17 
AI641169 Dr.22852  Transcribed locus 2.16 
AI878758 Dr.78891 glud1a Glutamate dehydrogenase 1a 2.16 
AF109780 Dr.81287 krml2 Kreisler (mouse) maf-related leucine zipper homolog 2 2.16 
AW154574 Dr.80589 scpep1 Serine carboxypeptidase 1 2.16 
AI882824 Dr.1508 acp5a Acid phosphatase 5a, tartrate resistant 2.16 
BI885477    2.15 
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AW174275 Dr.72427 zgc:153499 Wu:fi41b10 2.15 
BM186976 Dr.51640 zgc:171630 Zgc:171630 2.15 
BE015668 Dr.7375 wu:fj19b07 Wu:fj19b07 2.15 
AI884233 Dr.4964 fstl1a Follistatin-like 1a 2.15 
AI437134    2.14 
BI890279 Dr.105771 LOC100007704 Similar to Slc7a8-prov protein 2.13 
BI428543 Dr.75862 eif1b Eukaryotic translation initiation factor 1B 2.13 
BM026466 Dr.133764  Transcribed locus 2.13 
AW281931 Dr.5995 LOC100003403 Hypothetical protein LOC100003403 2.12 
AW076986 Dr.77799 zgc:153274 Zgc:153274 2.11 
BI890045 Dr.30707 perp PERP, TP53 apoptosis effector 2.10 
AF202639 Dr.77095 myog Myogenin 2.10 
BI866655 Dr.6448 csnk1da Casein kinase 1, delta a 2.10 
BI877861 Dr.83732 si:dkey-25f3.3 Si:dkey-25f3.3 2.10 
BG305485 Dr.77881 zgc:136474 Zgc:136474 2.10 
AB045624 Dr.82594 six4.3 Sine oculis homeobox homolog 4.3 2.09 
AI959690 Dr.106389 atp6v1c1 ATPase, H+ transporting, lysosomal, V1 subunit C, isoform 1 2.09 
BM071654 Dr.84783  Transcribed locus 2.09 
BE201771 Dr.82168  Transcribed locus, strongly similar to NP_001004652.1 COX17 
cytochrome c oxidase assembly homolog [Danio rerio] 
2.09 
AW019458 Dr.78484 zgc:85843 Hypothetical protein LOC791495 2.08 
AW232760 Dr.80946  Transcribed locus 2.07 
AI959644 Dr.66624 LOC798921 Hypothetical protein LOC798921 2.06 
BI885972 Dr.28739 LOC797658 Hypothetical protein LOC797658 2.06 
BI841081 Dr.84586 im:7136729 Im:7136729 2.05 
AW019613 Dr.80026  Transcribed locus 2.05 
AI974191 Dr.105092 zgc:136353 Zgc:136353 2.04 
AW019321 Dr.106461 zgc:92414 Zgc:92414 2.04 
AI416338    2.03 
AF295804 Dr.1706 rock2a Rho-associated, coiled-coil containing protein kinase 2a 2.03 
BM071941 Dr.78232  Transcribed locus, strongly similar to NP_001005955.1 myosin, 
light chain 6, alkali, smooth muscle and non-muscle like [Danio 
rerio] 
2.03 
AW059030 Dr.19144 p4ha2 Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-
hydroxylase), alpha polypeptide 2 
2.03 
BM096012 Dr.37828 zgc:162025 Zgc:162025 2.03 
BM070938 Dr.75809 cx43 Connexin 43 2.03 
BM082805 Dr.48536 zgc:158305 Zgc:158305 2.02 
BE605436 Dr.77974 zgc:92345 Zgc:92345 2.02 
BI896327 Dr.4724 eno1 Enolase 1, (alpha) 2.02 
BM154725 Dr.26893 mcl1b Myeloid cell leukemia sequence 1b 2.02 
BI889402 Dr.32436 zgc:101883 Hypothetical protein LOC792171 2.01 
BE606087 Dr.107610  Transcribed locus, moderately similar to XP_001346496.1 
PREDICTED: hypothetical protein, partial [Danio rerio] 
2.01 
AI884085 Dr.79409 drgm130 Cis-Golgi matrix protein GM130 2.00 
AI957547 Dr.76694 gnai2l Guanine nucleotide binding protein (G protein), alpha inhibiting 
activity polypeptide 2, like 
2.00 
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BM185380 Dr.119787 LOC554474 Similar to Protein phosphatase 1, regulatory (inhibitor) subunit 3B 2.00 
BI891948 Dr.79994 ctsll Cathepsin L, like 1.99 
Y12005    1.99 
AI617260    1.99 
BI850036 Dr.108126 zgc:65749 Zgc:65749 1.98 
BI843294    1.98 
AW171308 Dr.122256  Transcribed locus 1.98 
BI876766 Dr.121431 LOC563410 Hypothetical LOC563410 1.98 
BG305602 Dr.9871 rcv1 Hypothetical protein LOC792025 1.98 
BI887138 Dr.78430  Transcribed locus, strongly similar to XP_698433.2 PREDICTED: 
hypothetical protein [Danio rerio] 
1.97 
BI889086 Dr.31649 wu:fb16f09 Wu:fb16f09 1.97 
AI793554 Dr.104443 crabp2a Cellular retinoic acid binding protein 2, a 1.97 
AW078019 Dr.5878  Transcribed locus 1.97 
BI672678    1.97 
AW116694 Dr.80442  Transcribed locus, moderately similar to NP_001073476.1 
hypothetical protein LOC563346 [Danio rerio] 
1.97 
AF281003    1.96 
BI839853 Dr.116457 itm2bl Integral membrane protein 2B, like 1.96 
BI887651 Dr.75198 CH211-166A6.5 Hypothetical LOC563969 1.96 
BM071885 Dr.76427  Transcribed locus, moderately similar to NP_071918.1 zinc finger 
protein 106 homolog [Homo sapiens] 
1.96 
AI878636    1.95 
BG305595 Dr.81910  Hypothetical LOC558964 (LOC558964), mRNA 1.95 
AF273739 Dr.80622 hspe1 Heat shock 10kD protein 1 (chaperonin 10) 1.95 
BF158442 Dr.82488 zgc:64114 Hypothetical protein LOC792021 1.94 
BI850028 Dr.76526 lamb1 Similar to laminin beta 1; laminin B1 1.94 
BI475283    1.94 
BI891852 Dr.5361  Transcribed locus 1.93 
AI588163 Dr.104946  Transcribed locus 1.93 
AI957464 Dr.79446 metrnl Meteorin, glial cell differentiation regulator-like 1.93 
AF180893 Dr.75130 myhz1 Ns:zf-e523 1.93 
BE605781 Dr.76919 timm17a Translocase of inner mitochondrial membrane 17 homolog A 
(yeast) 
1.93 
BI318235    1.93 
BG729134 Dr.83203  Transcribed locus 1.92 
BI843145 Dr.82488 zgc:64114 Hypothetical protein LOC792021 1.92 
AI461372 Dr.132289  Transcribed locus, moderately similar to NP_001103309.1 
hypothetical protein LOC100126111 [Danio rerio] 
1.91 
AW420768 Dr.41221 si:dkey-222b8.2 Si:dkey-222b8.2 1.91 
BM102612    1.91 
S68799 Dr.141640 snai1a Snail homolog 1a (Drosophila) 1.91 
AI878397 Dr.1791 pdap1 Pdgfa associated protein 1 1.91 
BM035000 Dr.78811 rnaseh2b Ribonuclease H2, subunit B 1.91 
BM024762 Dr.114938 h2afx H2A histone family, member X 1.90 
AI884013 Dr.59760 adam17a A disintegrin and metalloproteinase domain 17a 1.90 
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BI846346 Dr.14218 LOC799363 Similar to hCG17599 1.90 
L35586 Dr.75834 hsp90a.1 Heat shock protein 90-alpha 1 1.90 
AW466509 Dr.78813 zgc:55549 Zgc:55549 1.90 
BI886789 Dr.10261 zgc:85717 Zgc:85717 1.89 
AW116618 Dr.78661 hspa4l Heat shock protein 4, like 1.89 
AI959203 Dr.77711 zgc:110188 Zgc:110188 1.89 
BG799399 Dr.76258 zgc:136929 Zgc:136929 1.89 
BI897147    1.89 
BM026616 Dr.17058  Transcribed locus 1.89 
AL591442    1.89 
BI474862    1.88 
AI658114    1.88 
AW019646 Dr.78040 slc39a5 Solute carrier family 39 (zinc transporter), member 5 1.87 
BE605692 Dr.1064 jun V-jun sarcoma virus 17 oncogene homolog (avian) 1.87 
BG306810 Dr.79210 gpd1b Glycerol-3-phosphate dehydrogenase 1b 1.87 
BI429605 Dr.84632  Transcribed locus 1.87 
AW077940 Dr.78902  Transcribed locus 1.87 
BI867933 Dr.84471 zgc:86811 Zgc:86811 1.87 
AW420739    1.87 
BG883652    1.87 
BI882683    1.87 
BI845385    1.86 
BI670914 Dr.72235  Transcribed locus 1.86 
AI958583    1.86 
BI672240 Dr.14414 zgc:112165 Zgc:112165 1.86 
BI896418 Dr.75520 gatm Glycine amidinotransferase (L-arginine:glycine 
amidinotransferase) 
1.86 
AW420897 Dr.32955 zgc:64012 Zgc:64012 1.86 
AI942952 Dr.75977  Transcribed locus 1.85 
BM071225 Dr.76452 aldoab Aldolase a, fructose-bisphosphate, b 1.85 
BI705721 Dr.108239 im:7149020 Similar to Niemann-Pick C disease protein 1.84 
AI883731    1.84 
BM036321 Dr.123282  Transcribed locus 1.84 
BI428435 Dr.108113 lyrm1 LYR motif containing 1 1.84 
AW466839 Dr.74561 LOC563338 Similar to PITP-less RdgB-like protein 1.84 
AI943105 Dr.78935  Transcribed locus 1.84 
AI384268    1.84 
BM185913 Dr.76090  Transcribed locus 1.84 
AI884074 Dr.79404  Transcribed locus 1.84 
BI866500 Dr.140777  Transcribed locus 1.84 
BM183269 Dr.84528  Transcribed locus 1.84 
AI878458 Dr.5571  Transcribed locus 1.84 
BM155459    1.84 
BI981305 Dr.118442 LOC563797 Hypothetical LOC563797 1.84 
BM024817 Dr.83567 DKEY-266K12.2 Similar to Intersectin 2 (SH3 domain-containing protein 1B) 
(SH3P18) (SH3P18-like WASP associated protein) 
1.84 
AI384860 Dr.4742 zgc:101121 Zgc:101121 1.83 
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AI878235    1.83 
BM156974 Dr.75376 zgc:55580 Zgc:55580 1.83 
AI477956 Dr.76040 zgc:103442 Zgc:103442 1.83 
AW777583 Dr.143672 fmo5 Flavin containing monooxygenase 5 1.83 
BI878893 Dr.83751 CH211-155M12.1 Hypothetical LOC567653 1.82 
BG985709    1.82 
AI384650    1.82 
BI671130 Dr.82668  Transcribed locus, strongly similar to NP_001018512.1 NADH 
dehydrogenase (ubiquinone) Fe-S protein 4, (NADH-coenzyme Q 
reductase) [Danio rerio] 
1.82 
AI584440 Dr.77594  Transcribed locus 1.82 
U42489 Dr.132862 bdnf Brain-derived neurotrophic factor 1.82 
BG306308 Dr.76976 wu:fb55g09 Wu:fb55g09 1.82 
AI657601    1.82 
BG306173 Dr.32532  Transcribed locus 1.82 
AW233562 Dr.81026 LOC567192 Hypothetical LOC567192 1.82 
BM184161 Dr.77771 si:dkey-252h13.6 Si:dkey-252h13.6 1.82 
BI980261 Dr.67738 zgc:153795 Zgc:153795 1.82 
BM035396 Dr.84470 LOC797345 Zgc:163126 1.82 
AW115960 Dr.80389 zgc:63470 Hypothetical LOC554542 1.81 
AI641408 Dr.32532  Transcribed locus 1.81 
BM036383    1.81 
BG305572 Dr.122633  Transcribed locus 1.81 
AI884299 Dr.106195  Transcribed locus 1.81 
BE017652 Dr.67645 LOC561592 Hypothetical LOC561592 1.81 
BI887172 Dr.84122 srp9 Hypothetical protein LOC792110 1.80 
BI865668    1.80 
AI943149 Dr.79505  Transcribed locus 1.80 
AW567328 Dr.77248 si:dkey-261e22.2 Si:dkey-261e22.2 1.80 
AI641409 Dr.74022  Transcribed locus 1.79 
BI879616 Dr.1362 sdhc Succinate dehydrogenase complex, subunit C, integral membrane 
protein 
1.79 
AW128561 Dr.76641 CH211-15B7.3 Novel protein similar to vertebrate ring finger protein 10 (RNF10) 1.79 
AI721732 Dr.76999  Transcribed locus 1.79 
BG303764 Dr.122702  Transcribed locus 1.79 
AA658586    1.79 
AW421160 Dr.23462  Transcribed locus 1.79 
BG305269    1.79 
BI878849 Dr.83792 zgc:158807 Zgc:158807 1.79 
AW058803 Dr.78064 nudt5 Nudix (nucleoside diphosphate linked moiety X)-type motif 5 1.79 
BI867256 Dr.143671  Transcribed locus, strongly similar to XP_001335024.1 
PREDICTED: hypothetical protein [Danio rerio] 
1.79 
BM035545 Dr.13947 LOC100006524 Hypothetical protein LOC100006524 1.78 
BI846489 Dr.28772  Transcribed locus 1.78 
BI843291 Dr.82002 pttg1ip Pituitary tumor-transforming 1 interacting protein 1.78 
BI563231 Dr.4096 zgc:65861 Zgc:65861 1.78 
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AW280767 Dr.78260 mycb Myelocytomatosis oncogene b 1.78 
BI672091    1.78 
BG892109    1.77 
AF155029 Dr.75505  CDNA clone IMAGE:7250007 1.77 
BI350468    1.77 
AI396671    1.77 
BM026251 Dr.93173 LOC571790 Similar to Tcte-1 peptide 1.77 
AI793509 Dr.47591 ets1b V-ets erythroblastosis virus E26 oncogene homolog 1b 1.77 
BI671334 Dr.79740 zgc:63523 Zgc:63523 1.77 
AW019238 Dr.132330  Transcribed locus 1.77 
BG884399 Dr.85716  Transcribed locus 1.76 
BM083940 Dr.34118 zgc:100864 Hypothetical LOC560614 1.76 
AI626591 Dr.21431  Transcribed locus 1.76 
AI958692    1.76 
AI204734 Dr.121590  Transcribed locus 1.76 
NC_002333    1.76 
BI673450 Dr.83490  Transcribed locus 1.76 
AW171079 Dr.51273 dag1 Dystroglycan 1 1.76 
BG892200 Dr.76282 arhgdig Rho GDP dissociation inhibitor (GDI) gamma 1.76 
AW116650 Dr.1505 sf3b4 Splicing factor 3b, subunit 4 1.76 
AY007990 Dr.74550 her8a Hairy-related 8a 1.75 
BI842416    1.75 
BE200552 Dr.141524  Transcribed locus 1.75 
BI883252 Dr.104956  Transcribed locus 1.75 
AF096508 Dr.76143  Transcribed locus 1.75 
AI588098 Dr.77167 zgc:77218 Zgc:77218 1.75 
AW279660    1.75 
AI957746 Dr.2940 col11a1 Hypothetical LOC572396 1.75 
AJ245492 Dr.76537 LOC565636 Similar to g-RICH 1.75 
BI672108 Dr.133869  Transcribed locus 1.75 
BM101502 Dr.140816  Transcribed locus, weakly similar to NP_001078916.1 hypothetical 
protein LOC129881 [Homo sapiens] 
1.75 
BM036509 Dr.14938 LOC798584 Hypothetical protein LOC798584 1.75 
AW175429 Dr.79346 dnttip2 Deoxynucleotidyltransferase, terminal, interacting protein 2 1.75 
AW165263 Dr.115807 LOC100007687 Similar to putative tumor suppressor 1.74 
AI793758 Dr.79005 fam107b Family with sequence similarity 107, member B 1.74 
BI428520 Dr.81806 chchd2 Coiled-coil-helix-coiled-coil-helix domain containing 2 1.74 
AW115990    1.74 
AW420684 Dr.122728  Transcribed locus 1.74 
BG985801 Dr.107890  Transcribed locus, strongly similar to NP_001017665.1 
hypothetical protein LOC550358 [Danio rerio] 
1.74 
BI842879 Dr.76594 LOC565069 Ferredoxin 1 1.74 
AW281860 Dr.81199 zgc:92795 Zgc:92795 1.74 
AW281721 Dr.132855 zgc:91860 Zgc:91860 1.74 
AI721918 Dr.105847  Transcribed locus 1.74 
AI666982    1.74 
BI879928 Dr.82669 zgc:64213 Zgc:64213 1.74 
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BM081743 Dr.123248  Transcribed locus 1.74 
BI887379 Dr.77795 fam3c Family with sequence similarity 3, member C 1.73 
AI588222 Dr.77739 zgc:77861 Zgc:77861 1.73 
BI841300    1.73 
AI397373    1.73 
BG306394 Dr.41000 ulk1 Unc-51-like kinase 1 (C. elegans) 1.73 
BG303613 Dr.76804 prpf40a PRP40 pre-mRNA processing factor 40 homolog A (yeast) 1.73 
AW281658 Dr.78598 sh3bp5 SH3-domain binding protein 5 (BTK-associated) 1.73 
BI863963 Dr.84333  Transcribed locus 1.72 
BI846604    1.72 
BM072351    1.72 
BG306112 Dr.116194 zgc:77806 Zgc:77806 1.72 
BI868029 Dr.84536  CDNA clone IMAGE:7086345 1.72 
AW019466 Dr.118483 LOC796656 Hypothetical protein LOC796656 1.72 
AW203115 Dr.106912  Transcribed locus 1.72 
AW116949 Dr.75325  Transcribed locus, strongly similar to NP_571866.1 cryptochrome 
2a [Danio rerio] 
1.72 
BI981857 Dr.133731  Transcribed locus 1.72 
BI879966 Dr.370 atp6v1g1 ATPase, H+ transporting, V1 subunit G isoform 1 1.72 
BI890367    1.72 
BM181944 Dr.113263 LOC793284 Similar to beta-microseminoprotein 1.71 
BM005075 Dr.16130 adh8b Alcohol dehydrogenase 8b 1.71 
BM026839 Dr.107435  CDNA clone IMAGE:7075120 1.71 
BI887627 Dr.79346 dnttip2 Deoxynucleotidyltransferase, terminal, interacting protein 2 1.71 
AI384738 Dr.76632 LOC558925 Hypothetical LOC558925 1.71 
AW019275    1.71 
BI885405    1.71 
AI584451 Dr.121884  Transcribed locus 1.71 
BE016451 Dr.106552  Transcribed locus, moderately similar to NP_001006087.1 ORM1-
like 3 [Danio rerio] 
1.71 
BE017462 Dr.105301  Transcribed locus, strongly similar to NP_001074158.1 dual-
specificity tyrosine-(Y)-phosphorylation regulated kinase 1A, a 
[Danio rerio] 
1.71 
BM025947 Dr.84888 zgc:100800 Hypothetical protein LOC791600 1.71 
AI106196 Dr.76094 uqcrq Ubiquinol-cytochrome c reductase, complex III subunit VII 1.71 
AF359430 Dr.122851 cldnj Claudin j 1.71 
AI353412 Dr.17984 wu:fb36d12 Wu:fb36d12 1.71 
AW343670 Dr.80127 zgc:77306 Zgc:77306 1.71 
AI601560 Dr.105450  Transcribed locus 1.71 
AW281075 Dr.76125 ndufb4 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4 1.71 
BI880905 Dr.34905 si:dkey-13i19.1 Si:dkey-13i19.1 1.71 
AI722355 Dr.114440 cyp3c1 Cytochrome P450, family 3, subfamily c, polypeptide 1 1.71 
AW420492    1.70 
AI641664 Dr.104555 LOC571928 Hypothetical LOC571928 1.70 
AI641052 Dr.122391  Transcribed locus 1.70 
BE201746 Dr.82165  Transcribed locus, moderately similar to NP_001004625.1 T-
lymphocyte maturation-associated protein-like [Danio rerio] 
1.70 
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BM103839 Dr.55456 LOC564443 Hypothetical LOC564443 1.70 
AF258786 Dr.2274 stard3 START domain containing 3 1.70 
BI883910 Dr.83960 zgc:154039 Zgc:154039 1.70 
BI885253 Dr.76610 psma5 Proteasome (prosome, macropain) subunit, alpha type,5 1.70 
AW128428 Dr.59 anxa1a Annexin A1a 1.70 
AF180921 Dr.75723 fabp2 Fatty acid binding protein 2, intestinal 1.70 
AW175460 Dr.36558 ehd3l EH-domain containing 3, like 1.70 
AI883443 Dr.32734 LOC797854 Similar to Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, epsilon polypeptide 1 
1.70 
AF180889 Dr.10335 tnnt3a Troponin T3a, skeletal, fast 1.70 
AI588172 Dr.208 slc11a2 Hypothetical protein LOC791813 1.70 
BI896442 Dr.2432 cs Citrate synthase 1.70 
AI666873 Dr.48445 slc35e3 Solute carrier family 35, member E3 1.70 
AW077762 Dr.76490 zgc:158746 Zgc:158746 1.70 
BG891950 Dr.99377 pabpc1b Poly A binding protein, cytoplasmic 1 b 1.70 
BI880088 Dr.2869 zgc:112367 Zgc:112367 1.70 
BI980224 Dr.75224  Transcribed locus 1.70 
BG307560    1.70 
BG727119 Dr.107002  Transcribed locus 1.70 
BM155652 Dr.119578  Transcribed locus, strongly similar to XP_685738.2 PREDICTED: 
novel protein similar to rho-associated, coiled-coil containing 
protein kinase 2 (rock2) [Danio rerio] 
1.70 
AJ301601 Dr.945 pgam1 Phosphoglycerate mutase 1 1.69 
BG306022    1.69 
BM182319 Dr.79948 slc31a1 Solute carrier family 31 (copper transporters), member 1 1.69 
BG306062 Dr.122650  Transcribed locus 1.69 
BI865453    1.69 
BI879735 Dr.81838 LOC567663 Similar to neurogranin 1.69 
AY028629 Dr.132267 atp1a1a.4 ATPase, Na+/K+ transporting, alpha 1a.4 polypeptide 1.69 
AI965025 Dr.77778 LOC791706 Hypothetical protein LOC791706 1.69 
BI673354 Dr.14504 zgc:171480 Zgc:171480 1.69 
BM187186    1.69 
AW116195 Dr.32320 lgmn Legumain 1.69 
BM103899 Dr.79367 elovl6l ELOVL family member 6, elongation of long chain fatty acids like 1.69 
AF136454 Dr.113686 lef1 Lymphocyte enhancer binding factor 1 1.69 
BG306386 Dr.122657  Transcribed locus 1.69 
AA495404 Dr.75374  Transcribed locus 1.69 
AI477029 Dr.3514 cox4nb Cox4 neighbor 1.69 
BG728488 Dr.7461 si:dkey-114g7.4 Si:dkey-114g7.4 1.68 
AI959694 Dr.74531 sdc4l Syndecan 4 like 1.68 
BF157296 Dr.26118 arrdc2 Arrestin domain containing 2 1.68 
AW184205 Dr.6709 LOC565309 Hypothetical LOC565309 1.68 
AI943392 Dr.75977  Transcribed locus 1.68 
L77146 Dr.75087 hspa8 Heat shock protein 8 1.68 
BG727634    1.68 
BI983853 Dr.80056 dhdds Dehydrodolichyl diphosphate synthase 1.68 
BG307449 Dr.82902  Transcribed locus 1.68 
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AI882884 Dr.76949 crtap Cartilage associated protein 1.68 
BI979541 Dr.142267  Transcribed locus 1.68 
AI959531    1.68 
BI886077    1.68 
BI846987 Dr.25277 agr2 Anterior gradient homolog 2 (Xenopus laevis) 1.68 
BI673398 Dr.77474 ell2 Elongation factor, RNA polymerase II, 2 1.68 
BM071810 Dr.108168 csad Cysteine sulfinic acid decarboxylase 1.68 
BI865551    1.68 
AI641396    1.68 
AI584734    1.68 
BI533295 Dr.142305  Transcribed locus, weakly similar to XP_001715876.1 
PREDICTED: hypothetical protein [Homo sapiens] 
1.68 
BE200753    1.67 
BG304092 Dr.132977  Transcribed locus 1.67 
AI545455 Dr.75310  Transcribed locus 1.67 
BI865976 Dr.123122  Transcribed locus 1.67 
BG303594 Dr.104643 zgc:113006 Zgc:113006 1.67 
AI878143 Dr.121668  Transcribed locus 1.67 
BF713861    1.67 
AI437376    1.67 
AW116367 Dr.75391 spint1a Serine protease inhibitor, Kunitz type 1 b 1.67 
BG739261 Dr.83355  Transcribed locus 1.67 
AW019720 Dr.122104  Transcribed locus 1.67 
BG307533 Dr.140471  Transcribed locus 1.67 
BI886358    1.67 
AW154176 Dr.114279 LOC555064 Hypothetical LOC555064 1.67 
BI673452 Dr.13604 gyg1 Glycogenin 1 1.67 
AI641040 Dr.31764 LOC562166 Similar to beta-chain clathrin associated protein complex AP-2 1.67 
BI879661 Dr.75057 col2a1a Collagen type II, alpha-1a 1.67 
BI890196    1.67 
BM185251 Dr.8144  Transcribed locus 1.67 
BI889398 Dr.84115 LOC570474 Similar to 5-hydroxyisourate hydrolase 1.67 
BM104065 Dr.132689 zgc:63587 Zgc:63587 1.67 
AI878441 Dr.105427  Transcribed locus 1.67 
AI588147    1.66 
BI888562 Dr.25202 znf259 Zinc finger protein 259 1.66 
BI846192 Dr.123231  Transcribed locus 1.66 
AI793934 Dr.79043 crygm4 Similar to fibulin-4 1.66 
BI350531    1.66 
BG727498    1.66 
AW343759 Dr.80136 LOC559027 Hypothetical LOC559027 1.66 
BM181766 Dr.13095 syap1 Synapse associated protein 1 1.66 
BM103957 Dr.2594 ahsa1l AHA1, activator of heat shock protein ATPase homolog 1, like 1.66 
AW175481 Dr.85086  Transcribed locus 1.66 
AW175497 Dr.20146 wu:fi25h02 Wu:fi25h02 1.66 
BG985522 Dr.77771 si:dkey-252h13.6 Si:dkey-252h13.6 1.66 
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BI474793    1.66 
BI430252 Dr.77925  Transcribed locus, strongly similar to XP_707374.2 PREDICTED: 
hypothetical protein isoform 2 [Danio rerio] 
1.66 
AI957768    1.66 
AW154483 Dr.75612 hif1a Hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix 
transcription factor) 
1.66 
BE605893 Dr.133021  Transcribed locus 1.66 
AJ275911 Dr.82564 esr2b Estrogen receptor 2b 1.66 
AI722566 Dr.76546 adipor1b Adiponectin receptor 1b 1.65 
BI889113 Dr.104850 eif2s1l Eukaryotic translation initiation factor 2, subunit 1 alpha, like 1.65 
BI879979    1.65 
AW826198 Dr.122521  Transcribed locus 1.65 
AY007434 Dr.1831 lfng Lunatic fringe homolog 1.65 
BG727484    1.65 
AW826345 Dr.118397 LOC797125 Hypothetical protein LOC797125 1.65 
AI958242 Dr.76874 tep1 Telomerase-associated protein 1 1.65 
BI892167 Dr.77735 LOC100003467 Hypothetical protein LOC100003467 1.65 
BI891199 Dr.105458 LOC566044 Hypothetical LOC566044 1.65 
AI545291 Dr.132336  Transcribed locus 1.65 
BI888943 Dr.39071 zgc:110304 Hypothetical protein LOC791868 1.65 
BI702687    1.65 
BI839784 Dr.76090  Transcribed locus 1.65 
AW420576 Dr.118157 wu:fc14a10 Wu:fc14a10 1.65 
BI841852    1.65 
BI671039 Dr.115424 LOC100001891 Hypothetical protein LOC100001891 1.65 
AI878632 Dr.79245  Transcribed locus 1.65 
BI891493 Dr.75158 LOC562726 Hypothetical LOC562726 1.65 
AJ249796 Dr.78738 nipsnap1 Nipsnap1 1.65 
BI882603    1.65 
AI588214 Dr.121803  Transcribed locus 1.65 
AI584672 Dr.77549  Transcribed locus 1.65 
AW232020 Dr.122293  Transcribed locus 1.65 
AB022286 Dr.133116 krml2.2 Kreisler (mouse) maf-related leucine zipper homolog 2.2 1.64 
BI705488 Dr.77293 LOC557176 Similar to phosphoinositide-3-kinase, regulatory subunit, 
polypeptide 1 
1.64 
BG308531 Dr.122674  Transcribed locus 1.64 
BI892317 Dr.76396 smg7 Smg-7 homolog, nonsense mediated mRNA decay factor (C. 
elegans) 
1.64 
AI794046 Dr.91107 LOC570966 Hypothetical LOC570966 1.64 
BI864981 Dr.133350 DKEY-211F22.1 Novel protein similar to vertebrate DOT1-like, histone H3 
methyltransferase (S. cerevisiae) (DOT1L) 
1.64 
BM155590 Dr.81975 zgc:92746 Zgc:92746 1.64 
AB036784 Dr.76624 btg2 B-cell translocation gene 2 1.64 
BM026778 Dr.86157  Transcribed locus 1.64 
AI878408    1.64 
AI877609 Dr.28553 zgc:92883 Zgc:92883 1.64 
BI671645    1.64 
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BI891991 Dr.134344 zgc:171599 Zgc:171599 1.64 
AW059069 Dr.80140 dact2 Dapper homolog 2, antagonist of beta-catenin (xenopus) 1.64 
AI545489 Dr.77420 zfyve21 Similar to ZFYVE21 protein 1.64 
AW184237 Dr.122280  CDNA clone IMAGE:6793184 1.64 
AI957567 Dr.76267 anxa11b Annexin A11b 1.63 
BI877729 Dr.83723 LOC100007808 Hypothetical protein LOC100007808 1.63 
AY057057 Dr.14671 birc5a Baculoviral IAP repeat-containing 5a 1.63 
AI943148 Dr.79503 si:dkey-110c1.6 Si:dkey-110c1.6 1.63 
AF322072 Dr.8516 sepp1b Selenoprotein P, plasma, 1b 1.63 
BI846718 Dr.84677 LOC557133 Hypothetical LOC557133 1.63 
AW154403 Dr.6448 csnk1da Casein kinase 1, delta a 1.63 
BI846635 Dr.133437  Transcribed locus 1.63 
AI522608 Dr.142259  Transcribed locus 1.63 
BM071213 Dr.80634 CH211-155M12.3 Novel protein similar to vertebrate tankyrase, TRF1-interacting 
ankyrin-related ADP-ribose polymerase (TNKS) 
1.63 
BI885541 Dr.11764 anxa13 Annexin A13 1.63 
BM070924 Dr.14772  Transcribed locus 1.63 
BI708067 Dr.78158 dhdhl Dihydrodiol dehydrogenase (dimeric), like 1.63 
NC_002333    1.63 
BI864190 Dr.79021 zgc:92903 Zgc:92903 1.63 
BI326273 Dr.76273 LOC100000992 Hypothetical protein LOC100000992 1.63 
AW116090 Dr.118663 zgc:64050 Hypothetical protein LOC794885 1.63 
AW115824 Dr.120694 slc35b4 Solute carrier family 35, member B4 1.63 
BM182575 Dr.84747 zgc:174935 Zgc:174935 1.63 
AW019436 Dr.79988 cebpb CCAAT/enhancer binding protein (C/EBP), beta 1.62 
BI847076    1.62 
U66872 Dr.265 erh Enhancer of rudimentary homolog (Drosophila) 1.62 
BE016108 Dr.82010 ccbl2 Cysteine conjugate-beta lyase 2 1.62 
AW154150 Dr.16838 atp2a2a ATPase, Ca++ transporting, cardiac muscle, slow twitch 2a 1.62 
BI710295    1.62 
BI879725 Dr.82645 atp6v1f ATPase, H+ transporting, V1 subunit F 1.62 
BM082961 Dr.81839 zgc:77563 Zgc:77563 1.62 
BI672617    1.62 
BG305838 Dr.122644  Transcribed locus 1.62 
BM026331    1.62 
AI522466 Dr.76870 gbgt1l4 Hypothetical protein LOC791581 1.62 
BI840999 Dr.76585 sox4a SRY (sex determining region Y)-box 4a 1.62 
BI882972 Dr.115639 rplp2l Ribosomal protein, large P2, like 1.62 
AI397408    1.62 
AW233103 Dr.80991  Transcribed locus, strongly similar to NP_001004623.1 
hypothetical protein LOC447884 [Danio rerio] 
1.62 
AW115594 Dr.77112 uap1 UDP-N-acteylglucosamine pyrophosphorylase 1 1.62 
BI885973 Dr.119871 zmat2 Zinc finger, matrin type 2 1.62 
AI584352    1.62 
AI641261    1.62 
BG305930    1.62 
AI641254 Dr.76394 zgc:64098 Zgc:64098 1.62 
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AW128242    1.62 
BM036795 Dr.104630 mbd3a Methyl-CpG binding domain protein 3a 1.62 
AW566954 Dr.81788 tbxas1 Thromboxane A synthase 1 (platelet, cytochrome P450, family 5, 
subfamily A) 
1.62 
BI845822 Dr.14153 zgc:153434 Zgc:153434 1.62 
AL591391    1.61 
BI879308 Dr.132380 cpvl Carboxypeptidase, vitellogenic-like 1.61 
AI476962 Dr.76980  Transcribed locus 1.61 
BI888548 Dr.76600 chac1 ChaC, cation transport regulator-like 1 1.61 
AW077743 Dr.121714  Transcribed locus 1.61 
NC_002333    1.61 
AI884112 Dr.78068 bzw1 Basic leucine zipper and W2 domains 1 1.61 
AW826467 Dr.76694 gnai2l Guanine nucleotide binding protein (G protein), alpha inhibiting 
activity polypeptide 2, like 
1.61 
BI888490 Dr.79819 LOC572323 Hypothetical LOC572323 1.61 
AW154401 Dr.9049 mapk4 Mitogen-activated protein kinase 4 1.61 
BI703306    1.61 
AW422974 Dr.79694 LOC100006657 Similar to zinc finger protein 445 1.61 
BE201310 Dr.82124 LOC100002182 Similar to Notch 2 1.61 
BI534163    1.61 
BI880069 Dr.82684  Transcribed locus 1.61 
BM155783 Dr.84908  Transcribed locus 1.61 
BI846291    1.61 
BI430088    1.61 
AI723154    1.61 
AW344002 Dr.206 zgc:55573 Zgc:55573 1.61 
BE017820 Dr.77541 zgc:64115 Zgc:64115 1.61 
AI601556    1.61 
BM185202 Dr.76418 tmem93 Transmembrane protein 93 1.61 
BI879759    1.61 
AW116978 Dr.7658 anxa6 Annexin A6 1.61 
AW019142 Dr.77180  Transcribed locus 1.61 
BI472731 Dr.85861 zgc:136569 Zgc:136569 1.61 
BE693163 Dr.76564 tfdp1 Transcription factor Dp-1 1.61 
BI886431 Dr.62418 LOC562564 Hypothetical LOC562564 1.60 
BI891855 Dr.123099  Transcribed locus 1.60 
BM024833 Dr.82530 gabarapl2 GABA(A) receptor-associated protein-like 2 1.60 
AW420636 Dr.132918  Transcribed locus 1.60 
AW777906 Dr.76405 xrcc5 X-ray repair complementing defective repair in Chinese hamster 
cells 5 
1.60 
AI964375 Dr.79779 ddx56 DEAD (Asp-Glu-Ala-Asp) box polypeptide 56 1.60 
BM104351 Dr.97360 zgc:111826 Zgc:111826 1.60 
AI878080 Dr.75364 amotl2 Angiomotin like 2 1.60 
AI544512 Dr.77257 otop1 Otopetrin 1 1.60 
AI721627 Dr.78765 zgc:64130 Zgc:64130 1.60 
BG307251 Dr.80286 atp6v1e1 ATPase, H+ transporting, lysosomal, V1 subunit E isoform 1 1.60 
BG985472 Dr.122777  Transcribed locus 1.60 
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AI588560    1.60 
AW595239 Dr.76088 zgc:153623 Zgc:153623 1.60 
AW019428 Dr.141676 zgc:64137 Zgc:64137 1.60 
BM071271 Dr.84702 kctd12.2 Potassium channel tetramerisation domain containing 12.2 1.60 
AI794024 Dr.79068  Transcribed locus, moderately similar to NP_001103210.1 
hypothetical protein LOC100006880 [Danio rerio] 
1.60 
AF448140 Dr.77311 rbp2a Retinol binding protein 2a, cellular 1.60 
BI887717 Dr.35811 paics Phosphoribosylaminoimidazole carboxylase, 
phosphoribosylaminoimidazole succinocarboxamide synthetase 
1.60 
BI842509    1.60 
AW344179 Dr.118415 LOC572868 Similar to ELL associated factor 1 1.60 
BI886814    1.60 
AI942960    1.60 
BM184209 Dr.82378 LOC563993 Similar to MGC80777 protein 1.60 
BI846592 Dr.14176 ctsh Cathepsin H 1.60 
BI891195 Dr.80589 scpep1 Serine carboxypeptidase 1 1.60 
BM184017 Dr.412 zgc:73136 Zgc:73136 1.60 
AF298898 Dr.76268 cbr1l Hypothetical protein LOC792137 1.60 
BM072375 Dr.7352 ube2d2 Ubiquitin-conjugating enzyme E2D 2 (UBC4/5 homolog, yeast) 1.60 
BM103978 Dr.76152 LOC560112 Hypothetical LOC560112 1.60 
BM154370 Dr.13779  Transcribed locus 1.60 
AW116284 Dr.76602 hsp90b1 Heat shock protein 90kDa beta (grp94), member 1 1.60 
BI326599 Dr.85802  Transcribed locus 1.60 
AW116035    1.60 
BM183152 Dr.140589  CDNA clone IMAGE:7177046 1.60 
AW826515    1.60 
BM036954 Dr.79556 gpr137bb G protein-coupled receptor 137bb 1.59 
BI980843 Dr.77014 wu:fb51a10 Wu:fb51a10 1.59 
BM156878 Dr.144152  Transcribed locus, weakly similar to XP_001339229.1 
PREDICTED: hypothetical protein [Danio rerio] 
1.59 
BE201971    1.59 
AW344043 Dr.106316 zgc:114204 Zgc:114204 1.59 
BI980495 Dr.30522  Transcribed locus, strongly similar to NP_991322.1 hypothetical 
protein LOC402965 [Danio rerio] 
1.59 
BM036297 Dr.78163 ppwd1 Peptidylprolyl isomerase domain and WD repeat containing 1 1.59 
AI964367 Dr.78654 si:dkey-217k21.2 Si:dkey-217k21.2 1.59 
AB023627    1.59 
BI326622 Dr.85805  Transcribed locus 1.59 
BM082666 Dr.76905 zgc:92744 Zgc:92744 1.59 
AW232580 Dr.76093 s100a10b S100 calcium binding protein A10b 1.59 
AL590150    1.59 
BI704327 Dr.115545 LOC798212 Similar to Glutamate-ammonia ligase (glutamine synthase) b 1.59 
AI497375 Dr.41005 im:7158588 Im:7158588 1.59 
BM005137    1.59 
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BI840867    1.59 
BI980643    1.59 
BI886847 Dr.76312 zgc:110330 Zgc:110330 1.59 
BI880045 Dr.77412 zgc:110603 Zgc:110603 1.59 
BM183857 Dr.78082 LOC100007086 Similar to aspartic acid-rich protein aspolin2-1 1.59 
BI326608    1.59 
AW170949 Dr.76588 zgc:63492 Zgc:63492 1.59 
AA606218 Dr.132213 polr3k Polymerase (RNA) III (DNA directed) polypeptide K 1.59 
BM071802 Dr.14012 chuk Conserved helix-loop-helix ubiquitous kinase 1.59 
BE201499 Dr.82135 tspan18b Tetraspanin 18b 1.59 
BG305367 Dr.11082 zgc:101696 Zgc:101696 1.59 
AI588271 Dr.121804  Transcribed locus 1.59 
AY036972 Dr.75117 ckma Creatine kinase, muscle a 1.59 
AW567349 Dr.10914 zgc:154020 Zgc:154020 1.59 
BI704278 Dr.104499 ctsl1a Cathepsin L1, a 1.59 
BI673169 Dr.78983 uqcrb Zgc:109893 1.58 
AW076959 Dr.143616 tpi1b Triosephosphate isomerase 1b 1.58 
AW282121 Dr.78089 cox5aa Cytochrome c oxidase subunit Vaa 1.58 
AW116100 Dr.80399 LOC556989 Similar to class IIIB myosin short 1.58 
AI657551 Dr.76090  Transcribed locus 1.58 
BI708259 Dr.83372 zgc:114172 Zgc:114172 1.58 
BI983014 Dr.84162  Transcribed locus, strongly similar to XP_001333097.1 
PREDICTED: hypothetical protein [Danio rerio] 
1.58 
AF285098 Dr.46820 gstp1 Glutathione S-transferase pi 1.58 
AI883903 Dr.132565  Transcribed locus 1.58 
BI672121 Dr.48734 zgc:101879 Zgc:101879 1.58 
BM171810    1.58 
AW170921 Dr.80664 zgc:77057 Zgc:77057 1.58 
BE558061 Dr.82273 zgc:77852 Hypothetical protein LOC791671 1.58 
AW171497 Dr.122259  Transcribed locus, weakly similar to NP_004330.1 pituitary tumor-
transforming gene 1 protein-interacting protein precursor [Homo 
sapiens] 
1.58 
BI850032 Dr.123171  Transcribed locus 1.58 
X12802    1.58 
BI889657 Dr.33841 LOC567202 Hypothetical LOC567202 1.58 
AI544683 Dr.77289 oxsr1a Oxidative-stress responsive 1a 1.58 
AI884046 Dr.79398 CH211-156J16.1 Hypothetical LOC564557 1.58 
BI841756    1.58 
BG308501 Dr.132457  Transcribed locus 1.58 
BG308454 Dr.78772 LOC558410 Hypothetical LOC558410 1.58 
BI705089    1.58 
BG891932 Dr.76350  Transcribed locus 1.58 
AI544657 Dr.31549 he2 Hatching enzyme 2 1.58 
BI882389    1.58 
BG985453 Dr.78595 LOC564527 Similar to WW domain containing E3 ubiquitin protein ligase 2 1.58 
AW280785    1.58 
BE017929    1.58 
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AW420769 Dr.9543  Transcribed locus 1.57 
AI666878 Dr.10199 tob1b Transducer of ERBB2, 1b 1.57 
AI588396 Dr.77810 ugt1aa UDP glucuronosyltransferase 1 family a, a 1.57 
BI673772 Dr.83245 skp1 S-phase kinase-associated protein 1 1.57 
AF414110 Dr.79682 h2afv H2A histone family, member V 1.57 
BG306327 Dr.6416 zgc:85777 Zgc:85777 1.57 
AI641363 Dr.22881  Transcribed locus 1.57 
BI704253 Dr.75658 tfa Transferrin-a 1.57 
BI886290 Dr.105598 taldo1 Transaldolase 1 1.57 
BI705531    1.57 
AI558273    1.57 
BI672378 Dr.76030 LOC798291 Similar to H+ transporting F1 ATP synthase epsilon subunit 1.57 
AF193837 Dr.82511 vox Ventral homeobox 1.57 
BE016746 Dr.75128  Transcribed locus 1.57 
AW466751 Dr.9659 gng5 Guanine nucleotide binding protein (G protein), gamma 5 1.57 
BI983233 Dr.77332 atp6v0d1 ATPase, H+ transporting, V0 subunit D isoform 1 1.57 
AF127920 Dr.117801 smad5 MAD homolog 5 (Drosophila) 1.57 
BI533225 Dr.122132  Transcribed locus 1.57 
BI891804    1.57 
BI845447    1.57 
AI943062 Dr.45781 zgc:109957 Zgc:109957 1.57 
BI983343 Dr.77012 rcc1 Regulator of chromosome condensation 1 1.57 
AI965283 Dr.79591 zgc:92542 Zgc:92542 1.57 
BI672555 Dr.83477 LOC569473 Hypothetical LOC569473 1.57 
BG305687 Dr.26261  Transcribed locus 1.57 
BI841761 Dr.3917 LOC100007228 Hypothetical protein LOC100007228 1.57 
AI496921 Dr.77140 rab1a RAB1A, member RAS oncogene family 1.57 
BI889810 Dr.122501 api5 Apoptosis inhibitor 5 1.57 
BI891150 Dr.75191 kdelr2 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention 
receptor 2 
1.57 
BM101821 Dr.10544 bsdc1 BSD domain containing 1 1.57 
BI891707 Dr.31373 zgc:92635 Zgc:92635 1.57 
AI723306 Dr.78910  Transcribed locus 1.57 
BI710058 Dr.86019 zgc:153408 Zgc:153408 1.57 
AI397087    1.57 
BI671185 Dr.116121 ahcyl1 S-adenosylhomocysteine hydrolase-like 1 1.57 
AI723041 Dr.7927 si:ch211-234f20.3 Zgc:158502 1.57 
AI584610    1.57 
AI330980 Dr.76303 psmb1 Proteasome (prosome, macropain) subunit, beta type, 1 1.57 
BM185314 Dr.133517 LOC100008265 Similar to Solute carrier family 25 (mitochondrial carrier, Aralar), 
member 12 
1.57 
BI896347 Dr.11690 ntd5 Ntl-dependent gene 5 1.57 
AI721688 Dr.77397  Transcribed locus 1.57 
BI886878    1.57 
AI793357 Dr.78870 nt5c2 5'-nucleotidase, cytosolic II 1.57 
BI896461 Dr.132490 zgc:77867 Zgc:77867 1.57 
BI673353 Dr.75502 zgc:112330 Novel IBR domain containing protein 1.57 
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BE605975 Dr.133019  Transcribed locus 1.57 
AI722515 Dr.114244  Transcribed locus, strongly similar to XP_001337510.1 
PREDICTED: similar to Major vault protein isoform 1 [Danio 
rerio] 
1.57 
BG304095 Dr.33003  Transcribed locus, weakly similar to XP_001513514.1 
PREDICTED: hypothetical protein [Ornithorhynchus anatinus] 
1.57 
BI673514 Dr.116247 slc25a37 Solute carrier family 25, member 37 1.57 
BM156782 Dr.116697 LOC558658 Hypothetical LOC558658 1.56 
U93474    1.56 
AJ278268 Dr.119088 ctsd Cathepsin D 1.56 
BI878269 Dr.141721  Transcribed locus, strongly similar to XP_001331314.1 
PREDICTED: hypothetical protein [Danio rerio] 
1.56 
BI892229 Dr.50843 cd9l CD9 antigen, like 1.56 
BF717706 Dr.102495 suclg2 Succinate-CoA ligase, GDP-forming, beta subunit 1.56 
BG728832    1.56 
AW116430 Dr.34799 zgc:171804 Zgc:171804 1.56 
BM181646 Dr.4501 zgc:56068 Zgc:56068 1.56 
BI868116 Dr.123167  Transcribed locus 1.56 
BG308695    1.56 
AI437385    1.56 
BI877751 Dr.43266 pdlim1 PDZ and LIM domain 1 (elfin) 1.56 
AI723219 Dr.32617 unc45b Unc-45 homolog B (C. elegans) 1.56 
BM071255 Dr.32570 arhgef18 Rho/rac guanine nucleotide exchange factor (GEF) 18 1.56 
BI983495 Dr.12918 fhit Fragile histidine triad gene 1.56 
AW281874 Dr.90586 camk2g1 Calcium/calmodulin-dependent protein kinase (CaM kinase) II 
gamma 1 
1.56 
BG305277 Dr.78925 si:dkey-218l8.1 Si:dkey-218l8.1 1.56 
AF359425 Dr.3454 cldne Claudin e 1.56 
BG306692    1.56 
BG727108    1.56 
BM101493 Dr.132579 zgc:153061 Zgc:153061 1.56 
BG308262 Dr.78053 zgc:73375 Zgc:73375 1.56 
AA606123 Dr.40232 alg3 Asparagine-linked glycosylation 3 homolog (S. cerevisiae, alpha-
1,3-mannosyltransferase) 
1.56 
NC_002333    1.56 
BM095962 Dr.121913  Transcribed locus 1.56 
AI584590    1.56 
AW826407 Dr.4055 LOC557373 Hypothetical LOC557373 1.56 
BI979096 Dr.132467  Transcribed locus 1.56 
BI318564 Dr.81960 wu:fk54a10 Wu:fk54a10 1.56 
AW059193 Dr.132583  Transcribed locus 1.55 
AW117105 Dr.118087 LOC798525 Similar to Coiled-coil-helix-coiled-coil-helix domain containing 2-
like 
1.55 
AI588209 Dr.77734  Transcribed locus 1.55 
AW059322 Dr.79991  Transcribed locus 1.55 
BI896303 Dr.77839 zgc:86838 Zgc:86838 1.55 
BM036992 Dr.106236 zgc:86738 Hypothetical protein LOC791861 1.55 
BI705776 Dr.83647 LOC100003757 Hypothetical protein LOC100003757 1.55 
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BM005062 Dr.6134 zgc:77069 Zgc:77069 1.55 
BI533195 Dr.78546 LOC572929 Similar to insulin-like growth factor 2 1.55 
BM026491    1.55 
AI545016 Dr.39150 zgc:112953 Zgc:112953 1.55 
BI846484 Dr.123228  Transcribed locus 1.55 
BI430189 Dr.85829 cetn2 Centrin, EF-hand protein, 2 1.55 
AW165310 Dr.91408 LOC564723 Similar to mesoderm induction early response 1 1.55 
BE201929 Dr.143680  Transcribed locus 1.55 
AW019729 Dr.78303  Transcribed locus 1.55 
AI584379    1.55 
AW202701 Dr.14079 ywhai Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, iota polypeptide 
1.55 
BG305684 Dr.107713 LOC560742 Hypothetical LOC560742 1.55 
AI397462 Dr.76795 wu:fb18b08 Wu:fb18b08 1.55 
AI959704 Dr.75245  Transcribed locus 1.55 
BI474896 Dr.105248  Transcribed locus, moderately similar to NP_001116831.1 
hypothetical protein LOC733162 [Xenopus laevis] 
1.55 
AW128372 Dr.122207  Transcribed locus 1.55 
AW077338    1.55 
AW184550    1.55 
BI881205 Dr.119190 ehd2 EH-domain containing 2 1.55 
AI667140    1.55 
AW115952 Dr.35556  Transcribed locus 1.55 
BI886657 Dr.82160 zgc:103632 Zgc:103632 1.55 
AW279786 Dr.26056  Transcribed locus 1.55 
BI703341    1.55 
AW420476    1.55 
BM181708 Dr.81341 caprin2 Caprin family member 2 1.55 
AI544570 Dr.137048  Transcribed locus 1.55 
AF195052 Dr.81309 psme1 Proteasome activator subunit 1 1.55 
BI883233 Dr.83940 zgc:64214 Zgc:64214 1.55 
BG305759    1.55 
AI584223    1.55 
BG728460 Dr.79456 pip5k3 Phosphatidylinositol-3-phosphate/phosphatidylinositol 5-kinase, 
type III 
1.55 
BI841916 Dr.78272 c20orf149l Chromosome 20 open reading frame 149, like 1.55 
AI942920 Dr.77355 tcf12 Transcription factor 12 1.55 
BI879509    1.55 
BI888750 Dr.123068  Transcribed locus 1.55 
BI888432 Dr.77287 zgc:92451 Zgc:92451 1.55 
BM072317    1.55 
AI721536 Dr.121552  Transcribed locus 1.55 
AW421100 Dr.78307 zfp36l1l Zinc finger protein 36, C3H type-like 1 like 1.55 
BI880587 Dr.82730 atp5i ATP synthase, H+ transporting, mitochondrial F0 complex, subunit 
e 
1.55 
AI545551 Dr.132338  Transcribed locus 1.55 
AI601782 Dr.78019  Transcribed locus 1.55 
 A-20
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BI842444 Dr.80186 LOC798989 Hypothetical protein LOC798989 1.55 
AW595341    1.54 
AW826477 Dr.9860 mdh1b Malate dehydrogenase 1b, NAD (soluble) 1.54 
AI794059 Dr.132516 cdh6 Cadherin 6 1.54 
AW280290 Dr.24246 h1fx H1 histone family, member X 1.54 
BI892416 Dr.76367 hig1 Hypoxia induced gene 1 1.54 
BG985785 Dr.75137 glrx5 Glutaredoxin 5 homolog (S. cerevisiae) 1.54 
BI706217    1.54 
AW018984 Dr.79961  Transcribed locus 1.54 
AI816663 Dr.84225 zgc:158242 Zgc:158242 1.54 
BI865832 Dr.3664 zgc:103627 Im:7139060 1.54 
BM034693 Dr.104473 wu:fb34a04 Wu:fb34a04 1.54 
BI884149 Dr.83994  Transcribed locus 1.54 
BM005319    1.54 
AI721745 Dr.78796  Transcribed locus 1.54 
BI878031    1.54 
AI545296    1.54 
BI850039 Dr.108043 LOC795749 Similar to Cleft lip and palate associated transmembrane protein 1 1.54 
BG305659 Dr.9851  Transcribed locus 1.54 
AW232975 Dr.65130 LOC557270 Hypothetical LOC557270 1.54 
BI884164 Dr.123009  Transcribed locus 1.54 
BI475950 Dr.110246  Transcribed locus 1.54 
AF052249 Dr.75816 foxd3 Forkhead box D3 1.54 
AI558288 Dr.60162  Transcribed locus 1.54 
BI888493 Dr.80149 LOC553515 Hypothetical protein LOC553515 1.54 
AW232057 Dr.75229  Transcribed locus 1.54 
AI721956    1.54 
BI845355 Dr.84658  Transcribed locus 1.54 
BM037469 Dr.83576 snrpd3 Small nuclear ribonucleoprotein D3 polypeptide 1.54 
BI891364    1.54 
BI891665 Dr.76817 matr3l Matrin 3-like 1.54 
AI331218 Dr.104626  Transcribed locus 1.54 
BI842456 Dr.118217  Transcribed locus 1.54 
AW232289 Dr.76172 fuca1 Fucosidase, alpha-L- 1, tissue 1.54 
AW279916    1.54 
BI888764 Dr.84069 bud31 BUD31 homolog (yeast) 1.54 
BI888977 Dr.67768 hnrpa1 Heterogeneous nuclear ribonucleoprotein A1 1.54 
BM026365 Dr.86218  Transcribed locus 1.54 
BI842412 Dr.76047 atp5l ATP synthase, H+ transporting, mitochondrial F0 complex, subunit 
g 
1.54 
BG303916 Dr.41072 zgc:158613 Zgc:158613 1.54 
AF160646 Dr.113951 LOC100003596 Hypothetical protein LOC100003596 1.54 
AI793437 Dr.76444 zgc:172180 Zgc:172180 1.54 
AI641084 Dr.122393  Transcribed locus 1.53 
BM184284 Dr.1920 derl1 Der1-like domain family, member 1 1.53 
AW232485    1.53 
 A-21
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AI626625 Dr.78373  Transcribed locus 1.53 
BI563047 Dr.78094 LOC402883 Hypothetical protein LOC402883 1.53 
BM187492    1.53 
BF717787 Dr.30213  Transcribed locus 1.53 
AI384655    1.53 
AW777326 Dr.78219  Transcribed locus 1.53 
AI722627    1.53 
AF395113 Dr.104285 ankrd6 Hypothetical protein LOC792095 1.53 
BM155603 Dr.15365  Transcribed locus 1.53 
BM104315 Dr.9166 blzf1 Hypothetical protein LOC791432 1.53 
AI794243    1.53 
BI891279 Dr.75743 zgc:136227 Hypothetical protein LOC791878 1.53 
AJ011788 Dr.75457 cldn7 Claudin 7 1.53 
BI878208 Dr.143697  Transcribed locus 1.53 
AW777769 Dr.77273 rab40c RAB40c, member RAS oncogene family 1.53 
AI957875 Dr.76798 sb:cb283 Zgc:152830 1.53 
BI844738    1.53 
AF282384 Dr.14260 tnnt2 Troponin T2, cardiac 1.53 
BI534261 Dr.76212 nat13 N-acetyltransferase 13 1.53 
AI957711 Dr.16978  Transcribed locus 1.53 
BM183746    1.53 
AW421022 Dr.106275  Transcribed locus 1.53 
AI883979 Dr.79354  Transcribed locus 1.53 
BI880439    1.53 
BG728749 Dr.36967 gna12 Guanine nucleotide binding protein (G protein) alpha 12 1.53 
AI585100 Dr.117532 LOC792537 Hypothetical protein LOC792537 1.53 
AW281816 Dr.31625 dlat Dihydrolipoamide S-acetyltransferase (E2 component of pyruvate 
dehydrogenase complex) 
1.53 
BG305623    1.53 
AF441284 Dr.26893 mcl1b Myeloid cell leukemia sequence 1b 1.53 
AI667214    1.53 
AI588216 Dr.39143 zgc:112982 Zgc:112982 1.53 
AI957915 Dr.122030  Transcribed locus, weakly similar to XP_001339229.1 
PREDICTED: hypothetical protein [Danio rerio] 
1.53 
BI881854 Dr.122963  Transcribed locus 1.53 
BI476461 Dr.81832 LOC553407 Hypothetical protein LOC100006308 1.53 
AW232844    1.53 
AW058744 Dr.76148 atp2b1a ATPase, Ca++ transporting, plasma membrane 1a 1.53 
BM037548 Dr.31316 zgc:77853 Zgc:77853 1.53 
BI867889 Dr.110726 LOC572168 Hypothetical LOC572168 1.52 
BI979095 Dr.79855 tollip Toll interacting protein 1.52 
BG985518 Dr.80110 zgc:55813 Zgc:55813 1.52 
BI888550 Dr.76256 dsc2l Desmocollin 2 like 1.52 
BG306318 Dr.5384 hexa Novel protein similar to vertebrate hexosaminidase A (alpha 
polypeptide) (HEXA) 
1.52 
BI708065 Dr.2621 aup1 Ancient ubiquitous protein 1 1.52 
AI667243    1.52 
 A-22
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BM026700 Dr.16907  Transcribed locus 1.52 
BM187053    1.52 
BI880095 Dr.76468 id2b Inhibitor of DNA binding 2, dominant negative helix-loop-helix 
protein, b 
1.52 
AW567366 Dr.76952 actn4 Actinin, alpha 4 1.52 
BE693173    1.52 
BI563190 Dr.106235 LOC565467 Hypothetical LOC565467 1.52 
AF307846 Dr.78549 lima1 LIM domain and actin binding 1 1.52 
BM103369 Dr.84448  Transcribed locus 1.52 
BG305296 Dr.105218 bccip BRCA2 and CDKN1A interacting protein 1.52 
BI879720 Dr.83846 LOC795165 Similar to synapsin II 1.52 
BM026049 Dr.86203  Transcribed locus, strongly similar to XP_684040.1 PREDICTED: 
hypothetical protein [Danio rerio] 
1.52 
AY028630 Dr.75307 atp1a1 ATPase, Na+/K+ transporting, alpha 1 polypeptide 1.52 
AI721479 Dr.75499 mycn V-myc myelocytomatosis viral related oncogene, neuroblastoma 
derived (avian) 
1.52 
AI959496 Dr.105120  Transcribed locus 1.52 
AI544544    1.52 
BG303518 Dr.31566  Transcribed locus 1.52 
AI957558 Dr.122020  Transcribed locus 1.52 
BI880966 Dr.82773 LOC572072 Hypothetical LOC572072 1.52 
BG728888    1.52 
BI983061 Dr.77106 rtn1a Hypothetical protein LOC791876 1.52 
AW019138 Dr.77399  Transcribed locus 1.52 
BI878301 Dr.74675  Transcribed locus 1.52 
AI545173 Dr.131930  Transcribed locus 1.52 
AI794113    1.52 
AI106437 Dr.120038 LOC568423 Hypothetical LOC568423 1.52 
BI673466 Dr.78523 sgk1 Serum/glucocorticoid regulated kinase 1 1.52 
AI793886 Dr.79033 ufd1l Ubiquitin fusion degradation 1-like 1.52 
BM095304 Dr.17077 sh3bp4 SH3-domain binding protein 4 1.52 
BI710046 Dr.85533 LOC100001662 Hypothetical protein LOC100001662 1.52 
BI891455 Dr.84195 LOC799210 Similar to Proteasome (prosome, macropain) 26S subunit, non-
ATPase, 6 
1.52 
AW115814 Dr.79834 zgc:163086 Zgc:163086 1.52 
AW233688 Dr.76262  Transcribed locus, strongly similar to NP_001002577.2 succinate-
CoA ligase, GDP-forming, alpha subunit [Danio rerio] 
1.51 
AW279698 Dr.132825 zgc:64095 Hypothetical protein LOC792222 1.51 
AI943210 Dr.79516 zgc:92027 Zgc:92027 1.51 
BG305656    1.51 
BG305324 Dr.82846 LOC569164 Similar to protein tyrosine phosphatase e 1.51 
BM155827 Dr.78154 lgals1l1 Hypothetical protein LOC791523 1.51 
BG728552 Dr.93140  Transcribed locus, strongly similar to NP_001034260.1 laminin, 
alpha 5 [Danio rerio] 
1.51 
BM154441    1.51 
BI533748    1.51 
BM072414 Dr.14876  Transcribed locus 1.51 
 A-23
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BI841751 Dr.123182  Transcribed locus 1.51 
BM187315    1.51 
BE605467 Dr.76221 LOC100004578 Similar to Tax1 (human T-cell leukemia virus type I) binding 
protein 1 
1.51 
BI983246 Dr.76119  Transcribed locus, strongly similar to XP_001335072.1 
PREDICTED: hypothetical protein, partial [Danio rerio] 
1.51 
BM184708 Dr.143614 ndufb5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex 5 1.51 
BI879757 Dr.78355  Transcribed locus 1.51 
AI793533 Dr.3984 kbtbd10 Kelch repeat and BTB (POZ) domain containing 10 1.51 
BI979955 Dr.132936 zgc:109924 Zgc:109924 1.51 
BI866341 Dr.70513  Transcribed locus 1.51 
BM095956 Dr.83942  Transcribed locus 1.51 
AW175518 Dr.115444 zgc:55448 Zgc:55448 1.51 
AI601576 Dr.132397  Transcribed locus 1.51 
AW420509 Dr.81513  Transcribed locus 1.51 
BI891773 Dr.32635 clint1 Clathrin interactor 1 1.51 
AI667665 Dr.29053 aktip Akt interacting protein 1.51 
AI601783 Dr.78020 LOC100003402 Hypothetical protein LOC100003402 1.51 
AW281988    1.51 
AW232630    1.51 
BG727249 Dr.28420 ddx5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 1.51 
AW567542    1.51 
AW077961 Dr.1190 anxa1b Annexin A1b 1.51 
AW128379 Dr.78107 tmem38a Transmembrane protein 38A 1.51 
BG303234 Dr.32117 zgc:92314 Zgc:92314 1.51 
BI840922    1.51 
L03398 Dr.193 raraa Retinoic acid receptor, alpha a 1.51 
BM096076 Dr.76910  Transcribed locus 1.51 
BM101600 Dr.109900 wac WW domain containing adaptor with coiled-coil 1.51 
BI880007    1.51 
BI885905 Dr.105032 fetub Fetuin B 1.51 
BI706446 Dr.78233 zgc:73139 Zgc:73139 1.51 
AI601580    1.50 
AW076708    1.50 
BI888534 Dr.33023 ube2l3 Ubiquitin-conjugating enzyme E2L 3 1.50 
AI965047    1.50 
BM095922 Dr.78599 gtf2b General transcription factor IIB 1.50 
AW344255 Dr.78239 ddi2 DNA-damage inducible protein 2 1.50 
BM154004 Dr.20191 seh1l SEH1-like (S. cerevisiae) 1.50 
BI704370 Dr.29749 eif4g2a Eukaryotic translation initiation factor 4, gamma 2a 1.50 
BM072363 Dr.123273  Transcribed locus 1.50 
BI885359 Dr.105808 grb10 Growth factor receptor-bound protein 10 1.50 
AW777378    1.50 
AA495040 Dr.492  Transcribed locus 1.50 
AW279775 Dr.75538 rgs4 Regulator of G-protein signalling 4 1.50 
AI544994    1.50 
BI845628    1.50 
 A-24
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BI881707 Dr.83909 LOC556971 Similar to vitamin K-dependent gamma-glutamyl carboxylase 1.50 
AW595163 Dr.142266 itgb1b Integrin, beta 1b 1.50 
 
 A-25
Blimp1 MO microarray – Blimp1 Activated Genes 
 
GenBank Unigene Gene symbol Gene Name Fold 
Change 
BI880448 Dr.81981  Transcribed locus -4.92 
AW019145 Dr.132653 zgc:162095 Zgc:162095 -4.86 
BI983366    -4.75 
AI522599 Dr.121718  Transcribed locus -4.73 
BI865864    -4.71 
AI667296 Dr.78628  Transcribed locus -4.17 
AW280058    -4.13 
AA495157 Dr.518  Transcribed locus -4.09 
AY050505 Dr.86944 gc3 Guanylyl cyclase 3 -4.08 
AW233504    -4.05 
BG305308    -4.04 
BI846505 Dr.123230  Transcribed locus -3.86 
BI706664    -3.84 
BM181897 Dr.79802 zgc:158856 Zgc:158856 -3.80 
BI671697    -3.79 
AW282103 Dr.22830 zgc:163122 Zgc:163122 -3.73 
AI641635 Dr.132895  Transcribed locus -3.70 
AI444198 Dr.4851 zgc:92040 Zgc:92040 -3.69 
AW420566 Dr.7234  Transcribed locus -3.65 
BM155560    -3.65 
BI671332    -3.64 
BI878746 Dr.75548 mybpc3 Myosin binding protein C, cardiac -3.62 
BM095827 Dr.86249 tbx15 T-box 15 -3.60 
BI840317    -3.59 
AW018956 Dr.22136  Transcribed locus -3.51 
BE605593    -3.49 
AW018972    -3.48 
AW019526 Dr.29122 zgc:112160 Zgc:112160 -3.46 
BG306103    -3.44 
AI384160 Dr.30361 oprd1b Hypothetical protein LOC792001 -3.43 
BI885526    -3.42 
BM037164 Dr.84884 LOC561438 Hypothetical LOC561438 -3.41 
BI475859 Dr.123618  Transcribed locus -3.40 
BG891940    -3.40 
AI384671 Dr.76613 zgc:136367 Zgc:136367 -3.40 
BI981903 Dr.69146 LOC799188 Hypothetical protein LOC799188 -3.34 
AI384929    -3.33 
L19451    -3.32 
AI626609 Dr.1692 zbtb2b Zinc finger and BTB domain containing 2b -3.32 
BI704922 Dr.85933  Transcribed locus -3.31 
AI384161    -3.30 
AW116691 Dr.26686 si:ch211-14c7.2 Si:ch211-14c7.2 -3.29 
AW826376 Dr.81946  Transcribed locus -3.29 
AI721560    -3.29 
 A-26
AF238292 Dr.81322 p2rx3a Purinergic receptor P2X, ligand-gated ion channel, 3a -3.29 
BI979640 Dr.86051  Transcribed locus -3.26 
AI477624 Dr.121696  Transcribed locus -3.25 
AW232473    -3.25 
BI880247    -3.24 
AI974197 Dr.34109 si:dkey-91f15.6 Si:dkey-91f15.6 -3.23 
BG304024 Dr.82467 LOC557760 Hypothetical LOC557760 -3.20 
AI384394    -3.18 
BI890096 Dr.109977  Transcribed locus, strongly similar to NP_524352.1 Histone H4 
replacement CG3379-PC, isoform C [Drosophila melanogaster] 
-3.18 
AW420550 Dr.41116 pdzk1ip1l PDZK1 interacting protein 1, like -3.10 
AW154715    -3.09 
BI865811 Dr.123138  Transcribed locus -3.09 
BG305360 Dr.25438 LOC795803 Similar to green sensitive cone opsin -3.09 
BI885472 Dr.80902  Transcribed locus -3.05 
AW344089 Dr.122384  Transcribed locus -3.05 
BG727513 Dr.82541 hsd17b1 Hypothetical protein LOC791515 -3.04 
AW232655    -3.04 
BI981548 Dr.16790 LOC100000820 Hypothetical protein LOC100000820 -3.02 
AW421803 Dr.80585 LOC553480 Hypothetical protein LOC553480 -3.01 
BG728993 Dr.83195  Transcribed locus -3.01 
AI544655    -3.00 
BE201681 Dr.82157 pvalb8 Parvalbumin 8 -2.97 
AF181996 Dr.82512 neurog3 Neurogenin 3 -2.96 
BI671992    -2.95 
BG305390    -2.94 
BM154125 Dr.19019  Transcribed locus -2.91 
BI671314 Dr.82605 rds4 Retinal degradation slow 4 -2.91 
AJ299412 Dr.104683 hdlbp High density lipoprotein-binding protein (vigilin) -2.90 
AI943263    -2.87 
BE017784 Dr.76636 zgc:101761 Zgc:101761 -2.87 
AI722801 Dr.101179 LOC572246 Hypothetical LOC572246 -2.86 
BM096099 Dr.85168 si:dkey-30j22.9 Si:dkey-30j22.9 -2.86 
BI880367 Dr.107516  Transcribed locus -2.86 
AF132084 Dr.81300 pthr1 Parathyroid hormone receptor 1 -2.85 
BG303759    -2.85 
BI884423 Dr.84012  Transcribed locus -2.83 
BI880388 Dr.82693  Transcribed locus -2.82 
BE605753 Dr.82093  Transcribed locus, weakly similar to NP_055542.1 
myeloid/lymphoid or mixed-lineage leukemia 4 [Homo sapiens] 
-2.82 
BE016385    -2.82 
BF158220 Dr.16810 LOC798400 Similar to N-acetylgalactosaminyltransferase -2.81 
AI958548 Dr.79632 CH211-29N12.1 Novel protein containing sushi domains (SCR repeats -2.81 
BM183271 Dr.15064 LOC566247 Hypothetical LOC566247 -2.81 
BI846981 Dr.75373 wu:fd12d03 Wu:fd12d03 -2.81 
AW203088 Dr.117746 LOC796402 Similar to putative transmembrane protein TA-2 -2.81 
BI983763    -2.80 
AI793765    -2.78 
 A-27
BI879860 Dr.122623  Transcribed locus -2.78 
BI841869    -2.78 
AI558965    -2.77 
BM187371 Dr.123354  Transcribed locus -2.76 
BG729143 Dr.83205  Transcribed locus -2.76 
AW018995 Dr.122079  Transcribed locus -2.76 
AI964122    -2.73 
BI847139    -2.73 
BM181130 Dr.133492  Transcribed locus -2.73 
BG306141 Dr.11225  Transcribed locus -2.71 
AW117144    -2.71 
BG308632 Dr.82618 zgc:73226 Zgc:73226 -2.71 
AI667166    -2.71 
AA495106 Dr.508  Transcribed locus -2.70 
BI979486 Dr.86035  Transcribed locus -2.68 
AW826383 Dr.105651 si:ch211-210h11.4 Si:ch211-210h11.4 -2.68 
BM156875 Dr.76459 bpnt1 Hypothetical protein LOC792101 -2.68 
BM005113 Dr.84823 LOC798433 Hypothetical protein LOC798433 -2.67 
BF157695 Dr.11439 si:ch211-223m11.2 Si:ch211-223m11.2 -2.67 
BI673604 Dr.78166 pvalb7 Parvalbumin -2.67 
BI865681    -2.66 
AL591382    -2.66 
AW566816    -2.65 
BI865922 Dr.123140  Transcribed locus -2.65 
BI890877 Dr.132455  Transcribed locus -2.64 
AI964823 Dr.75422 si:dkey-121a11.2 Si:dkey-121a11.2 -2.64 
BI880109 Dr.133240  Transcribed locus -2.62 
BE015653 Dr.81985 gad1 Glutamate decarboxylase 1 -2.61 
BM154436    -2.61 
AA566797 Dr.75696 tnni2a.3 Troponin I, skeletal, fast 2a.3 -2.60 
BI846345    -2.60 
BM037159    -2.60 
BG799437    -2.59 
AW420002 Dr.115368 LOC556744 Similar to MGC97780 protein -2.58 
BF938368    -2.57 
BM095420 Dr.80577 cry1b Cryptochrome 1b -2.57 
BG308756 Dr.82797  Transcribed locus -2.57 
BI880615 Dr.82734 LOC559006 Hypothetical LOC559006 -2.57 
BG883345    -2.57 
AW115823    -2.56 
BE201509 Dr.82137  Transcribed locus -2.56 
BE015655 Dr.115141 zgc:73336 Hypothetical protein LOC791604 -2.56 
BE016611 Dr.104267 wu:fk66a11 Wu:fk66a11 -2.55 
AF226619 Dr.10461 cyp19a1b Cytochrome P450, family 19, subfamily A, polypeptide 1b -2.55 
BI865994    -2.54 
AW280039 Dr.81092  Transcribed locus -2.53 
BI842186 Dr.84612  Transcribed locus -2.52 
AI616468    -2.51 
 A-28
BE201851    -2.51 
BM095624    -2.51 
AI722973 Dr.5549 zgc:66286 Zgc:66286 -2.51 
AW116495    -2.50 
AI354204 Dr.10397 si:ch211-258l4.7 Si:ch211-258l4.7 -2.50 
AB051678 Dr.83331 efna3 Ephrin A3 -2.50 
BG728551 Dr.107778  Transcribed locus -2.49 
BI847099 Dr.76106 LOC555409 Hypothetical LOC555409 -2.49 
BI841711 Dr.75442 vim Vimentin -2.49 
BI887525    -2.48 
U31823 Dr.21033 mtnr1al Melatonin receptor type 1A like -2.48 
BI671109 Dr.83102  Transcribed locus -2.48 
AW281960 Dr.81237 nmnat2 Nicotinamide nucleotide adenylyltransferase 2 -2.47 
BI841115 Dr.84588  Transcribed locus -2.46 
BG303457 Dr.11480 rap2ip Rap2 interacting protein -2.46 
AI384228    -2.45 
BI839565    -2.45 
BI839927 Dr.28459 LOC794906 Similar to DMbeta1 -2.45 
BI703300 Dr.85936  Transcribed locus -2.45 
AW281652 Dr.122354  Transcribed locus -2.45 
AI204794 Dr.137783  Transcribed locus -2.45 
BI866865 Dr.77103 wu:fb63a08 Wu:fb63a08 -2.45 
BM156307    -2.44 
AW019835    -2.44 
AI722564    -2.44 
BG799351    -2.44 
AI883326 Dr.33010 mcm6 MCM6 minichromosome maintenance deficient 6, mitotin (S. 
cerevisiae) 
-2.43 
BI841831    -2.43 
AI331731    -2.43 
BI703201    -2.43 
BI533424 Dr.14578  Transcribed locus -2.42 
AW019239    -2.42 
AW826882 Dr.120804 zgc:103631 Zgc:103631 -2.42 
BG305588    -2.42 
BI866586 Dr.84450 ryr2b Ryanodine receptor 2b (cardiac) -2.42 
AW115626 Dr.2291 mcm2 MCM2 minichromosome maintenance deficient 2, mitotin (S. 
cerevisiae) 
-2.42 
AW279803 Dr.22721  Transcribed locus -2.42 
BI708695 Dr.129040  Transcribed locus -2.41 
AW420516    -2.41 
AW077162 Dr.27747 zgc:153925 Zgc:153925 -2.41 
BI980704 Dr.84991 LOC567756 Similar to fmHP -2.40 
AW232222 Dr.132808  Transcribed locus -2.40 
BE201719    -2.40 
BG728522 Dr.83151 LOC561985 Hypothetical LOC561985 -2.40 
BI840762 Dr.28459 LOC794906 Similar to DMbeta1 -2.40 
AI793746 Dr.9125  Transcribed locus -2.40 
 A-29
AW826750 Dr.23279  Transcribed locus -2.40 
AW018942 Dr.79956  Transcribed locus -2.39 
BI710126 Dr.77565 LOC792618 Hypothetical protein LOC792618 -2.39 
AI330530 Dr.36926 samsn1 SAM domain, SH3 domain and nuclear localisation signals, 1 -2.39 
AW232291 Dr.80818 si:rp71-69p9.2 Si:rp71-69p9.2 -2.38 
BE200777 Dr.21399 ccng2 Cyclin G2 -2.37 
BI879640 Dr.104300  Transcribed locus -2.37 
BE557072 Dr.122560  Transcribed locus -2.37 
BI672245 Dr.14984 LOC562898 Hypothetical LOC562898 -2.37 
BI844865    -2.37 
BG305609 Dr.82861  Transcribed locus -2.37 
BE016992 Dr.104779 zgc:136930 Zgc:136930 -2.37 
AW420581 Dr.81574  CDNA clone IMAGE:8754855 -2.36 
AI959332 Dr.77746 pcdh1g22 Protocadherin 1 gamma 22 -2.36 
AW567032    -2.36 
BG308914    -2.36 
AW420699    -2.36 
BI672902 Dr.83456 LOC792489 Hypothetical protein LOC792489 -2.36 
AI722353    -2.36 
BG306104    -2.35 
BE557171    -2.35 
BG306450    -2.35 
BM104508 Dr.133781 zgc:153026 Zgc:153026 -2.35 
AY048970    -2.34 
AI884197 Dr.21865  Transcribed locus -2.34 
AW076580 Dr.80188  Transcribed locus, moderately similar to XP_421362.2 
PREDICTED: similar to echinoderm microtubule associated protein 
like 1 isoform 2 [Gallus gallus] 
-2.34 
U72692    -2.34 
BI888792 Dr.25812 rhoab Ras homolog gene family, member Ab -2.33 
BI710143    -2.33 
BE605300 Dr.122588  Transcribed locus -2.33 
BI890831    -2.32 
AW305583 Dr.81455  Transcribed locus, strongly similar to XP_001336772.1 
PREDICTED: similar to Calsenilin, presenilin binding protein, EF 
hand transcription factor [Danio rerio] 
-2.32 
BI709745    -2.32 
BI672929 Dr.83460  Transcribed locus -2.32 
BI881272 Dr.22717 zgc:92148 Zgc:92148 -2.31 
AI942915    -2.31 
BG303366    -2.31 
AW305488 Dr.81448 pvalb6 Parvalbumin 6 -2.31 
BM102834 Dr.16838 atp2a2a ATPase, Ca++ transporting, cardiac muscle, slow twitch 2a -2.31 
BG303762    -2.31 
BM157000 Dr.25609 spint1b Serine peptidase inhibitor, Kunitz type 1 b -2.30 
BG303025 Dr.79900 cx28.9 Connexin 28.9 -2.30 
BG728432 Dr.83145 sult1st4 Sulfotransferase family 1, cytosolic sulfotransferase 4 -2.30 
AI942926 Dr.122011  Transcribed locus -2.30 
 A-30
AI641086    -2.30 
AI722743    -2.30 
AI385039 Dr.23608 zgc:66409 Zgc:66409 -2.30 
BM186281 Dr.77919 plcxd3 Phosphatidylinositol-specific phospholipase C, X domain containing 
3 
-2.30 
AI384619    -2.29 
BM187499 Dr.132866 zgc:136551 Zgc:136551 -2.29 
AW826597 Dr.10592  Transcribed locus -2.29 
BI863848    -2.28 
AW174620 Dr.140304  CDNA clone IMAGE:7402628 -2.28 
AW154129 Dr.132763  Transcribed locus, weakly similar to NP_001026417.1 BRCA1 
associated RING domain 1 [Gallus gallus] 
-2.27 
BG303805 Dr.132523 zgc:158612 Zgc:158612 -2.27 
AW279757 Dr.22715  Transcribed locus -2.27 
BM154540    -2.27 
AI721305 Dr.78682 LOC553343 Hypothetical protein LOC553343 -2.26 
AW420765    -2.26 
BI879467 Dr.12769  Transcribed locus -2.26 
AF104037 Dr.82593 runx3 Runt-related transcription factor 3 -2.25 
AB055682 Dr.76932 snx1 Sorting nexin 1 -2.25 
BI842162 Dr.13917  Transcribed locus -2.25 
M81109    -2.25 
BG304888 Dr.82827 zgc:73153 Zgc:73153 -2.25 
AF139536 Dr.81321 wnt4b Wingless-type MMTV integration site family, member 4b -2.25 
BG892360 Dr.112896 LOC565641 Hypothetical LOC565641 -2.25 
BM185453 Dr.85013 zgc:92783 Zgc:92783 -2.25 
BI867354 Dr.133382 LOC100000250 Similar to arrestin domain-containing 4 -2.25 
AI330568 Dr.76251 si:dkey-231a18.1 Si:dkey-231a18.1 -2.25 
AI331804 Dr.132229  Transcribed locus -2.25 
BI865799 Dr.133366  Transcribed locus -2.25 
BI706776 Dr.83355  Transcribed locus -2.25 
BI670894 Dr.82951 guk1 Hypothetical protein LOC791705 -2.25 
BM183359 Dr.84955  Transcribed locus -2.24 
BI889166 Dr.119587 LOC797310 Similar to MCM3 minichromosome maintenance deficient 3 (S. 
cerevisiae) 
-2.24 
AI877586 Dr.105952 zgc:103762 Zgc:103762 -2.24 
AW076955 Dr.22350  Transcribed locus -2.24 
BG305568    -2.23 
BG303149 Dr.11453  Transcribed locus -2.23 
AF265343 Dr.30505 LOC405768 Protein kinase Npk -2.23 
BG305533    -2.23 
AW777426    -2.23 
BI841667 Dr.84597  Transcribed locus -2.23 
AI384843    -2.22 
AF112374    -2.22 
AI397370    -2.22 
BI672832 Dr.49116 LOC797675 Hypothetical protein LOC797675 -2.22 
AW171262 Dr.110015 zgc:123236 Hypothetical protein LOC792084 -2.22 
 A-31
BG308631    -2.22 
BI671149 Dr.120139 LOC792612 Hypothetical protein LOC792612 -2.22 
AW280165 Dr.81105  Transcribed locus -2.22 
BI864832 Dr.84361  Transcribed locus -2.21 
AW419957 Dr.118521 rhbg Rhesus blood group, B glycoprotein -2.21 
BI880387 Dr.121473 LOC100007784 Similar to Pdc2 protein -2.21 
AF001908 Dr.75762 rx2 Retinal homeobox gene 2 -2.21 
AW115526 Dr.39911 zgc:123278 Zgc:123278 -2.21 
BG306097    -2.21 
BM072624 Dr.84020 LOC797222 Hypothetical protein LOC797222 -2.20 
BM035491 Dr.84515  Transcribed locus, moderately similar to NP_001106657.1 
glutamate receptor, ionotrophic, AMPA 4 isoform 1 precursor 
[Gallus gallus] 
-2.20 
AW232796    -2.20 
AI601473    -2.20 
BI840863 Dr.13834  Transcribed locus -2.20 
BI706228    -2.20 
AF067204 Dr.75832 foxg1 Forkhead box G1 -2.19 
BG727323    -2.19 
BI882156    -2.19 
AI721567    -2.19 
AW077980    -2.19 
BI890456 Dr.83786 wdr51a WD repeat domain 51A -2.19 
AI878461    -2.18 
BI982778 Dr.107033 zgc:153426 Zgc:153426 -2.18 
BI980456 Dr.84710  Transcribed locus, strongly similar to NP_001006091.1 speedy 1 
[Danio rerio] 
-2.18 
BG883435 Dr.85568 tbpl1 TBP-like 1 -2.18 
BI865988    -2.18 
BI709148    -2.18 
AI883937    -2.18 
AF109371 Dr.81279 opn1lw1 Opsin 1 (cone pigments), long-wave-sensitive, 1 -2.18 
BI706474 Dr.82629 LOC563546 Hypothetical LOC563546 -2.18 
BM155145    -2.17 
BG308248 Dr.17375 zgc:66433 Zgc:73148 -2.17 
BI673669 Dr.83515  Transcribed locus -2.17 
AW154466 Dr.51201 zgc:66440 Zgc:66440 -2.17 
AW019584    -2.16 
AW279987 Dr.81083 pter Phosphotriesterase related -2.16 
AW305423    -2.16 
AF112374    -2.15 
AI588617    -2.15 
BM095156 Dr.81503 zgc:112063 Zgc:112063 -2.15 
BI877134 Dr.75551 sulf2 Sulfatase 2 -2.15 
BI671352    -2.15 
BI984424 Dr.81599 si:dkey-98p3.7 Si:dkey-98p3.7 -2.15 




BI980695 Dr.52170  Transcribed locus, strongly similar to NP_001002726.1 WD repeat 
and HMG-box DNA binding protein 1 [Danio rerio] 
-2.15 
AI588704 Dr.77749  Transcribed locus -2.14 
AI384866 Dr.3436 LOC100000870 Hypothetical protein LOC100000870 -2.14 
AW076611    -2.14 
AI721930    -2.14 
AW420904    -2.14 
BI982416    -2.13 
AI641716 Dr.78444 LOC563041 Similar to glutamine and serine rich 1 -2.13 
AW343084 Dr.42820 zgc:158609 Hypothetical protein LOC796347 -2.13 
AI721563 Dr.132465  Transcribed locus, weakly similar to NP_001093568.1 hypothetical 
protein LOC100006084 [Danio rerio] 
-2.13 
BI879528 Dr.83841  Transcribed locus -2.13 
AW019018 Dr.122080  Transcribed locus -2.13 
X68432 Dr.75078 pouc POU domain gene C -2.13 
AI331279 Dr.76343 limk2 LIM domain kinase 2 -2.13 
BI705669 Dr.105165 im:6895556 Im:6895556 -2.12 
AW343860    -2.12 
BI840552    -2.12 
AA658595 Dr.75974 pdzk1l PDZ domain containing 1 like -2.12 
BI875639 Dr.107194 LOC793096 Hypothetical protein LOC793096 -2.12 
BF717971 Dr.3619 mfsd2b Major facilitator superfamily domain containing 2b -2.12 
AW019201 Dr.51148 c9 Complement component 9 -2.12 
AW077637 Dr.110680 si:ch211-15p9.5 Si:ch211-15p9.5 -2.11 
BI672471 Dr.14469 LOC562825 Similar to Cyclin B1 interacting protein 1 -2.11 
AW077311 Dr.16352 LOC562471 Similar to SLIT and NTRK-like family, member 5 -2.11 
BE201646 Dr.40515 CH211-106A19.1 Novel protein similar to vertebrate oxysterol binding protein 
(OSBP) 
-2.11 
AI416335    -2.11 
BI847064 Dr.14064 zgc:55418 Zgc:55418 -2.11 
BI865909    -2.10 
BI473233    -2.10 
AI958455 Dr.104262 smyhc1 Slow myosin heavy chain 1 -2.10 




BI878229 Dr.83757 wu:fc54b01 Wu:fc54b01 -2.10 
BG884464    -2.10 
BM103780    -2.10 
AI641570    -2.10 
BG727645 Dr.11977 zgc:100989 Zgc:100989 -2.10 
BI979669 Dr.82820 LOC795739 Hypothetical protein LOC795739 -2.10 
AI384635 Dr.35202  Transcribed locus -2.10 
BI888965    -2.09 
BM154753 Dr.79361  Transcribed locus -2.09 
BI475920 Dr.85917  Transcribed locus -2.09 
AI331716 Dr.2364  Transcribed locus, weakly similar to NP_001038873.1 hypothetical 
protein LOC751695 [Danio rerio] 
-2.09 
BI885292 Dr.67637 grna Hypothetical protein LOC791524 -2.08 
 A-33
AI522746    -2.08 
AI957403 Dr.21967  Transcribed locus -2.08 
AF272965    -2.08 
BI671376 Dr.132854  Transcribed locus -2.08 
BI877542 Dr.107962 sycp1 Synaptonemal complex protein 1 -2.08 
BG303425 Dr.122695  Transcribed locus -2.08 
BI980313 Dr.16681 LOC558208 Similar to MAM domain-containing glycosylphosphatidylinositol 
anchor 2 
-2.07 
BI839255 Dr.26359  Transcribed locus -2.07 
AI544779 Dr.77299  Transcribed locus -2.07 
AW421330 Dr.23036 zgc:112282 Zgc:112282 -2.07 
AW420795 Dr.74644  Transcribed locus -2.07 
AW231999 Dr.106924 LOC555289 Hypothetical LOC555289 -2.07 
BG302614 Dr.12949 dio2 Deiodinase, iodothyronine, type II -2.07 
BI671258    -2.07 
BI671932    -2.07 
BI427749    -2.07 
BG737918 Dr.77945 dnmt5 DNA (cytosine-5-)-methyltransferase 5 -2.06 
BI979971 Dr.5432 LOC794880 Hypothetical protein LOC794880 -2.06 
BI880311 Dr.82714  Transcribed locus -2.06 
AW171151 Dr.20126 LOC100005300 Hypothetical protein LOC100005300 -2.06 
BI428733 Dr.85833  Transcribed locus -2.06 
AW282071 Dr.81033 zgc:112198 Zgc:112198 -2.06 
BI430133 Dr.123586  Transcribed locus -2.06 
AW171377 Dr.47843 si:rp71-1n18.2 Si:rp71-1n18.2 -2.06 
BI979807 Dr.7658 anxa6 Annexin A6 -2.05 
BI671544 Dr.43384 zgc:110253 Zgc:110253 -2.05 
BM102028 Dr.133200  Transcribed locus -2.05 
BM072355 Dr.106453 nxph1 Neurexophilin 1 -2.05 
AI384172    -2.05 
BM071153 Dr.14782  Transcribed locus -2.05 
AW174507 Dr.76275 mmp9 Matrix metalloproteinase 9 -2.05 
BM081849 Dr.1484 wu:fb14g01 Wu:fb14g01 -2.05 
AI965315    -2.04 
BG305908 Dr.82887  Transcribed locus -2.04 
BI891510 Dr.72042 zgc:101661 Zgc:101661 -2.04 
BM156084 Dr.81803 zgc:92463 Zgc:92463 -2.04 
AW154320 Dr.75180 hells Helicase, lymphoid specific -2.04 
AW826504    -2.04 
BI428482    -2.04 
BI982104 Dr.77426  Transcribed locus -2.04 
AI584310 Dr.21180  Transcribed locus -2.04 
BI705273 Dr.84698 zgc:162301 Zgc:162301 -2.03 
AI641420    -2.03 
BI879855 Dr.12823  Transcribed locus -2.03 
BI671633 Dr.132603  Transcribed locus -2.03 
AI641428 Dr.78477 LOC557806 Similar to G protein-coupled receptor family C group 6 member A -2.03 
 A-34
BI980180 Dr.86046 nr2f1l Nuclear receptor subfamily 2, group F, member 1, like -2.03 
AI641026    -2.02 
BG727211 Dr.83060  Transcribed locus -2.02 
BE016195 Dr.82018 zgc:153025 Zgc:153025 -2.02 
BI980783 Dr.16719  Transcribed locus -2.02 
BG304025 Dr.82468 tbc1d19 TBC1 domain family, member 19 -2.02 
BI430135 Dr.81064 stmn4 Stathmin-like 4 -2.02 
AW116234    -2.02 
BI867960 Dr.84473  Transcribed locus -2.02 
AI942974 Dr.79465 LOC794145 Hypothetical protein LOC794145 -2.02 
BI865624 Dr.13507  Transcribed locus -2.02 
AW174578 Dr.106150 adssl1 Hypothetical protein LOC792013 -2.02 
BI881018 Dr.62863 si:ch211-203l9.3 Si:ch211-203l9.3 -2.02 
BI864152 Dr.13425  Transcribed locus -2.02 
BI473169 Dr.85856  Transcribed locus -2.01 
AW058968    -2.01 
AF387343    -2.01 
AI353464    -2.01 
BM071805 Dr.75731 btg4 B-cell translocation gene 4 -2.01 
BI842764 Dr.14186 si:ch211-214p16.1 Si:ch211-214p16.1 -2.01 
BI887493 Dr.82604 cog8 Component of oligomeric golgi complex 8 -2.01 
BI879339 Dr.41804 zgc:153443 Zgc:153443 -2.01 
AF137532 Dr.79311 zbtb22 Zinc finger and BTB domain containing 22 -2.01 
BM005370 Dr.86145  Transcribed locus -2.00 
AI722449 Dr.77279  Transcribed locus, strongly similar to XP_001331962.1 
PREDICTED: similar to MGC78853 protein [Danio rerio] 
-2.00 
AI943204    -2.00 
BG985781 Dr.83325 id:ibd5114 Id:ibd5114 -2.00 
AY028626 Dr.25265 sim1 Single-minded homolog 1 (Drosophila) -2.00 
BI865700 Dr.82648  Transcribed locus -2.00 
AI878532    -1.99 
BI882561 Dr.47889  Transcribed locus, moderately similar to XP_865681.1 
PREDICTED: similar to Inositol 1,4,5-trisphosphate receptor type 2 
(Type 2 inositol 1,4,5-trisphosphate receptor) (Type 2 InsP3 
receptor) (IP3 receptor isoform 2) (InsP3R2) isoform 6 [Canis 
familiaris] 
-1.99 
AI942990 Dr.79468  Transcribed locus -1.99 
AW076820 Dr.7596 fgf13 Fibroblast growth factor 13 -1.99 
BI839526 Dr.78256 ivns1abpa Influenza virus NS1A binding protein a -1.99 
AW233591 Dr.78030 zgc:55336 Zgc:55336 -1.99 
BG305944 Dr.82896 smtn Hypothetical protein LOC100003468 -1.98 
BI886091 Dr.77689 zgc:153769 Zgc:153769 -1.98 
AI478008    -1.98 
BG307379 Dr.82639 LOC796440 Hypothetical protein LOC796440 -1.98 
BM071318 Dr.84777  Transcribed locus -1.98 
BM024131    -1.98 
AW421016 Dr.81592  Transcribed locus -1.98 
AI477323 Dr.36024 LOC571026 Hypothetical LOC571026 -1.98 
 A-35
BM005330 Dr.13934  Transcribed locus -1.98 
BG306175    -1.97 
AW019809 Dr.80066  Transcribed locus -1.97 
BM187094 Dr.132257 zgc:153012 Zgc:153012 -1.97 
BI882925 Dr.40469 CH211-112F11.1 Novel protein similar to vertebrate InaD-like protein (INADL) -1.97 
BI867022 Dr.13606 snx10a Sorting nexin 10a -1.97 
BE605648 Dr.82260 LOC565205 Hypothetical LOC565205 -1.97 
BM101931 Dr.18458 thop1 Thimet oligopeptidase 1 -1.97 
BG304266 Dr.82495  Transcribed locus -1.97 
BM082504 Dr.18807 bokb BCL2-related ovarian killer b -1.97 
AW420559    -1.96 
BI867800 Dr.133380  Transcribed locus -1.96 
AI601520 Dr.77960 si:dkeyp-84f11.5 Si:dkeyp-84f11.5 -1.96 
BI843139    -1.96 
BE016391 Dr.132990 zgc:162897 Zgc:162897 -1.96 
AW078202 Dr.7283 sid1 Secreted immunoglobulin domain 1 -1.96 
AW420982 Dr.23037  Transcribed locus -1.96 
AF160641 Dr.79856 si:dkey-7l12.1 Si:dkey-7l12.1 -1.96 
AF321294 Dr.77753 s1pr1 Sphingosine-1-phosphate receptor 1 -1.95 
AI666959 Dr.21471  Transcribed locus -1.95 
AF164512 Dr.81313 vdr Hypothetical LOC573180 -1.95 
BI710294 Dr.82998 LOC795119 Hypothetical protein LOC795119 -1.95 
BM102055    -1.95 
AF012752 Dr.75772 or111-10 Odorant receptor, family D, subfamily 111, member 10 -1.95 
AI943112 Dr.79493 zgc:113499 Hypothetical protein LOC100007620 -1.95 
BI890108 Dr.33010 mcm6 MCM6 minichromosome maintenance deficient 6, mitotin (S. 
cerevisiae) 
-1.95 
BM181896 Dr.33915 LOC100000998 Hypothetical protein LOC100000998 -1.95 
AF113023    -1.95 
BI882131 Dr.120146 si:ch211-129c21.1 Si:ch211-129c21.1 -1.95 
BE200932 Dr.119564 LOC799253 Hypothetical protein LOC799253 -1.95 
BG305103 Dr.78131 lin7a Lin-7 homolog A (C. elegans) -1.95 
BE015693 Dr.81853 LOC570112 Hypothetical LOC570112 -1.94 
AW058825 Dr.122110  Transcribed locus -1.94 
BM103988 Dr.86270 LOC795838 Hypothetical protein LOC795838 -1.94 
AW018996 Dr.94688 wu:fd58b05 Wu:fd58b05 -1.94 
BG737957 Dr.76191 wu:fb30e01 Wu:fb30e01 -1.94 
BI840114 Dr.78919 zgc:171831 Zgc:171831 -1.94 
AI444335    -1.94 
BI878775 Dr.122864  Transcribed locus -1.94 
BM155229 Dr.141750  Transcribed locus, weakly similar to XP_001345421.1 
PREDICTED: similar to zinc finger protein [Danio rerio] 
-1.93 
BI878412    -1.93 
BI705341 Dr.47088 pcdh1a6 Hypothetical protein LOC100004726 -1.93 
BI839216 Dr.84547  Transcribed locus -1.93 
BI671046 Dr.82855 zgc:110344 Zgc:110344 -1.93 
BM072402 Dr.12546  Transcribed locus -1.93 
AW567444 Dr.81808 zgc:91840 Zgc:91840 -1.93 
 A-36
BE558108 Dr.132994  Transcribed locus -1.93 
BE605950 Dr.82238 itgb4 Integrin, beta 4 -1.93 
BG985766 Dr.3790 sipa1l1 Signal-induced proliferation-associated 1 like 1 -1.93 
BI865936 Dr.84426  Transcribed locus -1.93 
BG985808 Dr.83328 id:ibd5135 Id:ibd5135 -1.93 
BI671872    -1.93 
BI841594 Dr.108135 zgc:165461 Zgc:165461 -1.93 
AI667397    -1.93 
BM186155 Dr.80227 zgc:113088 Zgc:113088 -1.93 
BI864995 Dr.84362  Transcribed locus -1.93 
BM185013 Dr.14618  Transcribed locus -1.93 
BI880231    -1.92 
BG308301 Dr.27148 penkl Proenkephalin-like -1.92 
BI472939 Dr.67395 amd1 Hypothetical protein LOC792097 -1.92 
AI601866    -1.92 
AI883293    -1.92 
AW019091 Dr.79907 nucb2b Nucleobindin 2b -1.92 
BI705588 Dr.82353 ela2 Similar to Ela2 protein -1.92 
AW344197    -1.92 
AI878627 Dr.77494 vrk1 Vaccinia related kinase 1 -1.91 
AI477500 Dr.140554  Transcribed locus, strongly similar to NP_989623.1 wingless-type 
MMTV integration site family, member 7A [Gallus gallus] 
-1.91 
AI396686    -1.91 
AW116064 Dr.33222 zgc:56053 Zgc:56053 -1.91 
BI863989 Dr.84336 penk Proenkephalin -1.91 
BI474975 Dr.83534 si:dkey-246g23.3 Si:dkey-246g23.3 -1.91 
BI672931 Dr.133179 LOC557579 Similar to Lhx6 protein -1.91 
AI883857 Dr.33271 fga Fibrinogen alpha chain -1.91 
BG883838    -1.91 
AI544688    -1.91 
AL591213    -1.90 
BI884127 Dr.78882 LOC100008150 Hypothetical protein LOC100008150 -1.90 
BG799370 Dr.82117 LOC566268 Similar to Regulator of G-protein signalling 4 -1.90 
BM083967 Dr.77333  Transcribed locus -1.90 
BI840936 Dr.74691  Transcribed locus -1.90 
BG985673 Dr.24989 zgc:110679 Zgc:110679 -1.90 
AI626619    -1.90 
AF221127 Dr.88606 LOC407643 Alpha-2 macroglobulin like-protein -1.90 
BM037629 Dr.7628 zgc:158611 Zgc:158611 -1.90 
AI722354    -1.90 
BM005010 Dr.86131  Transcribed locus -1.90 
BI880074 Dr.107682 LOC573953 Similar to cell adhesion molecule NCAM -1.90 
BI672435 Dr.83469 LOC570546 Hypothetical LOC570546 -1.90 
AI584977    -1.90 
BG729614 Dr.81533 pycrl Pyrroline-5-carboxylate reductase-like -1.90 
BI865966 Dr.75672 LOC796109 Similar to Eukaryotic translation initiation factor 3, subunit 8 -1.90 
BM172694    -1.89 
 A-37
BI879770 Dr.119174  Transcribed locus, strongly similar to XP_001337188.1 
PREDICTED: hypothetical protein [Danio rerio] 
-1.89 
BM101781 Dr.30707 perp PERP, TP53 apoptosis effector -1.89 
BG884523    -1.89 
BF717454 Dr.39930 ugt1ab Zgc:123097 -1.89 
BI845715 Dr.84659  Transcribed locus -1.89 
BI840547    -1.89 
BI876694 Dr.32418 lamp2 Lysosomal membrane glycoprotein 2 -1.89 
BM102179 Dr.123774  Transcribed locus -1.89 
AW421090 Dr.81597 LOC571774 Hypothetical LOC571774 -1.89 
AI878530 Dr.132545 golph3 Golgi phosphoprotein 3 -1.89 
BM037319 Dr.84539 zgc:153092 Zgc:153092 -1.89 
AI641666    -1.89 
BI430300 Dr.84831  Transcribed locus -1.89 
AI943188 Dr.27614  Transcribed locus -1.89 
BM026445    -1.88 
BI891345 Dr.84285 zgc:112155 Zgc:112155 -1.88 
BI840754 Dr.83446 efhc2 EF-hand domain (C-terminal) containing 2 -1.88 
AW826254    -1.88 
BM025966 Dr.85637 irf2 Interferon regulatory factor 2 -1.88 
AF272962    -1.88 
BI866535 Dr.11767 epo Erythropoietin -1.88 
X87752    -1.88 
AF052435 Dr.75836 zic1 Zic family member 1 (odd-paired homolog, Drosophila) -1.88 
BG884090 Dr.76188 c6orf115 Chromosome 6 open reading frame 115 (H. sapiens) -1.88 
AW018801 Dr.79930 zgc:113516 Zgc:113516 -1.88 
AF012749 Dr.75770 or111-5 Odorant receptor, family D, subfamily 111, member 5 -1.88 
AI384854 Dr.23573 LOC100005858 Similar to B-aggressive lymphoma 3 -1.88 
BI879014 Dr.18438 si:ch211-81a5.8 Si:ch211-81a5.8 -1.88 
AW019121 Dr.132359  Transcribed locus -1.88 
BM025973 Dr.133757 LOC571030 Hypothetical LOC571030 -1.87 
AI585113    -1.87 
AW281586 Dr.81202 oatx Similar to LOC555218 protein -1.87 
BM156806 Dr.7324 wu:fi37b05 Wu:fi37b05 -1.87 
BM070939 Dr.84757 gnrh2 Gonadotropin-releasing hormone 2 -1.87 
AL591401    -1.87 
AW127862 Dr.26610 zgc:66441 Zgc:66441 -1.87 
AI544522 Dr.77261  Transcribed locus -1.87 
BI563129 Dr.80983  Transcribed locus -1.87 
BI670920 Dr.81999 zgc:73075 Hypothetical protein LOC792069 -1.87 
BM184105 Dr.119346 zgc:175136 Zgc:175136 -1.87 
BI672098 Dr.83420  Transcribed locus -1.87 
AW076828 Dr.45605 LOC796390 Similar to GABAa receptor gamma2 subunit -1.87 
BI846301 Dr.84673  Transcribed locus -1.87 
AF076918 Dr.75838 zorba Orb/CPEB-related RNA-binding protein -1.87 
BE201677 Dr.82156 zgc:158531 Zgc:158531 -1.86 
BI428272 Dr.115457  Transcribed locus -1.86 
BI882119 Dr.75272 LOC567779 Novel protein similar to vertebrate neuron navigator family -1.86 
 A-38
AW077636 Dr.79853 LOC100000090 Similar to Solute carrier family 20, member 1a -1.86 
BI430253    -1.86 
BI670844 Dr.83340 als2cr4 Amyotrophic lateral sclerosis 2 (juvenile) chromosome region, 
candidate 4 
-1.86 
BI885276 Dr.84027  Transcribed locus -1.86 
BG729009 Dr.78947  Transcribed locus -1.86 
BI671175    -1.86 
BI475000    -1.85 
AI883922 Dr.28276 zgc:65956 Zgc:65956 -1.85 
AF354751 Dr.82172 psma6b Proteasome (prosome, macropain) subunit, alpha type, 6b -1.85 
BI864822 Dr.84360 zgc:158271 Zgc:158271 -1.85 
AI667508    -1.85 
AI667249 Dr.132396 pklr Pyruvate kinase, liver and RBC -1.85 
AF097477 Dr.105703 LOC407635 Protein tyrosine phosphatase H1 -1.85 
BM025461    -1.85 
BI980979 Dr.83643  Transcribed locus -1.85 
BE202204 Dr.122571  Transcribed locus -1.84 
BI326282 Dr.85775  Transcribed locus -1.84 
BI476513 Dr.7819  Transcribed locus -1.84 
BG891983 Dr.77297 arg2 Arginase, type II -1.84 
AW419516 Dr.122433  Transcribed locus -1.84 
BI879867 Dr.51620 npb Neuropeptide B -1.84 
BG303246 Dr.75493 zgc:55781 Zgc:55781 -1.84 
AI793798    -1.84 
AI722383    -1.84 
AI584429 Dr.77591 si:dkey-175g20.1 Si:dkey-175g20.1 -1.84 
BM036916 Dr.17319 zgc:152968 Zgc:152968 -1.84 
AF230807 Dr.81318 plrdgb PITP-less RdgB-like protein -1.84 
BI841843 Dr.84600  Transcribed locus -1.84 
BE016502 Dr.2414 smarca4 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
-1.83 
BI704187    -1.83 
AF024536 Dr.566 atoh1a Atonal homolog 1a -1.83 
AI658249    -1.83 
AW232403 Dr.22588  Transcribed locus -1.83 
BI983342    -1.83 
BG308582 Dr.80309 bcat1 Branched chain aminotransferase 1, cytosolic -1.83 
AF055906    -1.83 
AI721889 Dr.33008  Transcribed locus -1.83 
BI841688    -1.83 
AW171554 Dr.115060 nol6 Nucleolar protein family 6 (RNA-associated) -1.83 
BM184069 Dr.81036 LOC100006991 Similar to pol polyprotein -1.83 
AW280086 Dr.81095  Transcribed locus -1.83 
BE017917 Dr.1911 LOC564069 Hypothetical LOC564069 -1.83 
AW115826    -1.83 
AW154252 Dr.80560 si:dkey-202g15.7 Si:dkey-202g15.7 -1.83 
AI522669 Dr.12110 sc4mol Sterol-C4-methyl oxidase-like -1.82 
AW233610 Dr.81035 LOC559267 Similar to AI315068 protein -1.82 
 A-39
BM185116 Dr.77191 tuba2 Tubulin, alpha 2 -1.82 
AW153664 Dr.78616 zgc:111868 Hypothetical protein LOC791857 -1.82 
AI793444    -1.82 
BG985576 Dr.25756 hdac9b Histone deacetylase 9b -1.82 
BG306150 Dr.28459 LOC794906 Similar to DMbeta1 -1.82 
BI878985 Dr.12931  Transcribed locus -1.82 
BI885889 Dr.80181 si:dkey-14d8.5 Si:dkey-14d8.5 -1.82 
AI437390 Dr.132276  Transcribed locus -1.82 
AW018969 Dr.35698 LOC100003669 Hypothetical protein LOC100003669 -1.81 
D13045 Dr.29717 pou23 POU domain gene 23 -1.81 
AI354032 Dr.72101 nppa Natriuretic peptide precursor A -1.81 
AI658174    -1.81 
BM185375 Dr.85010 si:dkey-30c15.5 Si:dkey-30c15.5 -1.81 
AF030245    -1.81 
BM104374 Dr.142309  CDNA clone IMAGE:6997158 -1.81 
BG306678 Dr.81948 pdc1 Phosducin 1 -1.81 
AW077303 Dr.80267  Transcribed locus -1.81 
AW170826 Dr.80657 LOC565839 Hypothetical LOC565839 -1.81 
AW115757 Dr.80362 hpx Hemopexin -1.81 
BI839210    -1.81 
AI657694 Dr.21458  Transcribed locus -1.80 
AW019272 Dr.79975 si:ch211-87e4.2 Si:ch211-87e4.2 -1.80 
BM184316 Dr.31925 st8sia2 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 -1.80 
AI626641 Dr.185  Transcribed locus -1.80 
AI522420    -1.80 
AW133510 Dr.79165 sb:cb14 Sb:cb14 -1.80 
AW116809 Dr.77075 pole2 Polymerase (DNA directed), epsilon 2 -1.80 
BI709646 Dr.86022 per4 Period homolog 4 -1.80 
BI878927 Dr.8505 fgb Fibrinogen, B beta polypeptide -1.80 
AF036148 Dr.75801 neurod Neurogenic differentiation -1.80 
AI878170 Dr.79212  Transcribed locus -1.80 
BI878654 Dr.74466 si:dkey-264g21.1 Si:dkey-264g21.1 -1.80 
AI722545    -1.80 
BM095781 Dr.75301 tubgcp5 Tubulin, gamma complex associated protein 5 -1.80 
BI474304 Dr.133189 zgc:113363 Hypothetical protein LOC791449 -1.79 
BI672388 Dr.83459 styxl1 Serine/threonine/tyrosine interacting-like 1 -1.79 
AI544617 Dr.77277  Transcribed locus -1.79 
AI384460 Dr.76652  Transcribed locus -1.79 
BE016427 Dr.82026 LOC564158 Hypothetical LOC564158 -1.79 
AF192763    -1.79 
AI721647 Dr.78647 nr2e1 Nuclear receptor subfamily 2, group E, member 1 -1.79 
AF001907 Dr.75761 rx1 Retinal homeobox gene 1 -1.79 
AW281850 Dr.114378 zgc:77462 Zgc:77462 -1.79 
BI882797 Dr.83254  Transcribed locus, strongly similar to XP_001333623.1 
PREDICTED: similar to Si:ch211-191d7.4 isoform 1 [Danio rerio] 
-1.79 
BI705456 Dr.120728 LOC100005920 Hypothetical protein LOC100005920 -1.79 
U50380 Dr.23445 ba1 Hypothetical protein LOC791551 -1.78 
 A-40
AW076961 Dr.122135  Transcribed locus, strongly similar to NP_956270.1 superoxide 
dismutase 2, mitochondrial precursor [Danio rerio] 
-1.78 
BM023802 Dr.133752  Transcribed locus -1.78 
AW826373 Dr.137981  Transcribed locus -1.78 
BM037417 Dr.84897  Transcribed locus -1.78 
U31822 Dr.88564 mtnr1aa Melatonin receptor 1A a -1.78 
AI384212 Dr.76627  Transcribed locus -1.78 
BI879178 Dr.117127 pde6c Phosphodiesterase 6C, cGMP-specific, cone, alpha prime -1.78 
AB011681 Dr.8156 ZOR-2 ZOR-2 -1.78 
BI889554 Dr.80660 plk4 Polo-like kinase 4 (Drosophila) -1.78 
BI876170    -1.78 
U93469    -1.78 
BI473147 Dr.113791 LOC797593 Similar to ADAMTS-like protein 3 precursor (ADAMTSL-3) 
(Punctin-2) 
-1.78 
BI891593 Dr.7658 anxa6 Annexin A6 -1.78 
BG799357 Dr.132993 LOC559514 Similar to mKIAA1856 protein -1.78 
AW827044 Dr.48570 zgc:113974 Zgc:113974 -1.78 
BI983604 Dr.85463 LOC792638 Hypothetical protein LOC792638 -1.77 
AW058924    -1.77 
BM104172 Dr.48937 LOC797183 Hypothetical protein LOC797183 -1.77 
BI887470 Dr.104738  Transcribed locus -1.77 
AI959755 Dr.52559 erbb2 V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene homolog 
-1.77 
BG303492 Dr.82372 tph1b Tryptophan hydroxylase 1b -1.77 
AW281608 Dr.81171  Transcribed locus -1.77 
BI846800 Dr.81471 si:dkey-245f7.1 Si:dkey-245f7.1 -1.77 
BM103866 Dr.85158 zgc:162611 Zgc:162611 -1.77 
AI497124 Dr.77172 zgc:153968 Zgc:153968 -1.77 
AW595822 Dr.76206 LOC562449 Similar to MGC80493 protein -1.77 
AI641619 Dr.120216  Transcribed locus -1.77 
BI865600    -1.77 
AW344023 Dr.122381  Transcribed locus -1.76 
AI658316 Dr.78541 LOC556897 Zgc:172197 -1.76 
AI721331 Dr.78687  Transcribed locus -1.76 
BM037334 Dr.123279  Transcribed locus, strongly similar to NP_001073418.1 hypothetical 
protein LOC100003007 [Danio rerio] 
-1.76 
BE017389 Dr.120510 LOC100006022 Hypothetical protein LOC100006022 -1.76 
BI880521 Dr.122931  Transcribed locus -1.76 
AF273479 Dr.80831 CH211-173P18.8 Granulin 1 -1.76 
BI843027 Dr.75429 cpt2 Carnitine palmitoyltransferase II -1.76 
BM185360 Dr.78603 wu:fd14a06 Wu:fd14a06 -1.76 
AI794237 Dr.132522  Transcribed locus -1.76 
BI877959 Dr.132706 si:dkey-200h23.5 Si:dkey-200h23.5 -1.76 
X97331 Dr.75064 her3 Hairy-related 3 -1.76 
AI522589 Dr.77164 LOC560928 Si:rp71-15k1.1 -1.76 
BG892002    -1.76 
BG305578    -1.76 
AF112374    -1.75 
 A-41
AW154664 Dr.79298 LOC558626 Similar to DENN/MADD domain containing 4C -1.75 
AI522693    -1.75 
BI845348 Dr.90075  Transcribed locus -1.75 
BM026423 Dr.115656 LOC799275 Hypothetical protein LOC799275 -1.75 
BI865912 Dr.77753 s1pr1 Sphingosine-1-phosphate receptor 1 -1.75 
AW077137 Dr.22365  Si:dkey-181f18.3 (si:dkey-181f18.3), mRNA -1.75 
AF037401    -1.75 
AI353927 Dr.53564 zgc:152732 Ventricular myosin heavy chain -1.75 
AW232463 Dr.122317  Transcribed locus, strongly similar to XP_001336220.1 
PREDICTED: similar to odorant receptor [Danio rerio] 
-1.75 
BM186913    -1.75 
BM036403 Dr.84871  Transcribed locus -1.75 
AI497222 Dr.114476 zgc:92161 Hypothetical protein LOC791539 -1.74 
BI865569 Dr.84392  Transcribed locus -1.74 
AI721501 Dr.78732 zgc:100787 Zgc:100787 -1.74 
BI841405 Dr.133397  Transcribed locus -1.74 
BM035710 Dr.50626 LOC555838 Hypothetical LOC555838 -1.74 
BI889768    -1.74 
BM183654 Dr.111554 dnl2l Dynein light chain 2, like -1.74 
BG304261 Dr.82493 tmem68 Hypothetical LOC555124 -1.74 
BI704912 Dr.136426  Transcribed locus -1.74 
L19454    -1.74 
BI710602 Dr.85296 si:dkeyp-114f9.4 Si:dkeyp-114f9.4 -1.74 
BM081030 Dr.84712 LOC100004074 Hypothetical protein LOC100004074 -1.74 
AF308599 Dr.77442 atp1a3a ATPase, Na+/K+ transporting, alpha 3a polypeptide -1.74 
AW116611 Dr.80438 vil1l Villin 1 like -1.74 
BI839750 Dr.41078 si:dkey-12e7.1 Si:dkey-12e7.1 -1.74 
BI840500    -1.73 
BI875793 Dr.93531 smarca2 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
-1.73 
BI842482    -1.73 
AI883944 Dr.79393 si:ch211-218c6.6 Si:ch211-218c6.6 -1.73 
BI325085 Dr.132169 nap1l1 Nucleosome assembly protein 1, like 1 -1.73 
AF047412 Dr.29756 bfb Complement component bfb -1.73 
BM024389 Dr.76258 zgc:136929 Zgc:136929 -1.73 
BI877637 Dr.81676 zgc:171416 Zgc:171416 -1.73 
BM005096 Dr.123726  Transcribed locus -1.73 
AI545660 Dr.4243 cx32.3 Connexin 32.3 -1.73 
BI980021 Dr.84711  Transcribed locus -1.73 
AW826642 Dr.28100  Transcribed locus -1.72 
BI672078    -1.72 
AB049457 Dr.82507 atoh7 Atonal homolog 7 -1.72 
BM101997 Dr.86263  Transcribed locus -1.72 
BI980890 Dr.83615  Transcribed locus -1.72 
BE557147    -1.72 
 A-42
AI397328 Dr.77744  Transcribed locus, weakly similar to NP_899191.2 sulfotransferase 
family 1, cytosolic sulfotransferase 3 [Danio rerio] 
-1.72 
AI544800 Dr.76987 ace2 Angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 -1.72 
BI534295 Dr.76914  Transcribed locus, strongly similar to NP_001038553.1 hypothetical 
protein LOC565827 [Danio rerio] 
-1.72 
BF717452    -1.72 
AI522688 Dr.2455 tat Tyrosine aminotransferase -1.72 
BI841611 Dr.133400  Transcribed locus -1.72 
BG306302    -1.72 
BI429322 Dr.83547 amph Amphiphysin -1.72 
AI588546 Dr.121800  Transcribed locus -1.72 
AI416336    -1.71 
AI878133 Dr.76191 wu:fb30e01 Wu:fb30e01 -1.71 
AW305943 Dr.81475 mmp13 Matrix metalloproteinase 13 -1.71 
AW076862    -1.71 
BM154534 Dr.132311 cel.1 Carboxyl ester lipase, tandem duplicate 1 -1.71 
AI626492 Dr.35891 tubb5 Tubulin, beta 5 -1.71 
BE017626 Dr.107097 wu:fk81d02 Wu:fk81d02 -1.71 
BI533401    -1.71 
BE605613 Dr.80832  Transcribed locus -1.71 
AY026507 Dr.75601 dhfr Dihydrofolate reductase -1.71 
BM101640 Dr.4740 zgc:111983 Zgc:111983 -1.71 
BI865911 Dr.84423  Transcribed locus -1.71 
BI430366 Dr.120745 LOC561625 Hypothetical LOC561625 -1.71 
AA495026 Dr.75269 picalml Phosphatidylinositol binding clathrin assembly protein, like -1.71 
AW777351 Dr.102941 aebp2 AE binding protein 2 -1.71 
BI845580    -1.71 
AW076661 Dr.80220  Transcribed locus, moderately similar to XP_688369.2 
PREDICTED: hypothetical protein [Danio rerio] 
-1.70 
BG308485 Dr.122673  Transcribed locus -1.70 
AI558632 Dr.77514 ela3l Elastase 3 like -1.70 
BM182376 Dr.81689 zgc:55733 Zgc:55733 -1.70 
AF327410 Dr.81726 caspb Caspase b -1.70 
BG883797    -1.70 
BI533409 Dr.80235 zgc:136828 Zgc:136828 -1.70 
AL591213    -1.70 
AI959752 Dr.79747 mycl1a V-myc myelocytomatosis viral oncogene homolog 1, lung carcinoma 
derived (avian) a 
-1.70 
AI545289    -1.70 
BM182566 Dr.118754 LOC100006179 Similar to DNA polymerase epsilon subunit B -1.70 
U14591 Dr.30626 otx1 Orthodenticle homolog 1 -1.70 
BI982877 Dr.15231  Transcribed locus -1.70 
AW116052 Dr.26647 LOC554983 Hypothetical LOC554983 -1.70 
BM154135 Dr.119809 ghrb Growth hormone receptor b -1.69 
BM025400    -1.69 
AL590147    -1.69 
BI672313 Dr.107926  Transcribed locus -1.69 
BG306460    -1.69 
 A-43
BI839870 Dr.105269 supt16h Suppressor of Ty 16 homolog -1.69 
BI878766 Dr.106694 LOC563225 Hypothetical LOC563225 -1.69 
BM184007 Dr.122870  Transcribed locus, moderately similar to NP_001103190.1 
hypothetical protein LOC571939 [Danio rerio] 
-1.69 
BG305456    -1.69 
BG727594 Dr.12251 antxr2a Anthrax toxin receptor 2a -1.69 
X96422 Dr.75088 pou50 POU domain gene 50 -1.69 
AB055668 Dr.101715 ogfod1 2-oxoglutarate and iron-dependent oxygenase domain containing 1 -1.69 
BF938393 Dr.133058 cyp11b2 Cytochrome P450, family 11, subfamily B, polypeptide 2 -1.69 
BM104000 Dr.75717 si:ch211-14a17.7 Si:ch211-14a17.7 -1.69 
AY038031 Dr.15056 mab21l2 Mab-21-like 2 -1.69 
BI890578 Dr.35640 gapdh Glyceraldehyde-3-phosphate dehydrogenase -1.69 
AI957812 Dr.78448 dpysl3 Dihydropyrimidinase-like 3 -1.69 
BM103378 Dr.123778  Transcribed locus -1.69 
AW421323 Dr.132784  Transcribed locus, weakly similar to NP_033525.1 vasodilator-
stimulated phosphoprotein [Mus musculus] 
-1.69 
AI667256 Dr.76567 rgs7 Regulator of G-protein signalling 7 -1.69 
BI879974 Dr.121395 zgc:171674 Zgc:171674 -1.69 
BI878195 Dr.78614 retsatl Retinol saturase (all-trans-retinol 13,14-reductase) like -1.69 
AI964206 Dr.106400 LOC553340 Hypothetical protein LOC553340 -1.69 
AI545105    -1.69 
AW175150 Dr.80755 ttk Ttk protein kinase -1.69 
BI891313 Dr.103638 LOC558276 Zgc:162875 -1.69 
BI880025 Dr.81974 LOC100000094 Hypothetical protein LOC100000094 -1.69 
BI879861 Dr.67202 arhgap12 Rho GTPase activating protein 12 -1.68 
AF286364    -1.68 
AI584334 Dr.77577 zgc:92476 Zgc:92476 -1.68 
AW171071 Dr.76537 LOC565636 Similar to g-RICH -1.68 
AI667279 Dr.32964 mre11a Meiotic recombination 11 homolog A (S. cerevisiae) -1.68 
U52220 Dr.134330 mtnr1ba Melatonin receptor type 1B a -1.68 
AI384799 Dr.40732 chchd7 Coiled-coil-helix-coiled-coil-helix domain containing 7 -1.68 
BI840104 Dr.119870 LOC100005141 Similar to Solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 3 
-1.68 
AI204715 Dr.142254  Transcribed locus -1.68 
BE693124    -1.68 
BF717502    -1.68 
BM102367 Dr.83618 zgc:175128 Zgc:175128 -1.68 
BI888955 Dr.132178 mat2a Methionine adenosyltransferase II, alpha -1.68 
AI957919 Dr.78518 zgc:55908 Zgc:55908 -1.68 
BE556996 Dr.82132 LOC564267 Hypothetical LOC564267 -1.68 
BE557132 Dr.82145 LOC559066 Hypothetical LOC559066 -1.68 
AW076635 Dr.74580 LOC565925 Hypothetical LOC565925 -1.68 
BI843439 Dr.84633 abhd2b Zgc:153750 -1.68 
AI667240 Dr.77173 cpb1 Carboxypeptidase B1 (tissue) -1.67 
BI706677 Dr.82647 LOC572012 Hypothetical LOC572012 -1.67 
BI671031 Dr.83351  Transcribed locus -1.67 
AI722557 Dr.78831  Transcribed locus -1.67 
 A-44
AF121796 Dr.113486 slc34a2a Solute carrier family 34 (sodium phosphate), member 2a -1.67 
AF246176 Dr.88593  Isolate 3746 T-cell receptor alpha variable region -1.67 
AI878468    -1.67 
BI705759    -1.67 
BM104174    -1.67 
BI877681 Dr.83720  Transcribed locus -1.67 
BM156006 Dr.12583 igfbp3 Insulin-like growth factor binding protein 3 -1.67 
BI851057 Dr.111672 LOC572280 Similar to KIAA1199 protein -1.67 
AW154771 Dr.96259 msi2 Musashi homolog 2 (Drosophila) -1.67 
BM072606 Dr.14870  Transcribed locus -1.67 
AA494787 Dr.75213 zgc:174862 Zgc:174862 -1.67 
BI708320 Dr.112519 zgc:158852 Zgc:158852 -1.67 
BG306663    -1.67 
BG883922 Dr.20668 zgc:112986 Zgc:112986 -1.67 
AF052248 Dr.589 foxb1.1 Forkhead box B1.1 -1.67 
AI384219 Dr.23569 LOC797653 Similar to T cell receptor beta 2 -1.67 
AW279867 Dr.81072  Transcribed locus -1.67 
AI544976 Dr.3619 mfsd2b Major facilitator superfamily domain containing 2b -1.66 
BI882155 Dr.122971  Transcribed locus -1.66 
BI980240 Dr.16625  Transcribed locus -1.66 
BM072610 Dr.83781 sirt3 Sirtuin (silent mating type information regulation 2 homolog) 3 (S. 
cerevisiae) 
-1.66 
BI705537 Dr.82349 zgc:123274 Zgc:123274 -1.66 
BI879589 Dr.88955 LOC100002374 Hypothetical protein LOC100002374 -1.66 
AI477237 Dr.77024 LOC566728 Similar to Olig3 protein -1.66 
AF017370 Dr.81271 fgd Hypothetical protein LOC791736 -1.66 
AI497228 Dr.39930 ugt1ab Zgc:123097 -1.66 
BI889820 Dr.118654 wu:fq44d08 Wu:fq44d08 -1.66 
AA606101 Dr.13140 zgc:63850 Zgc:63850 -1.66 
BG303991 Dr.110715  Transcribed locus -1.66 
AI415883    -1.66 
U29894 Dr.624 rxrab Retinoid x receptor, alpha b -1.66 
AW116023 Dr.75676 zgc:153017 Zgc:153017 -1.66 
BI430353 Dr.32632 sp8 Sp8 transcription factor -1.66 
AI477584 Dr.77051  Transcribed locus -1.66 
AI721906    -1.66 
AF246172    -1.66 
BM182611 Dr.107845 LOC795944 Similar to proteophosphoglycan 5 -1.65 
AI667241 Dr.78617 LOC570554 Similar to Mint2; neuronal munc18-1 binding protein -1.65 
AW420553 Dr.81572 rgs7bp Regulator of G-protein signaling 7 binding protein -1.65 
BF937564 Dr.82660 zgc:85969 Zgc:85969 -1.65 
AI558350 Dr.75532  Transcribed locus, strongly similar to XP_692180.2 PREDICTED: 
hypothetical protein [Danio rerio] 
-1.65 
AW077443    -1.65 
BI880677    -1.65 
BI842409 Dr.18889 LOC566511 Similar to granzyme-like III -1.65 
BI888559    -1.65 
BI884875 Dr.78570 zgc:56454 Zgc:56454 -1.65 
 A-45
BM103148    -1.65 
BE017842 Dr.104525 zgc:110137 Hypothetical protein LOC791577 -1.65 
BM101771 Dr.79982 LOC100000892 Similar to Erf protein -1.65 
BM070526 Dr.84755  Transcribed locus -1.65 
BI673529 Dr.83496 zgc:158624 Hypothetical protein LOC100004743 -1.65 
AI641460 Dr.122410  Transcribed locus -1.65 
BI841137 Dr.119602 LOC100006861 Hypothetical protein LOC100006861 -1.65 
BI980892    -1.65 
BG738618 Dr.83354 glrbb Glycine receptor, beta b -1.65 
AF395831 Dr.83621 pou4f2 POU domain, class 4, transcription factor 2 -1.65 
BM155508 Dr.81794  Transcribed locus -1.65 
AW421213 Dr.76274 pah Phenylalanine hydroxylase -1.65 
AW344075 Dr.80608 wu:fi30e01 Wu:fi30e01 -1.64 
AW128383 Dr.80505 zgc:154017 Zgc:154017 -1.64 
AI667175    -1.64 
AI496817    -1.64 
AI641071 Dr.130606  Transcribed locus -1.64 
AW343842 Dr.113833 syt11 Synaptotagmin XI -1.64 
BI845593 Dr.105556  Transcribed locus, weakly similar to XP_392578.3 PREDICTED: 
similar to Ank2 CG7462-PB, isoform B [Apis mellifera] 
-1.64 
Y13948 Dr.88617 hoxd3a Homeo box D3a -1.64 
AI793676    -1.64 
AW184640 Dr.45818 zgc:110441 Zgc:110441 -1.64 
X68447 Dr.498 eng2b Engrailed 2b -1.64 
BG307330    -1.64 
AI626804 Dr.78398  Transcribed locus -1.64 
AI722310    -1.64 
BM026303 Dr.97583 LOC555381 Hypothetical LOC555381 -1.64 
AL591391    -1.64 
BI534332    -1.64 
BI891827 Dr.38242 LOC556015 Similar to EMO2 -1.64 
BG985742    -1.64 
AF097875 Dr.25162 dnmt1 DNA (cytosine-5-)-methyltransferase 1 -1.63 
AW510092 Dr.4770 cx35.4 Hypothetical protein LOC792008 -1.63 
BM081100 Dr.123247  Transcribed locus -1.63 
AF339837 Dr.5206 aldh1a2 Aldehyde dehydrogenase 1 family, member A2 -1.63 
BI476419 Dr.83663 LOC100003386 Hypothetical protein LOC100003386 -1.63 
AI641236 Dr.77582 LOC560453 Similar to KIAA1794 -1.63 
AI667187    -1.63 
BM070916    -1.63 
BM037003 Dr.40998 cdc27 Cell division cycle 27 -1.63 
AI497491 Dr.72371 wu:fb60g05 Wu:fb60g05 -1.63 
BE017314 Dr.82060  Transcribed locus -1.63 
AF211890    -1.63 
BI475045 Dr.32515 usp33 Ubiquitin specific peptidase 33 -1.63 
BM154106    -1.63 
BM184527 Dr.81476 si:dkey-171o17.7 Si:dkey-171o17.7 -1.63 
BM154439 Dr.87389 LOC794259 Similar to Acly protein -1.63 
 A-46
AI794001 Dr.76656 capn8 Calpain 8 -1.63 
AB006323 Dr.120867 maf V-maf musculoaponeurotic fibrosarcoma (avian) oncogene homolog -1.63 
BM023805    -1.63 
AW279898 Dr.22733 wu:fj46d11 Wu:fj46d11 -1.63 
BI876262    -1.63 
BI864920 Dr.105556  Transcribed locus, weakly similar to XP_392578.3 PREDICTED: 
similar to Ank2 CG7462-PB, isoform B [Apis mellifera] 
-1.63 
BI891946    -1.63 
BI867763 Dr.78172 LOC556245 Hypothetical LOC556245 -1.63 
BM187330    -1.63 
AF318177 Dr.83333 slc6a3 Solute carrier family 6 (neurotransmitter transporter, dopamine), 
member 3 
-1.63 
BE605535 Dr.76229 wu:fk89a06 Wu:fk89a06 -1.63 
BI878483 Dr.82476 zgc:112072 Zgc:112072 -1.63 
BM095705 Dr.21332 zgc:110804 Zgc:110804 -1.62 
AB020758 Dr.79224 bmpr1b Bone morphogenetic protein receptor, type 1b -1.62 
BG727480 Dr.83090 ehmt1a Euchromatic histone-lysine N-methyltransferase 1a -1.62 
BG306351    -1.62 
BI673701 Dr.14536 dcst1 DC-STAMP domain containing 1 -1.62 
BI878433 Dr.114857 LOC100000821 Hypothetical protein LOC100000821 -1.62 
AF280090 Dr.82316 dct Dopachrome tautomerase -1.62 
AW282014 Dr.80263 stxbp1 Syntaxin binding protein 1 -1.62 
AW058902 Dr.28707 mcm5 MCM5 minichromosome maintenance deficient 5 (S. cerevisiae) -1.62 
BG306132 Dr.82913  Transcribed locus -1.62 
BM183176    -1.62 
AI626141    -1.62 
AW174245 Dr.76603 mcm4 MCM4 minichromosome maintenance deficient 4, mitotin (S. 
cerevisiae) 
-1.62 
AI883092 Dr.18416 LOC100004131 Similar to Selenium binding protein 1 -1.62 
BM071659 Dr.81011 irf1 Hypothetical protein LOC791863 -1.62 
BI842252    -1.62 
BI980153 Dr.16668  Transcribed locus -1.62 
BG727990 Dr.77106 rtn1a Hypothetical protein LOC791876 -1.61 
BI891546 Dr.7974 cdc45l Cell division cycle 45-like -1.61 
AF262978 Dr.77887 klf4 Kruppel-like factor 4 -1.61 
AW154070    -1.61 
AI883476    -1.61 
BI841800 Dr.84595  Transcribed locus -1.61 
BI865710 Dr.133362  Transcribed locus -1.61 
BI892255 Dr.80291 gpsm2 G-protein signalling modulator 2 (AGS3-like, C. elegans) -1.61 
BM181811 Dr.117780 LOC569278 Similar to hCG2044799 -1.61 
BM023853    -1.61 
AW280206 Dr.22774  Transcribed locus -1.61 
AW282034    -1.61 
BI705180    -1.61 
AW059062 Dr.106515 LOC795458 Similar to ENSANGP00000022061 -1.61 
AA605937 Dr.75918 wu:fa25h05 Wu:fa25h05 -1.61 
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BI879829 Dr.9836 nme2l Non-metastatic cells 2-like, protein (NM23B) expressed in -1.60 
AW175107 Dr.132789  Transcribed locus, strongly similar to XP_001333536.1 
PREDICTED: hypothetical protein [Danio rerio] 
-1.60 
BG728701 Dr.28180 ripk2 Receptor-interacting serine-threonine kinase 2 -1.60 
AW421190 Dr.141679  Transcribed locus, strongly similar to NP_998038.1 hypothetical 
protein LOC405809 [Danio rerio] 
-1.60 
AW566986    -1.60 
BG729152 Dr.83206  Transcribed locus -1.60 
AW566981    -1.60 
BI875848 Dr.81648 LOC799746 Hypothetical protein LOC799746 -1.60 
BM101539 Dr.132459 zgc:173837 Zgc:173837 -1.60 
AW127840 Dr.105605 wu:fj98g07 Wu:fj98g07 -1.60 
BI705257 Dr.85956  Transcribed locus -1.60 
BM103996 Dr.33521 krcp Kelch repeat-containing protein -1.60 
BF717472 Dr.24956 sepx1 Selenoprotein X, 1 -1.60 
AW153708 Dr.140590  CDNA clone MGC:173911 IMAGE:5915517 -1.60 
AW202760 Dr.10015 wu:fk84e06 Wu:fk84e06 -1.60 
BE017682 Dr.141691  Transcribed locus, strongly similar to NP_997981.1 glycine N-
methyltransferase [Danio rerio] 
-1.60 
BE015686 Dr.104581  Transcribed locus -1.60 
BM156753 Dr.29104 figla Factor in the germline alpha -1.60 
BE605965 Dr.82280 irf7 Interferon regulatory factor 7 -1.60 
AI544565 Dr.77270 sb:cb474 Sb:cb474 -1.60 
BM026060 Dr.86207 LOC798784 Hypothetical protein LOC798784 -1.60 
BI890097 Dr.118941 LOC795752 Hypothetical protein LOC795752 -1.60 
BI889666 Dr.32637  Transcribed locus, strongly similar to NP_001013519.1 calpain 2, 
(m/II) large subunit a [Danio rerio] 
-1.59 
BI704361    -1.59 
AW281831 Dr.85513 wu:fc54a11 Wu:fc54a11 -1.59 
AI721651    -1.59 
AF073289 Dr.114037 sema4e Semaphorin 4e -1.59 
AI331578 Dr.76318 si:ch211-106n13.3 Si:ch211-106n13.3 -1.59 
AW421163    -1.59 
BF156293 Dr.82337 kbtbd4 Kelch repeat and BTB (POZ) domain containing 4 -1.59 
AI477081 Dr.23702  Transcribed locus -1.59 
AB055671 Dr.107959 cnpy1 Canopy1 -1.59 
BI709116 Dr.84058 mfge8l Milk fat globule-EGF factor 8 protein, like -1.59 
BM072035 Dr.14829 gcdhl Glutaryl-Coenzyme A dehydrogenase, like -1.59 
BI866879 Dr.75098 rrm2 Ribonucleotide reductase M2 polypeptide -1.59 
U03875 Dr.2 dlx2a Distal-less homeobox gene 2a -1.59 
BI843576 Dr.84028 LOC100004787 Hypothetical protein LOC100004787 -1.59 
AW466862 Dr.107389 moxd1 Monooxygenase, DBH-like 1 -1.59 
BE201990    -1.59 
BG985563 Dr.104297 id:ibd5007 Zgc:123035 -1.59 
U93462    -1.58 
BI880711 Dr.82746 zgc:153442 Zgc:153442 -1.58 
AF278758 Dr.83043 cbfb Core-binding factor, beta subunit -1.58 




U67845 Dr.75093 dlx4b Distal-less homeobox gene 4b -1.58 
BE201510 Dr.82138 fbxl4 F-box and leucine-rich repeat protein 4 -1.58 
BI842909 Dr.76477  Transcribed locus -1.58 
BI876553 Dr.82452 kdelc1 KDEL (Lys-Asp-Glu-Leu) containing 1 -1.58 
BG302883 Dr.11424 LOC555630 Similar to RIKEN cDNA 1110008L16 gene -1.58 
AW282065 Dr.78930 adnp2 ADNP homeobox 2 -1.58 
AI588293 Dr.77760 pus1 Hypothetical protein LOC792133 -1.58 
BI673927 Dr.83519 LOC565904 Similar to RNA binding motif protein 7 -1.58 
BM183923 Dr.79770  Transcribed locus, weakly similar to XP_001370581.1 
PREDICTED: hypothetical protein [Monodelphis domestica] 
-1.58 
AW203163 Dr.106921 zgc:110586 Zgc:110586 -1.58 
BM101681 Dr.77022 chaf1b Hypothetical protein LOC791760 -1.58 
BM101561 Dr.77126 ctrb1 Chymotrypsinogen B1 -1.58 
BI845315 Dr.115339  Transcribed locus, strongly similar to XP_706506.1 PREDICTED: 
hypothetical protein [Danio rerio] 
-1.58 
BM182311 Dr.80595 pias4l Hypothetical protein LOC792278 -1.58 
AF155030 Dr.76695 wu:fb10a11 Wu:fb10a11 -1.58 
BI846216    -1.58 
AI558790 Dr.36596 wu:fb80e05 Wu:fb80e05 -1.58 
BE605883 Dr.13009 spry2 Sprouty homolog 2 -1.58 
BG308318 Dr.82700  Transcribed locus -1.58 
BM036924 Dr.133485 si:dkey-4c15.5 Si:dkey-4c15.5 -1.57 
AW280208 Dr.67746 LOC561416 Similar to MGC68847 protein -1.57 
BG304253    -1.57 
BI876291 Dr.143409 rorab RAR-related orphan receptor A, paralog b -1.57 
BI882837 Dr.13078  Transcribed locus -1.57 
BM181735 Dr.84921 prkcb1 Protein kinase C, beta 1 -1.57 
AI959042 Dr.137052  Transcribed locus -1.57 
BG303948 Dr.81324 LOC799498 Hypothetical protein LOC799498 -1.57 
AF204240 Dr.10718 neurod4 Neurogenic differentiation 4 -1.57 
BM185295 Dr.85000 zgc:112531 Zgc:112531 -1.57 
AA494831 Dr.74552  Transcribed locus -1.57 
AI641187    -1.57 
BG728407 Dr.46194 zgc:103534 Zgc:103534 -1.57 
AI330951    -1.57 
BI672372 Dr.83455 LOC571144 Similar to Aspartyl-tRNA synthetase 2 (mitochondrial) -1.57 
BI886971 Dr.82466 LOC402864 Hypothetical protein LOC402864 -1.57 
AF179844    -1.57 
AI584552    -1.57 
BI881716 Dr.48996 mdm4 Transformed 3T3 cell double minute 4 homolog (mouse) -1.57 
BI867040 Dr.84486 LOC558790 Similar to novel sulfotransferase family protein -1.57 
AI330587    -1.57 
BI704246 Dr.114838 cdca8l Hypothetical protein LOC791579 -1.57 
AI722307 Dr.78844 pdgfab Platelet derived growth factor alpha b -1.57 
BI982411 Dr.35716 cplx2 Complexin 2 -1.57 
U02544 Dr.342 wnt10a Wingless-type MMTV integration site family, member 10a -1.57 
AW116368 Dr.80414 LOC100006915 Hypothetical protein LOC100006915 -1.56 
AF247823 Dr.81771 aspn Asporin (LRR class 1) -1.56 
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BI840835 Dr.84562  Transcribed locus -1.56 
BM157226 Dr.74671 si:ch211-149p10.2 Si:ch211-149p10.2 -1.56 
AW184529 Dr.41031 smarcd2 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily d, member 2 
-1.56 
AI943072 Dr.79486 gcat Glycine C-acetyltransferase -1.56 
AI722363    -1.56 
BM183246 Dr.133501  Transcribed locus -1.56 
AF169639 Dr.107616 fzd9 Frizzled homolog 9 -1.56 
AW154454 Dr.87159 znf367 Hyaluronan binding protein 4 -1.56 
BM104640 Dr.17300 LOC559362 Hypothetical LOC559362 -1.56 
AW203093 Dr.39062 zgc:91965 Zgc:91965 -1.56 
BG305409 Dr.82821  Transcribed locus -1.56 
AW019603 Dr.22220 im:7245905 Im:7245905 -1.56 
BG737645 Dr.80225 bcl2l13 BCL2-like 13 (apoptosis facilitator) -1.56 
U57965 Dr.75098 rrm2 Ribonucleotide reductase M2 polypeptide -1.56 
AW184271 Dr.17642 zgc:101679 Zgc:101679 -1.56 
AI106277    -1.56 
BI709611 Dr.80737 zgc:110307 Hypothetical protein LOC791571 -1.56 
BI866493 Dr.84380  Transcribed locus -1.55 
BI885998 Dr.81316 cdc25 Cdc25 -1.55 
AA495060 Dr.75282 dctn5 Dynactin 5 -1.55 
BI671169 Dr.9850 opn1mw2 Opsin 1 (cone pigments), medium-wave-sensitive, 2 -1.55 
BI473402 Dr.118348 zgc:103602 Zgc:103602 -1.55 
AW279725 Dr.81131 si:ch211-268e23.1 Si:ch211-268e23.1 -1.55 
AI959361    -1.55 
U57964 Dr.33356 rrm1 Ribonucleotide reductase M1 polypeptide -1.55 
AF234784 Dr.51365 ccna2 Cyclin A2 -1.55 
BI882220 Dr.81745 LOC794975 Similar to Attractin precursor (Mahogany homolog) (DPPT-L) -1.55 
BM025986 Dr.81108  Transcribed locus -1.55 
AJ001423 Dr.104489 tnw Tenascin W -1.55 
AI384218 Dr.23568  Transcribed locus -1.55 
AI584489 Dr.143593 pcm1 Pericentriolar material 1 -1.55 
AW233478 Dr.135155  Transcribed locus -1.55 
AW279945 Dr.81081  Transcribed locus -1.55 
BF717500 Dr.36780 acox1 Acyl-Coenzyme A oxidase 1, palmitoyl -1.55 
BI839258    -1.55 
BM070746 Dr.114688 si:ch211-235l7.2 Si:ch211-235l7.2 -1.55 
AW232135 Dr.78060 si:dkey-180p18.9 Si:dkey-180p18.9 -1.55 
Y10354 Dr.75826 notch2 Notch homolog 2 -1.55 
BM103155 Dr.25204 aacs Acetoacetyl-CoA synthetase -1.54 
BM102099 Dr.5000  Transcribed locus -1.54 
AJ400460    -1.54 
AJ301589    -1.54 
AF318402 Dr.12429 nitr4a Novel immune-type receptor 4a -1.54 
BG304333 Dr.76376 eif3ea Eukaryotic translation initiation factor 3, subunit E, a -1.54 
AW174734 Dr.75702 zgc:174506 Zgc:174506 -1.54 
AW343811 Dr.77926 zgc:63774 Zgc:109744 -1.54 
BI889807 Dr.30571 LOC407704 Hypothetical protein LOC407704 -1.54 
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BI704423 Dr.110696 sb:cb986 Sb:cb986 -1.54 
U08871    -1.54 
AW019041 Dr.22150 zgc:158314 Zgc:158314 -1.54 
AW116994 Dr.7577  Transcribed locus, strongly similar to XP_691993.2 PREDICTED: 
similar to pogo transposable element with ZNF domain [Danio 
rerio] 
-1.54 
AI722292 Dr.78840  Transcribed locus -1.54 
AI545010    -1.54 
AI601423 Dr.77922  Transcribed locus -1.54 
AW233752 Dr.81047  Transcribed locus -1.54 
BI887824 Dr.75152 cdk2 Cyclin-dependent kinase 2 -1.54 
BI890559 Dr.78287 pb1 Polybromo 1 -1.54 
AI878433 Dr.121954  Transcribed locus -1.54 
BI879671 Dr.105977 zgc:136689 Zgc:136689 -1.54 
BM026522 Dr.133767  Transcribed locus, strongly similar to NP_956839.1 hypothetical 
protein LOC393517 [Danio rerio] 
-1.54 
BE693151    -1.54 
BM095174 Dr.79891 slc38a4 Solute carrier family 38, member 4 -1.54 
AW128737 Dr.79117 si:dkey-97o5.1 Si:dkey-97o5.1 -1.54 
AI558727 Dr.77529 mlh1 MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) -1.54 
AW128221    -1.53 
BM104281 Dr.3526 dtl Denticleless homolog (Drosophila) -1.53 
BM104057 Dr.84790 ung Uracil-DNA glycosylase -1.53 
BI866297 Dr.105658  Transcribed locus -1.53 
AW170989 Dr.76961 zgc:158157 Zgc:158157 -1.53 
AW281891 Dr.72340 wu:fj58g06 Wu:fj58g06 -1.53 
BF717537 Dr.86370 zgc:77076 Zgc:173915 -1.53 
BI430229 Dr.133524  Transcribed locus, strongly similar to NP_001071270.1 hypothetical 
protein LOC798716 [Danio rerio] 
-1.53 
AW077770 Dr.80306  Transcribed locus -1.53 
X87750    -1.53 
BM156040 Dr.123333  Transcribed locus -1.53 
BI887709 Dr.5648 ewsr1a Ewing sarcoma breakpoint region 1a -1.53 
AF412834 Dr.4108 msh6 MutS homolog 6 (E. coli) -1.53 
BG799445 Dr.83250  Transcribed locus, strongly similar to XP_697889.1 PREDICTED: 
hypothetical protein [Danio rerio] 
-1.53 
BI863994 Dr.77937 wu:fc07b10 Wu:fc07b10 -1.53 
Y15075 Dr.104488 mapk12 Mitogen-activated protein kinase 12 -1.53 
BI886724 Dr.123043  Transcribed locus -1.53 
AF283813 Dr.81638 cyp2k6 Cytochrome P450, family 2, subfamily K, polypeptide 6 -1.53 
BI982810 Dr.78506 LOC100000814 Hypothetical protein LOC100000814 -1.53 
AW184676 Dr.78294  Transcribed locus -1.53 
BI475899 Dr.123620  Transcribed locus -1.53 
AW343961 Dr.72264  Transcribed locus -1.53 
BI840144 Dr.123239  Transcribed locus -1.53 
BI891683 Dr.42729 LOC797948 Hypothetical protein LOC797948 -1.53 
BI710508 Dr.14761  Transcribed locus -1.53 
AW279667 Dr.42859 zgc:165628 Zgc:165628 -1.53 
AJ301582 Dr.82521 zgc:73144 Hypothetical protein LOC792240 -1.53 
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AI667329    -1.52 
BE557515    -1.52 
BM103892    -1.52 
BI864836 Dr.84363  Transcribed locus, moderately similar to XP_698845.2 
PREDICTED: hypothetical protein [Danio rerio] 
-1.52 
AI626822    -1.52 
BF717392 Dr.81544  Transcribed locus -1.52 
BE557035 Dr.116619 LOC792338 Similar to integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 
receptor) 
-1.52 
AW116727 Dr.46626 LOC100002480 Similar to A kinase (PRKA) anchor protein 1 -1.52 
BI843091 Dr.6070 zgc:153345 Zgc:153345 -1.52 
BG303282    -1.52 
BG308728 Dr.78793 fkbp5 FK506 binding protein 5 -1.52 
AI353786    -1.52 
BI891098 Dr.6325 LOC569206 Hypothetical LOC569206 -1.52 
BI879765 Dr.82650 pp Hypothetical protein LOC791859 -1.52 
BM081334 Dr.84666 fbxo25 F-box protein 25 -1.52 
AW019709 Dr.80051  Transcribed locus -1.52 
AF237948 Dr.81319 hey2 Zgc:136746 -1.52 
AW826859 Dr.78433 si:ch211-132p20.4 Si:ch211-132p20.4 -1.52 
BI839707 Dr.107116 LOC797972 Hypothetical protein LOC797972 -1.52 
AI585141 Dr.105269 supt16h Suppressor of Ty 16 homolog -1.52 
BG303273 Dr.122690  Transcribed locus -1.52 
AW117137 Dr.106714  Transcribed locus, strongly similar to NP_001017751.1 hypothetical 
protein LOC550447 [Danio rerio] 
-1.52 
BI846314 Dr.132613  Transcribed locus -1.52 
AL590146    -1.52 
AI476972 Dr.4851 zgc:92040 Zgc:92040 -1.51 
BI430211 Dr.80907 LOC795008 Hypothetical protein LOC795008 -1.51 
BI888748 Dr.75207 ncl Zgc:152810 -1.51 
AI384725 Dr.24997  Transcribed locus -1.51 
BI673483 Dr.7378  Transcribed locus -1.51 
BE017398    -1.51 
BI889244    -1.51 
AB055681 Dr.76065 zgc:110766 Zgc:110766 -1.51 
BI889053    -1.51 
AI353704    -1.51 
BI886492 Dr.133005 LOC100001846 Hypothetical protein LOC100001846 -1.51 
AW171130 Dr.12496 zgc:55456 Zgc:55456 -1.51 
BM026010 Dr.83443 LOC563682 Similar to KIAA1410 protein -1.51 
BG727595 Dr.122729  Transcribed locus -1.51 
BM096011 Dr.78616 zgc:111868 Hypothetical protein LOC791857 -1.51 
BI878244 Dr.83759  Transcribed locus -1.51 
AI617585    -1.51 
AA542593 Dr.75525  Transcribed locus -1.51 
BM034975 Dr.84814 LOC100001298 Similar to Coronin, actin binding protein, 2A -1.51 
BI880107 Dr.137583  Transcribed locus -1.51 
BI865589 Dr.123130  Transcribed locus -1.51 
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AW826605 Dr.77286 zgc:123214 Zgc:123214 -1.51 
AW826494 Dr.122531  Transcribed locus -1.51 
BI845357 Dr.14095  Transcribed locus -1.51 
BG306597 Dr.82937 cdh18 Cadherin 18, type 2 -1.51 
AF265346 Dr.76006 zgc:55865 Zgc:55865 -1.51 
AF318395 Dr.83336 nitr2b Novel immune-type receptor 2b -1.50 
AI588436 Dr.77823  Transcribed locus -1.50 
BM156924    -1.50 
BI841629 Dr.77340 sc:d185 Sc:d185 -1.50 
AI667023 Dr.78005 mpz Sc:d0186 -1.50 
BM095504 Dr.88635 si:ch211-139a5.6 Si:ch211-139a5.6 -1.50 
U67842 Dr.128 dlx1a Distal-less homeobox gene 1a -1.50 
BI890682 Dr.116552 sb:cb730 Sb:cb730 -1.50 
BM185873 Dr.14860 zgc:92004 Zgc:92004 -1.50 
BM185242 Dr.133464 LOC557883 Hypothetical LOC557883 -1.50 
AF097479 Dr.75962 LOC100007280 Hypothetical protein LOC100007280 -1.50 
BI476251 Dr.16405 zgc:56429 Zgc:56429 -1.50 
BI892410    -1.50 
BG302931 Dr.75916 LOC799257 Hypothetical protein LOC799257 -1.50 
BI880563 Dr.12908 zgc:73100 Zgc:73100 -1.50 
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Gene Symbol Gene Name 
ache acetylcholinesterase 
als2 amyotrophic lateral sclerosis 2 (juvenile) 
aplnrb apelin receptor b 
arrb2 arrestin, beta 2 
bmp2b bone morphogenetic protein 2b 
cav3 caveolin 3 
chrna1 cholinergic receptor, nicotinic, alpha polypeptide 1 
chrnd cholinergic receptor, nicotinic, delta polypeptide 
crk v-crk sarcoma virus CT10 oncogene homolog (avian) 
crkl v-crk sarcoma virus CT10 oncogene homolog (avian)-like 
cx36.7 connexin 36.7 
cxcl12a chemokine (C-X-C motif) ligand 12a (stromal cell-derived factor 1) 
cxcr4a chemokine (C-X-C motif) receptor 4a 
dag1 dystroglycan 1 
disp1 dispatched homolog 1 (Drosophila) 
dmd dystrophin 
dock1 dedicator of cytokinesis 1 
dock5 dedicator of cytokinesis 5 
fermt2 fermitin family homolog 2 (Drosophila) 
fgf8a fibroblast growth factor 8 a 
fgfr1 fibroblast growth factor receptor 1 
gli2a GLI-Kruppel family member GLI2a 
hhip hedgehog interacting protein 
hmgcra 3-hydroxy-3-methylglutaryl-Coenzyme A reductase a 
hsp90a.1 heat shock protein 90-alpha 1 
hspg2 heparan sulfate proteoglycan 2 
ihhb Indian hedgehog homolog b 
kirrel3 kin of IRRE like 3 (Drosophila) 
kny knypek 
lama2 laminin, alpha 2 
mef2a myocyte enhancer factor 2a 
mef2ca myocyte enhancer factor 2ca 
mef2d myocyte enhancer factor 2d 
mstn myostatin 
musk muscle, skeletal, receptor tyrosine kinase 
myf5 myogenic factor 5 
myf6 myogenic factor 6 
myh6 myosin, heavy polypeptide 6, cardiac muscle, alpha 
myl7 myosin, light polypeptide 7, regulatory 
mylk3 myosin light chain kinase 3 
myod1 myogenic differentiation 1 
obscn obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF 
obscnl obscurin like 
pbx2 pre-B-cell leukemia transcription factor 2 
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pbx4 pre-B-cell leukemia transcription factor 4 
postn periostin, osteoblast specific factor 
ppargc1al peroxisome proliferator-activated receptor gamma, coactivator 1 alpha like 
prdm1a PR domain containing 1a, with ZNF domain 
prox1 prospero-related homeobox gene 1 
ptc1 patched 1 
ptc2 patched 2 
rac1 ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) 
scube2 signal peptide, CUB domain, EGF-like 2 
sepn1 selenoprotein N, 1 
sgcd sarcoglycan, delta (dystrophin-associated glycoprotein) 
shha sonic hedgehog a 
shhb sonic hedgehog b 
slc8a1a solute carrier family 8 (sodium/calcium exchanger), member 1a 
smo smoothened homolog (Drosophila) 
smyd1b SET and MYND domain containing 1b 
speg SPEG complex locus 
st8sia3 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 
tcf3 transcription factor 3 
tnnt2 troponin T2, cardiac 
ttna titin a 
ttnb titin b 
unc45b unc-45 homolog B (C. elegans) 
vangl2 vang-like 2 (van gogh, Drosophila) 
vmhc ventricular myosin heavy chain 
 
 
